B7-H4 antibody and anti-B7-H4 antibody / IL-15 fusion protein
A fusion protein of anti-B7-H4 antibody and IL-15Rα sushi domain selectively targets B7-H4-expressing cells, addressing systemic toxicity issues in cytokine treatments by enhancing T cell activation and improving cancer therapy efficacy.
Patent Information
- Application Number
- JP2024532180
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-29
- Publication Date
- 2024-11-26
AI Technical Summary
Current cancer treatments using cytokines like IL-15 and IL-15Rα suffer from nonspecific immune activation leading to systemic toxicity and lack of targeting specificity, necessitating a strategy to deliver these molecules selectively to disease sites while minimizing side effects.
A fusion protein comprising an anti-B7-H4 antibody or antigen-binding fragment conjugated to an IL-15Rα sushi domain, which specifically targets B7-H4-expressing cells, enhancing immune activation without systemic toxicity.
The fusion protein effectively targets B7-H4-expressing cells, enhancing T cell activation and immune response, reducing systemic toxicity and improving therapeutic efficacy in treating cancers like ovarian and triple-negative breast cancer.
Smart Images

Figure 2024543942000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure generally relates to the fields of molecular biology and medicine. More specifically, the present disclosure provides a fusion protein comprising an anti-B7-H4 antibody or antigen-binding fragment thereof bound to an IL-15 polypeptide, the fusion protein comprising an IL-15 receptor alpha (IL-15Rα) sushi domain, bound to an IL-15Rα polypeptide. Additionally, the present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to B7-H4, and fusion proteins comprising such anti-B7-H4 antibodies or B7-H4-binding fragments thereof. Therapeutic compositions comprising the antibody fusions or antibodies for treating disease are also disclosed. [Background technology]
[0002] B7-H4 is a co-inhibitory ligand of the B7 family that is expressed exclusively on tumor cells, antigen-presenting cells (APCs), and tumor-associated macrophages (TAMs). B7-H4 binds to an unidentified cognate receptor on T cells. While expression of PD-L1 is associated with immunologically "hot" tumors, expression of B7-H4 is characterized by a "cold" environment. Expression of B7-H4 is negatively correlated with expression of PD-L1. Importantly, overexpression of B7-H4 correlates with advanced disease stage and poor prognosis in cancer patients. B7-H4 expressed by tumors and TAMs suppresses the activity of antitumor T cells, promotes an exhausted and dysfunctional state of T cells, promotes tumor-associated neutrophils (myeloid-derived suppressor cells), and promotes regulatory T cells (T regs ), which induces IL-6 and IL-10 production.
[0003] IL-15 is a 12.5 kDa glycoprotein with 114 amino acids that belongs to the four α-helical bundle family of cytokines, which also includes IL-2, IL-4, IL-7, IL-9, granulocyte colony-stimulating factor (G-CSF) and GM-CSF. IL-15 is secreted by macrophages, dendritic cells and monocytes. IL-15 can stimulate central memory CD8 cells to exert immunity without modulating the effect on other T cells. Furthermore, IL-15 can activate natural killer (NK) cells as well as effector and memory CD8 T cells, and inhibit T regs Administration of IL-15 is also associated with a lower risk of inducing systemic toxicity, even at high doses, compared to other cytokines. Human IL-15 can be soluble or membrane-bound. Membrane-bound IL-15 is the major form of IL-15, formed either by direct binding of IL-15 to the cell membrane or by presentation of IL-15 by the membrane-bound IL-15R receptor. The IL-15 receptor is composed of three subunits: IL-15Rα, IL-15Rβ, and IL-15Rγ. IL-15 typically forms a complex with the IL-15 receptor α expressed on APCs before binding to the functional IL-15Rβ and γ units on T cells and NK cells. IL-15 is an affinity (K D ≒ It can bind to the IL-15Rα receptor alone with low affinity (K D ≒IL-15 binds to the IL-15Rβγc signaling complex (at 1 nM). The sushi domain (29.5 kDa) of IL-15Rα plays an important role in the formation of the complex of IL-15 and IL-15Rα. One of the limitations of systemic therapy with IL-15 is its very short half-life in vivo. Therefore, there is a need to produce suitable immunostimulatory forms of IL-15 / IL-15Rα that have a longer half-life in vivo while retaining the ability to modulate immune responses. Furthermore, there is a need for effective IL-15 antagonists that can be selectively targeted to disease sites to avoid undesirable systemic toxicity and provide more effective therapeutic benefits.
[0004] Combination therapies involving B7-H4 antibodies with various cytokines such as IL-2, IL-15, IL-21, tumor necrosis factor (TNF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) may have some efficacy in the treatment of cancer and infectious diseases, however these therapies are limited by systemic toxicity associated with both the high circulating concentrations of cytokines required for efficacy and the lack of specificity of the administered cytokines to the affected cells and tissues. Summary of the Invention [Problem to be solved by the invention]
[0005] Thus, there is a significant unmet need to develop novel strategies to target disease sites with a variety of effector molecules that will provide therapeutic benefit without the side effects associated with non-specific immune activity. [Means for solving the problem]
[0006] Provided herein is a fusion protein comprising an anti-B7-H4 antibody or antigen-binding fragment thereof bound to an IL-15 polypeptide, the fusion protein comprising an IL-15 receptor alpha (IL-15Rα) sushi domain bound to an IL-15Rα polypeptide. The disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to B7-H4, and fusion proteins comprising such anti-B7-H4 antibodies or B7-H4-binding fragments thereof. Methods of using the disclosed anti-B7-H4 antibodies, or antigen-binding fragments thereof, or fusion proteins to treat a subject in need of treatment are also disclosed.
[0007] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3, a. CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, and CDR3H comprises SEQ ID NO: 18; i. CDR1L comprises SEQ ID NO: 20, CDR2L comprises SEQ ID NO: 21, and CDR3L comprises SEQ ID NO: 22; or ii. CDR1L comprises SEQ ID NO: 66, CDR2L comprises SEQ ID NO: 67, and CDR3L comprises SEQ ID NO: 68; or iii. CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72; or b. CDR1H comprises SEQ ID NO:4, CDR2H comprises SEQ ID NO:5, and CDR3H comprises SEQ ID NO:6; i. CDR1L comprises SEQ ID NO:8, CDR2L comprises SEQ ID NO:9, and CDR3L comprises SEQ ID NO:10; or ii. CDR1L comprises SEQ ID NO: 77, CDR2L comprises SEQ ID NO: 78, and CDR3L comprises SEQ ID NO: 79; or iii. CDR1L comprises SEQ ID NO: 81, CDR2L comprises SEQ ID NO: 82, and CDR3L comprises SEQ ID NO: 83.
[0008] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72.
[0009] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, a. the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15; i. the light chain variable region comprises SEQ ID NO:19, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:19; ii. the light chain variable region comprises SEQ ID NO:65, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:65; or iii. the light chain variable region comprises SEQ ID NO:69, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69; or b. the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3; i. the light chain variable region comprises SEQ ID NO:7, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:7; ii. the light chain variable region comprises SEQ ID NO:76, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:76; or iii. the light chain variable region comprises SEQ ID NO:80, or a sequence which is at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:80.
[0010] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:69, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69.
[0011] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, a. the heavy chain variable region comprises SEQ ID NO:15; i. the light chain variable region comprises SEQ ID NO:19; ii. the light chain variable region comprises SEQ ID NO:65; iii. the light chain variable region comprises SEQ ID NO:69; or b. the heavy chain variable region comprises SEQ ID NO:3; i. the light chain variable region comprises SEQ ID NO:7; ii. the light chain variable region comprises SEQ ID NO: 76; or iii. the light chain variable region comprises SEQ ID NO:80.
[0012] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:69.
[0013] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the antibody, or antigen-binding fragment thereof, binds to the IgV domain of human hB7-H4.
[0014] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprises CDR1, CDR2 and CDR3, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47 and CDR3H comprises SEQ ID NO: 48; a. CDR1L comprises SEQ ID NO:50, CDR2L comprises SEQ ID NO:51, and CDR3L comprises SEQ ID NO:52; or b. CDR1L comprises SEQ ID NO:88, CDR2L comprises SEQ ID NO:89, and CDR3L comprises SEQ ID NO:90; or c. CDR1L comprises SEQ ID NO: 92, CDR2L comprises SEQ ID NO: 93, and CDR3L comprises SEQ ID NO: 94; or d. CDR1L comprises SEQ ID NO: 96, CDR2L comprises SEQ ID NO: 97, and CDR3L comprises SEQ ID NO: 98; or e. CDR1L comprises SEQ ID NO: 100, CDR2L comprises SEQ ID NO: 101, and CDR3L comprises SEQ ID NO: 102; or f. CDR1L comprises SEQ ID NO: 104, CDR2L comprises SEQ ID NO: 105, and CDR3L comprises SEQ ID NO: 106, or g. CDR1L comprises SEQ ID NO:108, CDR2L comprises SEQ ID NO:109, and CDR3L comprises SEQ ID NO:110.
[0015] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 108, CDR2L comprises SEQ ID NO: 109, and CDR3L comprises SEQ ID NO: 110.
[0016] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45; a. the light chain variable region comprises SEQ ID NO:49, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:49; b. the light chain variable region comprises SEQ ID NO:87, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:87; c. the light chain variable region comprises SEQ ID NO:91, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:91; d. the light chain variable region comprises SEQ ID NO:95, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:95; e. the light chain variable region comprises SEQ ID NO:99, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:99; f. the light chain variable region comprises SEQ ID NO:103, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:103; or g. The light chain variable region comprises SEQ ID NO:107, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:107.
[0017] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:107, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:107.
[0018] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:45, a. the light chain variable region comprises SEQ ID NO:49; b. the light chain variable region comprises SEQ ID NO:87; c. the light chain variable region comprises SEQ ID NO:91; d. the light chain variable region comprises SEQ ID NO:95; e. the light chain variable region comprises SEQ ID NO: 99; f. the light chain variable region comprises SEQ ID NO: 103; or g. The light chain variable region comprises SEQ ID NO:107.
[0019] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:107.
[0020] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, which antibody, or antigen-binding fragment thereof, binds to the IgC domain of human and mouse hB7-H4.
[0021] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprises CDR1, CDR2 and CDR3, wherein CDR1H comprises SEQ ID NO: 58, CDR2H comprises SEQ ID NO: 59 and CDR3H comprises SEQ ID NO: 60; a. CDR1L comprises SEQ ID NO:62, CDR2L comprises SEQ ID NO:63, and CDR3L comprises SEQ ID NO:64; or b. CDR1L comprises SEQ ID NO: 115, CDR2L comprises SEQ ID NO: 116, and CDR3L comprises SEQ ID NO: 117; or c. CDR1L comprises SEQ ID NO: 119, CDR2L comprises SEQ ID NO: 120, and CDR3L comprises SEQ ID NO: 121; or d. CDR1L comprises SEQ ID NO: 123, CDR2L comprises SEQ ID NO: 124, and CDR3L comprises SEQ ID NO: 125; or e. CDR1L comprises SEQ ID NO: 127, CDR2L comprises SEQ ID NO: 128, and CDR3L comprises SEQ ID NO: 129, or f. CDR1L comprises SEQ ID NO:131, CDR2L comprises SEQ ID NO:132, and CDR3L comprises SEQ ID NO:133.
[0022] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:119, CDR2L comprises SEQ ID NO:120, and CDR3L comprises SEQ ID NO:121.
[0023] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57; a. the light chain variable region comprises SEQ ID NO:61, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:61; b. the light chain variable region comprises SEQ ID NO:114, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:114; c. the light chain variable region comprises SEQ ID NO:118, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118; d. the light chain variable region comprises SEQ ID NO:122, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:122; e. the light chain variable region comprises SEQ ID NO:126, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:126; or f. the light chain variable region comprises SEQ ID NO:130, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:130.
[0024] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:118, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118.
[0025] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:57, a. the light chain variable region comprises SEQ ID NO:61; b. the light chain variable region comprises SEQ ID NO: 114; c. the light chain variable region comprises SEQ ID NO: 118; d. the light chain variable region comprises SEQ ID NO: 122; e. the light chain variable region comprises SEQ ID NO: 126; or f. The light chain variable region comprises SEQ ID NO:130.
[0026] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:118.
[0027] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, which antibody, or antigen-binding fragment thereof, binds to the IgV domain of human and mouse hB7-H4.
[0028] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided that binds to the same epitope on B7-H4 as the anti-B7-H4 antibodies, or antigen-binding fragments thereof, disclosed herein.
[0029] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the antibody, or antigen-binding fragment, is a chimeric, CDR-grafted, or humanized antibody, or antigen-binding fragment thereof.
[0030] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the antibody, or antigen-binding fragment, is a multispecific or bispecific antibody, or antigen-binding fragment thereof.
[0031] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, the antibody, or antigen-binding fragment being an scFv, Fv, Fab', F(ab') 2 or a diabody.
[0032] In one embodiment, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, wherein the antibody is an immunoglobulin of the IgG class.
[0033] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the antibody, or antigen-binding fragment, has the isotype IgG1.
[0034] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, wherein the antibody, or antigen-binding fragment, is aglycosylated.
[0035] In one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, is provided, the antibody, or antigen-binding fragment thereof, comprising a first heavy chain constant region and a second heavy chain constant region, the antibody, or antigen-binding fragment thereof comprising at least one modification in the CH3 domain of the first heavy chain constant region and the second heavy chain constant region that causes heterodimerization. In one embodiment, the modification in the CH3 domain of the first heavy chain constant region is different from the modification in the CH3 domain of the second heavy chain constant region. In one embodiment, the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat). In some embodiments, (i) the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), or (ii) the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat). In some embodiments, (i) the first heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V (EU index numbering according to Kabat), or (ii) the second heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V.In one embodiment, the first heavy chain constant region, the second heavy chain constant region, or both, contain the amino acid substitutions M428L and N434S (EU index numbering according to Kabat).
[0036] In one aspect, a. an anti-B7-H4 antibody or antigen-binding fragment thereof; b. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence which is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; c. An IL-15 polypeptide comprising SEQ ID NO:166, or an amino acid sequence which is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:166.
[0037] In some embodiments, the fusion protein comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), where CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72. In some embodiments, the fusion protein comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), where CDR1H comprises SEQ ID NO: 172, CDR2H comprises SEQ ID NO: 173, CDR3H comprises SEQ ID NO: 174, CDR1L comprises SEQ ID NO: 175, CDR2L comprises SEQ ID NO: 176, and CDR3L comprises SEQ ID NO: 177. In some embodiments, the fusion protein comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), where CDR1H comprises SEQ ID NO: 178, CDR2H comprises SEQ ID NO: 179, CDR3H comprises SEQ ID NO: 180, CDR1L comprises SEQ ID NO: 181, CDR2L comprises SEQ ID NO: 182, and CDR3L comprises SEQ ID NO: 183. In some embodiments, the fusion protein comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), where CDR1H comprises SEQ ID NO: 184, CDR2H comprises SEQ ID NO: 185, CDR3H comprises SEQ ID NO: 186, CDR1L comprises SEQ ID NO: 187, CDR2L comprises SEQ ID NO: 188, and CDR3L comprises SEQ ID NO: 189.
[0038] In one embodiment, the IL-15Rα sushi domain polypeptide comprises SEQ ID NO: 167. In one embodiment, the IL-15Rα sushi domain polypeptide consists of the amino acid sequence of SEQ ID NO: 167. In one embodiment, the IL-15 polypeptide comprises SEQ ID NO: 166. In one embodiment, the IL-15 polypeptide consists of SEQ ID NO: 166. In one embodiment, the IL-15Rα sushi domain polypeptide is fused to the N-terminus of the IL-15 polypeptide.
[0039] In one embodiment, the anti-B7-H4 antibody, or antigen-binding fragment thereof, comprises a first heavy chain constant region and a second heavy chain constant region, and the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide are fused to the C-terminus of the first heavy chain constant region. In one embodiment, the fusion protein comprises a linker connecting (i) the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide and (ii) the C-terminus of the constant region. In some embodiments, the linker is 25-35 amino acids in length. In some embodiments, the linker consists essentially of Gly (G), Asn (N), Ser (S), Thr (T), Ala (A), Leu (L), and Gln (Q). In one embodiment, the linker comprises SEQ ID NO: 168. In one embodiment, the fusion protein comprises SEQ ID NO: 169. In one embodiment, the first heavy chain constant region and the second heavy chain constant region comprise at least one modification in the CH3 domain of the first heavy chain constant region and the second heavy chain constant region that causes heterodimerization. In one embodiment, the modification in the CH3 domain of the first heavy chain constant region is different from the modification in the CH3 domain of the second heavy chain constant region. In one embodiment, the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat). In some embodiments, (i) the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), or (ii) the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat).In some embodiments, (i) the first heavy chain constant region comprises amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises amino acid substitutions Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), or (ii) the second heavy chain constant region comprises amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises amino acid substitutions Y349C, T366S, L368A and Y407V. In one embodiment, the first heavy chain constant region, the second heavy chain constant region or both comprise amino acid substitutions M428L and N434S (EU index numbering according to Kabat). In one embodiment, the fusion protein comprises no more than one IL-15Rα sushi domain polypeptide and no more than one IL-15 polypeptide. In some embodiments, the fusion protein comprises an anti-B7-H4 antibody, or an antigen-binding fragment thereof, disclosed herein.
[0040] In one aspect, a. a light chain comprising SEQ ID NO:69 and / or SEQ ID NO:145; b. a first heavy chain comprising SEQ ID NO: 150 or SEQ ID NO: 151; and c. a second heavy chain comprising SEQ ID NO: 157 or SEQ ID NO: 158.
[0041] In one embodiment, the first heavy chain comprises SEQ ID NO: 150 and the second heavy chain comprises SEQ ID NO: 157. In one embodiment, the first heavy chain comprises SEQ ID NO: 151 and the second heavy chain comprises SEQ ID NO: 158.
[0042] In one aspect, a. a light chain comprising SEQ ID NO:118 and / or SEQ ID NO:144; b. a first heavy chain comprising SEQ ID NO: 148 or SEQ ID NO: 149; and c. a second heavy chain comprising SEQ ID NO: 155 or SEQ ID NO: 156.
[0043] In one embodiment, the first heavy chain comprises SEQ ID NO:148 and the second heavy chain comprises SEQ ID NO:155.
[0044] In one embodiment, the first heavy chain comprises SEQ ID NO:149 and the second heavy chain comprises SEQ ID NO:156.
[0045] In one aspect, a fusion protein is provided comprising a light chain comprising SEQ ID NO: 145, a first heavy chain comprising SEQ ID NO: 150, and a second heavy chain comprising SEQ ID NO: 157.
[0046] In one aspect, a nucleic acid sequence encoding an anti-B7-H4 antibody, or antigen-binding fragment thereof, or a fusion protein disclosed herein is provided.
[0047] Disclosed herein are vectors comprising the nucleic acids disclosed herein. Disclosed herein are sets of vectors comprising two or more nucleic acid molecules disclosed herein.
[0048] Disclosed herein are cells comprising the nucleic acids or vectors disclosed herein. Disclosed herein are cells expressing the anti-B7-H4 antibodies, or antigen-binding fragments thereof, or fusion proteins disclosed herein. Disclosed herein are T cells expressing the anti-B7-H4 antibodies, or antigen-binding fragments thereof, or fusion proteins disclosed herein. Disclosed herein are T cells expressing anti-B7-H4 binding proteins comprising the variable heavy chain and variable light chain of the anti-B7-H4 antibodies, or antigen-binding fragments thereof, disclosed herein. In some embodiments, the cells are isolated.
[0049] In some embodiments, the anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein is conjugated to one or more of a cytotoxin, a fluorescent label, and an imaging agent.
[0050] Provided herein is a pharmaceutical composition comprising (i) an anti-B7-H4 antibody, or antigen-binding fragment thereof, or a fusion protein disclosed herein, and (ii) a pharma- ceutically acceptable carrier.
[0051] Provided herein is a method of producing an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein, the method comprising culturing a cell disclosed herein under conditions such that the anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein is produced.
[0052] Provided herein are methods for inhibiting binding of B7-H4 to its ligand in a subject in need of inhibiting binding of B7-H4 to its ligand, the methods comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0053] Provided herein is a method of enhancing T cell activation in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0054] Provided herein is a method of enhancing CD8+ T cell proliferation in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0055] Provided herein is a method for inducing antibody dependent cell mediated cytotoxicity (ADCC) in B7-H4 expressing cells in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0056] Provided herein is a method of stimulating the immune system in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0057] Provided herein are methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein. In some embodiments, the cancer is ovarian cancer, melanoma, pancreatic cancer, thyroid cancer, lung cancer, colon cancer, squamous cell carcinoma, prostate cancer, breast cancer, bladder cancer, or gastric cancer. In some embodiments, the cancer is triple-negative breast cancer or ovarian cancer.
[0058] Provided herein are methods of reducing tumor growth in a subject in need thereof, the methods comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0059] Provided herein is a method of reducing tumor metastasis in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein.
[0060] In one embodiment, the method further comprises administering an additional therapeutic agent or additional therapy. In some embodiments, the additional therapeutic agent is selected from the group consisting of a cancer vaccine, a checkpoint inhibitor, an antibody against a tumor-specific antigen, a Bacillus Calmette-Guerin vaccine, a cytotoxin, an interleukin 6 receptor (IL-6R) inhibitor, an interleukin 4 receptor (IL-4R) inhibitor, an IL-10 inhibitor, IL-2, IL-7, IL-21, IL-15, an antibody drug conjugate, an anti-inflammatory drug, and a dietary supplement. In some embodiments, the checkpoint inhibitor is a CTLA-4, PD-1, PD-L1, or PD-L2 inhibitor. In some embodiments, the additional therapeutic agent is an inhibitor of LAG3, TIGIT, LAP, podoplanin, protein C receptor, ICOS, GITR, CD226, or CD160. In some embodiments, the additional therapy is chemotherapy, radiation therapy, or surgery. In some embodiments, the additional therapeutic agent or additional therapy is administered simultaneously or sequentially with the anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein. In some embodiments, the additional therapeutic agent is administered separately from the anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein, or in a mixture thereof.
[0061] In one embodiment, the subject upregulates expression of B7-H4 or the subject is identified as positive for expression of B7-H4. In one embodiment, the subject does not respond to therapy with a checkpoint inhibitor or does not initially respond to checkpoint inhibitor treatment but later becomes resistant to checkpoint inhibitor blocking. In one embodiment, the subject is a human.
[0062] In one aspect, a method of detecting B7-H4 in a sample is provided, the method comprising contacting the sample with an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein. [Brief description of the drawings]
[0063] [Figure 1A]The unique structure of B7-H4' is shown, including hyperglycosylated IgC and a very short cytoplasmic tail. [Figure 1B] 1 shows an exemplary fusion protein disclosed herein. [Diagram 2] The process of obtaining high affinity B7-H4 antibodies by panning a fully human scFv phage display library (Superman 2.0 from Distributed Bio) on B7-H4, followed by affinity maturation (light chain shuffling) is shown. [Figure 3A-3B] Binding of antibodies 1D3, 3F2, 1A12, 1F11 and 6C3 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 3A), hB7-H4-his (Figure 3B), mB7-H4-Fc (Figure 3C) and hB7-H4 IgV domain (Figure 3D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 3E) or mB7-H4 (Figure 3F). Antibodies 1D3, 3F2, 1A12, 1F11 and 6C3 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. [Figure 3C-3D] Binding of antibodies 1D3, 3F2, 1A12, 1F11 and 6C3 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 3A), hB7-H4-his (Figure 3B), mB7-H4-Fc (Figure 3C) and hB7-H4 IgV domain (Figure 3D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 3E) or mB7-H4 (Figure 3F). Antibodies 1D3, 3F2, 1A12, 1F11 and 6C3 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. [Fig. 3E-3F]Binding of antibodies 1D3, 3F2, 1A12, 1F11 and 6C3 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 3A), hB7-H4-his (Figure 3B), mB7-H4-Fc (Figure 3C) and hB7-H4 IgV domain (Figure 3D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 3E) or mB7-H4 (Figure 3F). Antibodies 1D3, 3F2, 1A12, 1F11 and 6C3 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. [Figure 4A-4B] Figure 4 shows the binding of antibodies 6C3, 1D3, 3D1 and 4H6 to both soluble and cellular B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 4A), hB7-H4-his (Figure 4B), hB7-H4 IgV domain (Figure 4C) and mB7-H4 IgV domain (Figure 4D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 4E) or mB7-H4 (Figure 4F). Antibodies 6C3, 1D3, 3D1 and 4H6 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. As a control, a cross-reactive IgV-binding antibody was used. [Fig. 4C-4D] Figure 4 shows the binding of antibodies 6C3, 1D3, 3D1 and 4H6 to both soluble and cellular B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 4A), hB7-H4-his (Figure 4B), hB7-H4 IgV domain (Figure 4C) and mB7-H4 IgV domain (Figure 4D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 4E) or mB7-H4 (Figure 4F). Antibodies 6C3, 1D3, 3D1 and 4H6 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. As a control, a cross-reactive IgV-binding antibody was used. [Fig. 4E-4F]Figure 4 shows the binding of antibodies 6C3, 1D3, 3D1 and 4H6 to both soluble and cellular B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 4A), hB7-H4-his (Figure 4B), hB7-H4 IgV domain (Figure 4C) and mB7-H4 IgV domain (Figure 4D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 4E) or mB7-H4 (Figure 4F). Antibodies 6C3, 1D3, 3D1 and 4H6 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. As a control, a cross-reactive IgV-binding antibody was used. [Figure 5A-5B] Binding of antibody 9H2 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 5A), hB7-H4-his (Figure 5B), mB7-H4-Fc domain (Figure 5C), hB7-H4 IgV domain (Figure 5D) and hB7-H4 IgC domain (Figure 5E). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 5F) or mB7-H4 (Figure 5G). Antibody 9H2 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. Cross-reactive IgV- and IgC-binding antibodies were used as controls. [Fig. 5C-5D] Binding of antibody 9H2 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 5A), hB7-H4-his (Figure 5B), mB7-H4-Fc domain (Figure 5C), hB7-H4 IgV domain (Figure 5D) and hB7-H4 IgC domain (Figure 5E). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 5F) or mB7-H4 (Figure 5G). Antibody 9H2 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. Cross-reactive IgV- and IgC-binding antibodies were used as controls. [Fig. 5E-5F]Binding of antibody 9H2 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 5A), hB7-H4-his (Figure 5B), mB7-H4-Fc domain (Figure 5C), hB7-H4 IgV domain (Figure 5D) and hB7-H4 IgC domain (Figure 5E). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 5F) or mB7-H4 (Figure 5G). Antibody 9H2 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. Cross-reactive IgV- and IgC-binding antibodies were used as controls. [Figure 5G] Binding of antibody 9H2 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 5A), hB7-H4-his (Figure 5B), mB7-H4-Fc domain (Figure 5C), hB7-H4 IgV domain (Figure 5D) and hB7-H4 IgC domain (Figure 5E). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 5F) or mB7-H4 (Figure 5G). Antibody 9H2 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4. Cross-reactive IgV- and IgC-binding antibodies were used as controls. [Figure 6A-6B] Binding of antibodies 5G6, 9E1, 5F4, 5E4 and 4B9 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 6A), mB7-H4-hFc (Figure 6B), hB7-H4 IgV domain (Figure 6C) and mB7-H4 IgV domain (Figure 6D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 6E) or mB7-H4 (Figure 6F). Antibodies 5E4, 5F4, 5G6 and 9E1 bound to the IgC domain of both human and mouse B7-H4. Antibody 4B9 bound tightly to hB7-H4-Fc but not to mB7-H4. Binding of antibody 4B9 required both IgV and IgC. As a control, a cross-reactive IgV-binding antibody was used. [Figure 6C-6D] Binding of antibodies 5G6, 9E1, 5F4, 5E4 and 4B9 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 6A), mB7-H4-hFc (Figure 6B), hB7-H4 IgV domain (Figure 6C) and mB7-H4 IgV domain (Figure 6D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 6E) or mB7-H4 (Figure 6F). Antibodies 5E4, 5F4, 5G6 and 9E1 bound to the IgC domain of both human and mouse B7-H4. Antibody 4B9 bound tightly to hB7-H4-Fc but not to mB7-H4. Binding of antibody 4B9 required both IgV and IgC. As a control, a cross-reactive IgV-binding antibody was used. [Figure 6E-6F] Binding of antibodies 5G6, 9E1, 5F4, 5E4 and 4B9 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 6A), mB7-H4-hFc (Figure 6B), hB7-H4 IgV domain (Figure 6C) and mB7-H4 IgV domain (Figure 6D). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 6E) or mB7-H4 (Figure 6F). Antibodies 5E4, 5F4, 5G6 and 9E1 bound to the IgC domain of both human and mouse B7-H4. Antibody 4B9 bound tightly to hB7-H4-Fc but not to mB7-H4. Binding of antibody 4B9 required both IgV and IgC. As a control, a cross-reactive IgV-binding antibody was used. [Figure 7A-7B]Binding of antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 7A), hB7-H4-His (Figure 7B), mB7-H4-hFc (Figure 7C), mB7-H4-His (Figure 7D), hB7-H4 IgC domain (Figure 7E) and mB7-H4 IgC domain (Figure 7F). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 7G) or mB7-H4 (Figure 7H). Antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 bound to the IgC domain of both human and mouse B7-H4. As controls, cross-reactive IgC-binding antibodies were used. [Figure 7C-7D] Binding of antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 7A), hB7-H4-His (Figure 7B), mB7-H4-hFc (Figure 7C), mB7-H4-His (Figure 7D), hB7-H4 IgC domain (Figure 7E) and mB7-H4 IgC domain (Figure 7F). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 7G) or mB7-H4 (Figure 7H). Antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 bound to the IgC domain of both human and mouse B7-H4. As controls, cross-reactive IgC-binding antibodies were used. [Fig. 7E-7F]Binding of antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 7A), hB7-H4-His (Figure 7B), mB7-H4-hFc (Figure 7C), mB7-H4-His (Figure 7D), hB7-H4 IgC domain (Figure 7E) and mB7-H4 IgC domain (Figure 7F). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 7G) or mB7-H4 (Figure 7H). Antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 bound to the IgC domain of both human and mouse B7-H4. As controls, cross-reactive IgC-binding antibodies were used. [Fig. 7G-7H] Binding of antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 7A), hB7-H4-His (Figure 7B), mB7-H4-hFc (Figure 7C), mB7-H4-His (Figure 7D), hB7-H4 IgC domain (Figure 7E) and mB7-H4 IgC domain (Figure 7F). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 7G) or mB7-H4 (Figure 7H). Antibodies 9D11, 24B6, 15B11, 30G4 and 24F4 bound to the IgC domain of both human and mouse B7-H4. As controls, cross-reactive IgC-binding antibodies were used. [Figure 8A-8B]Binding of antibodies 39A11 and 31D7 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 8A), hB7-H4-His (Figure 8B), mB7-H4-hFc (Figure 8C), mB7-H4-His (Figure 8D), hB7-H4 IgV domain (Figure 8E), hB7-H4 IgC domain (Figure 8F), mB7-H4 IgV domain (Figure 8G), and mB7-H4 IgC domain (Figure 8H). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 8I) or mB7-H4 (Figure 8J). Antibodies 39A11 and 31D7 bound to the IgV domains of both human and mouse B7-H4. As controls, cross-reactive IgV-binding antibodies were used. [Fig. 8C-8D] Binding of antibodies 39A11 and 31D7 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 8A), hB7-H4-His (Figure 8B), mB7-H4-hFc (Figure 8C), mB7-H4-His (Figure 8D), hB7-H4 IgV domain (Figure 8E), hB7-H4 IgC domain (Figure 8F), mB7-H4 IgV domain (Figure 8G), and mB7-H4 IgC domain (Figure 8H). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 8I) or mB7-H4 (Figure 8J). Antibodies 39A11 and 31D7 bound to the IgV domains of both human and mouse B7-H4. As controls, cross-reactive IgV-binding antibodies were used. [Fig. 8E-8F]Binding of antibodies 39A11 and 31D7 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 8A), hB7-H4-His (Figure 8B), mB7-H4-hFc (Figure 8C), mB7-H4-His (Figure 8D), hB7-H4 IgV domain (Figure 8E), hB7-H4 IgC domain (Figure 8F), mB7-H4 IgV domain (Figure 8G), and mB7-H4 IgC domain (Figure 8H). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 8I) or mB7-H4 (Figure 8J). Antibodies 39A11 and 31D7 bound to the IgV domains of both human and mouse B7-H4. As controls, cross-reactive IgV-binding antibodies were used. [Fig. 8G-8H] Binding of antibodies 39A11 and 31D7 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 8A), hB7-H4-His (Figure 8B), mB7-H4-hFc (Figure 8C), mB7-H4-His (Figure 8D), hB7-H4 IgV domain (Figure 8E), hB7-H4 IgC domain (Figure 8F), mB7-H4 IgV domain (Figure 8G), and mB7-H4 IgC domain (Figure 8H). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 8I) or mB7-H4 (Figure 8J). Antibodies 39A11 and 31D7 bound to the IgV domains of both human and mouse B7-H4. As controls, cross-reactive IgV-binding antibodies were used. [Fig. 8I-8J]Binding of antibodies 39A11 and 31D7 to both soluble and cellular B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 8A), hB7-H4-His (Figure 8B), mB7-H4-hFc (Figure 8C), mB7-H4-His (Figure 8D), hB7-H4 IgV domain (Figure 8E), hB7-H4 IgC domain (Figure 8F), mB7-H4 IgV domain (Figure 8G), and mB7-H4 IgC domain (Figure 8H). Flow cytometry experiments were performed to determine binding to CHO cells expressing hB7-H4 (Figure 8I) or mB7-H4 (Figure 8J). Antibodies 39A11 and 31D7 bound to the IgV domains of both human and mouse B7-H4. As controls, cross-reactive IgV-binding antibodies were used. [Figure 9A-9B] Binding of antibodies 1D3 / 1D3, 1D3 / 1D3 derivative 1D3 / 45A2, 1D3 / 1D3 derivative 1D3 / 47B2, 3F2 / 3F2, 3F2 / 3F2 derivative 3F2 / 50A10, and 3F2 / 3F2 derivative 3F2 / 49A2 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 9A), mB7-H4-Fc (Figure 9B), hB7-H4-his (Figure 9C), mB7-H4-his (Figure 9D), hB7-H4 IgV domain (Figure 9E), mB7-H4 IgV domain (Figure 9F), hB7-H4 IgC domain (Figure 9G), and mB7-H4 IgC domain (Figure 9H). The 3F2 derivatives 3F2 / 50A10 and 3F2 / 49A2 have the same heavy chain sequence as 3F2 but a different light chain sequence from 3F2. The 1D3 derivatives 1D3 / 47B2 and 1D3 / 45A2 have the same heavy chain sequence as 1D3 but a different light chain sequence from 1D3. Antibodies C3 and 49A2 have the same VH and VL sequences. [Fig. 9C-9D]Binding of antibodies 1D3 / 1D3, 1D3 / 1D3 derivative 1D3 / 45A2, 1D3 / 1D3 derivative 1D3 / 47B2, 3F2 / 3F2, 3F2 / 3F2 derivative 3F2 / 50A10, and 3F2 / 3F2 derivative 3F2 / 49A2 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 9A), mB7-H4-Fc (Figure 9B), hB7-H4-his (Figure 9C), mB7-H4-his (Figure 9D), hB7-H4 IgV domain (Figure 9E), mB7-H4 IgV domain (Figure 9F), hB7-H4 IgC domain (Figure 9G), and mB7-H4 IgC domain (Figure 9H). The 3F2 derivatives 3F2 / 50A10 and 3F2 / 49A2 have the same heavy chain sequence as 3F2 but a different light chain sequence from 3F2. The 1D3 derivatives 1D3 / 47B2 and 1D3 / 45A2 have the same heavy chain sequence as 1D3 but a different light chain sequence from 1D3. Antibodies C3 and 49A2 have the same VH and VL sequences. [Fig. 9E-9F] Binding of antibodies 1D3 / 1D3, 1D3 / 1D3 derivative 1D3 / 45A2, 1D3 / 1D3 derivative 1D3 / 47B2, 3F2 / 3F2, 3F2 / 3F2 derivative 3F2 / 50A10, and 3F2 / 3F2 derivative 3F2 / 49A2 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 9A), mB7-H4-Fc (Figure 9B), hB7-H4-his (Figure 9C), mB7-H4-his (Figure 9D), hB7-H4 IgV domain (Figure 9E), mB7-H4 IgV domain (Figure 9F), hB7-H4 IgC domain (Figure 9G), and mB7-H4 IgC domain (Figure 9H). The 3F2 derivatives 3F2 / 50A10 and 3F2 / 49A2 have the same heavy chain sequence as 3F2 but a different light chain sequence from 3F2. The 1D3 derivatives 1D3 / 47B2 and 1D3 / 45A2 have the same heavy chain sequence as 1D3 but a different light chain sequence from 1D3. Antibodies C3 and 49A2 have the same VH and VL sequences. [Fig. 9G-9H]Binding of antibodies 1D3 / 1D3, 1D3 / 1D3 derivative 1D3 / 45A2, 1D3 / 1D3 derivative 1D3 / 47B2, 3F2 / 3F2, 3F2 / 3F2 derivative 3F2 / 50A10, and 3F2 / 3F2 derivative 3F2 / 49A2 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 9A), mB7-H4-Fc (Figure 9B), hB7-H4-his (Figure 9C), mB7-H4-his (Figure 9D), hB7-H4 IgV domain (Figure 9E), mB7-H4 IgV domain (Figure 9F), hB7-H4 IgC domain (Figure 9G), and mB7-H4 IgC domain (Figure 9H). The 3F2 derivatives 3F2 / 50A10 and 3F2 / 49A2 have the same heavy chain sequence as 3F2 but a different light chain sequence from 3F2. The 1D3 derivatives 1D3 / 47B2 and 1D3 / 45A2 have the same heavy chain sequence as 1D3 but a different light chain sequence from 1D3. Antibodies C3 and 49A2 have the same VH and VL sequences. [Figure 10A-10B] 10 shows the binding of antibodies 1D3 / 1D3, 1D3 / 1D3 derivative 1D3 / 45A2, 1D3 / 1D3 derivative 1D3 / 47B2, 3F2 / 3F2, 3F2 / 3F2 derivative 3F2 / 50A10 and 3F2 / 3F2 derivative 3F2 / 49A2 to cell-bound B7-H4. Flow cytometry experiments were performed to determine binding to hB7-H4 expressing CHO cells (FIG. 10A), mB7-H4 expressing CHO cells (FIG. 10B), hB7-H4 expressing triple-negative breast cancer cell line MDA-MB-468 cells (FIG. 10C) and hB7-H4 expressing ovarian cancer cell line SK-BR-3 cells (FIG. 10D). [Fig. 10C-10D]10 shows the binding of antibodies 1D3 / 1D3, 1D3 / 1D3 derivative 1D3 / 45A2, 1D3 / 1D3 derivative 1D3 / 47B2, 3F2 / 3F2, 3F2 / 3F2 derivative 3F2 / 50A10 and 3F2 / 3F2 derivative 3F2 / 49A2 to cell-bound B7-H4. Flow cytometry experiments were performed to determine binding to hB7-H4 expressing CHO cells (FIG. 10A), mB7-H4 expressing CHO cells (FIG. 10B), hB7-H4 expressing triple-negative breast cancer cell line MDA-MB-468 cells (FIG. 10C) and hB7-H4 expressing ovarian cancer cell line SK-BR-3 cells (FIG. 10D). [Figure 11A-11B] Binding of antibody 9D11 / 9D11 and 9D11 / 9D11 derivatives 9D11 / 67H9, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67E12, and 9D11 / 67G3 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 11A), mB7-H4-Fc (FIG. 11B), hB7-H4 IgC domain (FIG. 11C), mB7-H4 IgC domain (FIG. 11D), hB7-H4 IgV domain (FIG. 11E), and mB7-H4 IgV domain (FIG. 11F). The 9D11 derivatives 9D11 / 67E12, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67H9, 9D11 / 67G3 and 9D11 / 68F5 have the same heavy chain sequence as 9D11 but a different light chain sequence from 9D11. [Fig. 11C-11D] Binding of antibody 9D11 / 9D11 and 9D11 / 9D11 derivatives 9D11 / 67H9, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67E12, and 9D11 / 67G3 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 11A), mB7-H4-Fc (FIG. 11B), hB7-H4 IgC domain (FIG. 11C), mB7-H4 IgC domain (FIG. 11D), hB7-H4 IgV domain (FIG. 11E), and mB7-H4 IgV domain (FIG. 11F). The 9D11 derivatives 9D11 / 67E12, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67H9, 9D11 / 67G3 and 9D11 / 68F5 have the same heavy chain sequence as 9D11 but a different light chain sequence from 9D11. [Fig. 11E-11F] Binding of antibody 9D11 / 9D11 and 9D11 / 9D11 derivatives 9D11 / 67H9, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67E12, and 9D11 / 67G3 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 11A), mB7-H4-Fc (FIG. 11B), hB7-H4 IgC domain (FIG. 11C), mB7-H4 IgC domain (FIG. 11D), hB7-H4 IgV domain (FIG. 11E), and mB7-H4 IgV domain (FIG. 11F). The 9D11 derivatives 9D11 / 67E12, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67H9, 9D11 / 67G3 and 9D11 / 68F5 have the same heavy chain sequence as 9D11 but a different light chain sequence from 9D11. [Figure 12A-12B] Binding of 9D11 / 9D11 derivatives 9D11 / 67C3, 9D11 / 67E12, and 9D11 / 68F5 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 12A), mB7-H4-Fc (FIG. 12B), hB7-H4-his (FIG. 12C), and hB7-H4-his (FIG. 12D). 9D11 derivatives 9D11 / 67C3, 9D11 / 67E12, and 9D11 / 68F5 have the same heavy chain sequence as 9D11, but a different light chain sequence from 9D11. [Fig. 12C-12D] Binding of 9D11 / 9D11 derivatives 9D11 / 67C3, 9D11 / 67E12, and 9D11 / 68F5 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 12A), mB7-H4-Fc (FIG. 12B), hB7-H4-his (FIG. 12C), and hB7-H4-his (FIG. 12D). 9D11 derivatives 9D11 / 67C3, 9D11 / 67E12, and 9D11 / 68F5 have the same heavy chain sequence as 9D11, but a different light chain sequence from 9D11. [Figure 13A-13B]13 shows the binding of antibody 9D11 / 9D11 and 9D11 / 9D11 derivatives 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67E12, 9D11 / 67G3, 9D11 / 67H9, and 9D11 / 68F5 to cell-bound B7-H4. Flow cytometry experiments were performed to determine binding to CT26 cells expressing mB7-H4 (FIG. 13A) or SK-BR-3 cells expressing hB7-H4 (FIG. 13B). 9D11 derivatives 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67E12, 9D11 / 67G3, 9D11 / 67H9, and 9D11 / 68F5 have the same heavy chain sequence as 9D11, but a different light chain sequence from 9D11. [Figure 14A-14B] Binding of antibodies 39A11 / 39A11 and 39A11 / 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 14A), mB7-H4-Fc (FIG. 14B), hB7-H4 IgV domain (FIG. 14C), mB7-H4 IgV domain (FIG. 14D), hB7-H4 IgC domain (FIG. 14E), and mB7-H4 IgC domain (FIG. 14F). The 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 have the same heavy chain sequence as 39A11, but different light chain sequences from 39A11. [Fig. 14C-14D]Binding of antibodies 39A11 / 39A11 and 39A11 / 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 14A), mB7-H4-Fc (FIG. 14B), hB7-H4 IgV domain (FIG. 14C), mB7-H4 IgV domain (FIG. 14D), hB7-H4 IgC domain (FIG. 14E), and mB7-H4 IgC domain (FIG. 14F). The 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 have the same heavy chain sequence as 39A11, but different light chain sequences from 39A11. [Fig. 14E-14F] Binding of antibodies 39A11 / 39A11 and 39A11 / 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 to soluble B7-H4. ELISA experiments were performed to determine binding to hB7-H4-Fc (FIG. 14A), mB7-H4-Fc (FIG. 14B), hB7-H4 IgV domain (FIG. 14C), mB7-H4 IgV domain (FIG. 14D), hB7-H4 IgC domain (FIG. 14E), and mB7-H4 IgC domain (FIG. 14F). The 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 have the same heavy chain sequence as 39A11, but different light chain sequences from 39A11. [Figure 15A-15B]15A-B show the binding of antibody 39A11 / 39A11 and 39A11 / 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 to cell-bound B7-H4. Flow cytometry experiments were performed to determine binding to CT26 cells expressing mB7-H4 (FIG. 15A) or SK-BR-3 cells expressing hB7-H4 (FIG. 15B). The 39A11 derivatives 39A11 / 62F9, 39A11 / 56H7, 39A11 / 57G8, 39A11 / 57H3, and 39A11 / 56A9 have the same heavy chain sequence as 39A11, but different light chain sequences from 39A11. [Figure 16A-16B] Binding of antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to soluble B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 16A), mB7-H4-Fc (Figure 16B), hB7-H4 IgV domain (Figure 16C), mB7-H4 IgV domain (Figure 16D), hB7-H4 IgC domain (Figure 16E) and mB7-H4 IgC domain (Figure 16F). As controls, antibodies binding to IgV or IgC, respectively, were used. [Fig. 16C-16D] Binding of antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to soluble B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 16A), mB7-H4-Fc (Figure 16B), hB7-H4 IgV domain (Figure 16C), mB7-H4 IgV domain (Figure 16D), hB7-H4 IgC domain (Figure 16E) and mB7-H4 IgC domain (Figure 16F). As controls, antibodies binding to IgV or IgC, respectively, were used. [Fig. 16E-16F]Binding of antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to soluble B7-H4 is shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 16A), mB7-H4-Fc (Figure 16B), hB7-H4 IgV domain (Figure 16C), mB7-H4 IgV domain (Figure 16D), hB7-H4 IgC domain (Figure 16E) and mB7-H4 IgC domain (Figure 16F). As controls, antibodies binding to IgV or IgC, respectively, were used. [Figure 17A-17B] 17 shows the binding of antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody), and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to cell-bound B7-H4. Flow cytometry experiments were performed to determine binding to SK-BR-3 cells expressing hB7-H4 (FIG. 17A), CT26 cells expressing mB7-H4 (FIG. 17B), and MDA-MB-468 cells expressing hB7-H4 (FIG. 17C). [Figure 17C] 17 shows the binding of antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody), and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to cell-bound B7-H4. Flow cytometry experiments were performed to determine binding to SK-BR-3 cells expressing hB7-H4 (FIG. 17A), CT26 cells expressing mB7-H4 (FIG. 17B), and MDA-MB-468 cells expressing hB7-H4 (FIG. 17C). [Figure 18A]Figure 18 shows the internalization of anti-B7-H4 antibodies, antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) after binding to hB7-H4. The antibodies were mixed with an antibody labeling reagent (i.e., Fc region-targeted Fab fragments conjugated to a pH-sensitive fluorescent probe). Fluorogenic signals are observed as the Fab-Ab complexes are internalized and processed through acidic (pH 4.5-5.5) lysosomes and endosomes. Internalization is shown for SK-BR-3 cells expressing hB7-H4 (Figure 18A) and MDA-MB-468 cells expressing hB7-H4 (Figure 18B). As controls, IgV or IgC binding antibodies, respectively, were used. [Figure 18B] Figure 18 shows the internalization of anti-B7-H4 antibodies, antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) after binding to hB7-H4. The antibodies were mixed with an antibody labeling reagent (i.e., Fc region-targeted Fab fragments conjugated to a pH-sensitive fluorescent probe). Fluorogenic signals are observed as the Fab-Ab complexes are internalized and processed through acidic (pH 4.5-5.5) lysosomes and endosomes. Internalization is shown for SK-BR-3 cells expressing hB7-H4 (Figure 18A) and MDA-MB-468 cells expressing hB7-H4 (Figure 18B). As controls, IgV or IgC binding antibodies, respectively, were used. [Figure 19A] Restoration of T cell cytokine secretion function (here IFNγ secretion) by antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) (Figure 19A), and antibody 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) (Figure 19B) is shown. As controls, IgV or IgC binding antibodies, respectively, were used. An irrelevant control antibody was also included. [Figure 19B]Restoration of T cell cytokine secretion function (here IFNγ secretion) by antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) (Figure 19A), and antibody 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) (Figure 19B) is shown. As controls, IgV or IgC binding antibodies, respectively, were used. An irrelevant control antibody was also included. [Figure 20A-20B] 20A-20C show that antibodies 3F2 / 50A10 (hB7-H4-IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody), and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) induce antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells. Tumor cell killing is shown for SK-BR-3 cells expressing hB7-H4 (FIG. 20A) and MDA-MB-468 cells expressing hB7-H4 (FIG. 20B). [Figure 21A-21B] We show that IgV domain-binding antibodies 3F2 / 50A10 and 39A11 / 57G8 kill tumor cells in an IncuCyte® immune cell killing assay. To analyze ADCC, a SKBR3 / hPBMC co-culture model was prepared, in which SK-BR-3 cancer cells were mixed with hPBMCs at a ratio of 1:5 (FIG. 21A) or 1:10 (FIG. 21B), respectively. DP47 served as a control antibody. [Fig. 22A-22B] Binding of antibody 39A11 / 57G8 and a positive control antibody (IgV binding antibody) to B7-H4, respectively, and binding of a fusion protein containing antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15) or a fusion protein containing a positive control antibody (i.e., fusion protein (+)Ab1 / IL15) are shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 22A), hB7-H4-his (Figure 22B), hB7-H4 IgV domain (Figure 22C), mB7-H4-Fc (Figure 22D), mB7-H4-his (Figure 22E), mB7-H4 IgV domain (Figure 22F). [Fig. 22C-22D]Binding of antibody 39A11 / 57G8 and a positive control antibody (IgV binding antibody) to B7-H4, respectively, and binding of a fusion protein containing antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15) or a fusion protein containing a positive control antibody (i.e., fusion protein (+)Ab1 / IL15) are shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 22A), hB7-H4-his (Figure 22B), hB7-H4 IgV domain (Figure 22C), mB7-H4-Fc (Figure 22D), mB7-H4-his (Figure 22E), mB7-H4 IgV domain (Figure 22F). [Fig. 22E-22F] Binding of antibody 39A11 / 57G8 and a positive control antibody (IgV binding antibody) to B7-H4, respectively, and binding of a fusion protein containing antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15) or a fusion protein containing a positive control antibody (i.e., fusion protein (+)Ab1 / IL15) are shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 22A), hB7-H4-his (Figure 22B), hB7-H4 IgV domain (Figure 22C), mB7-H4-Fc (Figure 22D), mB7-H4-his (Figure 22E), mB7-H4 IgV domain (Figure 22F). [Figure 23A-23B] Binding of antibody 3F2 / 50A10 and a positive control antibody (IgV binding antibody) to B7-H4, respectively, and binding of a fusion protein containing antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15) or a fusion protein containing a positive control antibody (i.e., fusion protein (+)Ab1 / IL15) are shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 23A), hB7-H4-his (Figure 23B), hB7-H4 IgV domain (Figure 23C), mB7-H4-Fc (Figure 23D), mB7-H4-his (Figure 23E), mB7-H4 IgV domain (Figure 23F). [Fig. 23C-23D]Binding of antibody 3F2 / 50A10 and a positive control antibody (IgV binding antibody) to B7-H4, respectively, and binding of a fusion protein containing antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15) or a fusion protein containing a positive control antibody (i.e., fusion protein (+)Ab1 / IL15) are shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 23A), hB7-H4-his (Figure 23B), hB7-H4 IgV domain (Figure 23C), mB7-H4-Fc (Figure 23D), mB7-H4-his (Figure 23E), mB7-H4 IgV domain (Figure 23F). [Fig. 23E-23F] Binding of antibody 3F2 / 50A10 and a positive control antibody (IgV binding antibody) to B7-H4, respectively, and binding of a fusion protein containing antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15) or a fusion protein containing a positive control antibody (i.e., fusion protein (+)Ab1 / IL15) are shown. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 23A), hB7-H4-his (Figure 23B), hB7-H4 IgV domain (Figure 23C), mB7-H4-Fc (Figure 23D), mB7-H4-his (Figure 23E), mB7-H4 IgV domain (Figure 23F). [Fig. 24A-24B] 24A and 24B show binding of antibodies 3F2 / 50A10, 39A11 / 57G8 and a positive control antibody (binding to the B7-H5 IgV domain) to cells B7-H4, as well as binding of a fusion protein comprising antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15), a fusion protein comprising antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15) or a fusion protein comprising a positive control antibody (i.e., fusion protein (+)Ab1 / IL15). Flow cytometry experiments were performed to determine binding to SK-BR-3 cells expressing hB7-H4 (Figures 24A and 24B) or CT26 cells expressing mB7-H4 (Figures 24C and 24D). [Fig. 24C-24D]24A and 24B show binding of antibodies 3F2 / 50A10, 39A11 / 57G8 and a positive control antibody (binding to the B7-H5 IgV domain) to cells B7-H4, as well as binding of a fusion protein comprising antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15), a fusion protein comprising antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15) or a fusion protein comprising a positive control antibody (i.e., fusion protein (+)Ab1 / IL15). Flow cytometry experiments were performed to determine binding to SK-BR-3 cells expressing hB7-H4 (Figures 24A and 24B) or CT26 cells expressing mB7-H4 (Figures 24C and 24D). [Fig. 25A-25B] 25A and 25B) or MX-1 cells (FIGS. 25C and 25D) as determined by flow cytometry, showing the binding of antibodies 3F2 / 50A10, 39A11 / 57G8 and the negative control antibody DP47, as well as the binding of a fusion protein comprising antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15), a fusion protein comprising antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15), or a fusion protein comprising a negative control antibody (i.e., fusion protein DP47 / IL15). [Fig. 25C-25D] 25A and 25B) or MX-1 cells (FIGS. 25C and 25D) as determined by flow cytometry, showing the binding of antibodies 3F2 / 50A10, 39A11 / 57G8 and the negative control antibody DP47, as well as the binding of a fusion protein comprising antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15), a fusion protein comprising antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15), or a fusion protein comprising a negative control antibody (i.e., fusion protein DP47 / IL15). [Figure 26A-26B]Figure 26 shows tumor cell killing by antibodies 3F2 / 50A10, 39A11 / 57G8 and negative control antibody DP47, as well as tumor cell killing by fusion proteins comprising antibody 3F2 / 50A10 (i.e., fusion protein 50A10 / IL15), antibody 39A11 / 57G8 (i.e., fusion protein 57G8 / IL15) or negative control antibody (i.e., fusion protein DP47 / IL15) using an IncuCyte® immune cell killing assay. Killing of SD-BR-3 cells is shown for 3F2 / 50A10 and fusion protein 50A10 / IL15 (Figure 26A) and for 39A11 / 57G8 and fusion protein 57G8 / IL15 (Figure 26B). [Figure 26C] Killing of MDA-MB-468 cells is shown for 3F2 / 50A10 and the fusion protein 50A10 / IL15. [Figure 26D] The endpoint values of the curve shown in FIG. 26C are shown. [Figure 26E] 1 shows apoptosis of MDA-MB-468 cells following treatment with 50A10 / IL-15, 57G8 / IL-15, 57G8 and 50A1. [Figure 27A-27B] The effect of antibodies 39A11 / 57G8 and 3F2 / 50A10 and fusion proteins 57G8 / IL15 and 50A10 / IL15 on the proliferation of hPBMCs (Figure 27A) and specific CD8+ T cells (Figure 27B) and CD4+ T cells (Figure 27C) is shown. As controls, antibody DP47 and IL-15 fusion protein containing DP47 were used. [Figure 27C] The effect of antibodies 39A11 / 57G8 and 3F2 / 50A10 and fusion proteins 57G8 / IL15 and 50A10 / IL15 on the proliferation of hPBMCs (Figure 27A) and specific CD8+ T cells (Figure 27B) and CD4+ T cells (Figure 27C) is shown. As controls, antibody DP47 and IL-15 fusion protein containing DP47 were used. [Fig. 28A-28B]Figure 28 shows the ability of antibodies 39A11 / 57G8 and 3F2 / 50A10, and fusion proteins 57G8 / IL15 and 50A10 / IL115 to activate the p-STAT5 signaling pathway via the IL-2 receptor. Figure 28A shows the STAT5 signaling pathway. Figure 28B shows activation of the pathway by the indicated antibodies and fusion proteins. As controls, antibody DP47 and an IL-15 fusion protein containing DP47 were used. [Figure 29A-29B] Figure 29 shows that antibodies 39A11 / 57G8 and 3F2 / 50A10 and fusion proteins 57G8 / IL15 and 50A10 / IL15 induce antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells. Tumor cell killing is shown for SK-BR-3 cells expressing hB7-H4 (Figure 29A) and MDA-MB-468 cells expressing hB7-H4 (Figure 29B). [Fig. 30A-30B] Binding of fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS to soluble B7-H4 is shown. The "LS" mutations (M428L / N434S) in the constant region of the antibody enhance the affinity to FcRn and decrease the Koff rate at pH 6, thus resulting in an extended serum half-life. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 30A), mB7-H4-Fc (Figure 30B), hB7-H4-His (Figure 30C) and mB7-H4-his (Figure 30D). As a control, IL-15 fusion protein with DP47 was used. [Fig. 30C-30D] Binding of fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS to soluble B7-H4 is shown. The "LS" mutations (M428L / N434S) in the constant region of the antibody enhance the affinity to FcRn and decrease the Koff rate at pH 6, thus resulting in an extended serum half-life. ELISA experiments were performed to determine binding to hB7-H4-Fc (Figure 30A), mB7-H4-Fc (Figure 30B), hB7-H4-His (Figure 30C) and mB7-H4-his (Figure 30D). As a control, IL-15 fusion protein with DP47 was used. [Fig. 31A-31B] Binding of fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS to cell-bound B7-H4 is shown. Flow cytometry experiments were performed to determine binding to SK-BR-3 cells expressing hB7-H4 (FIG. 31A) or CT26 cells expressing mB7-H4 (FIG. 31B). As a control, an IL-15 fusion protein containing DP47 was used. [Diagram 32] The ability of fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS to induce proliferation of IL-2-dependent M07e cells is shown. As a control, an IL-15 fusion protein containing DP47 was used. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0064] Fusion proteins B7-H4 (also known as V-set domain-containing inhibitor of T-cell activation 1, also known as B7 homolog 4, B7h.5, immune costimulatory protein B7-H4, protein B7S1 or T cell costimulatory molecule B7x) is an immune regulatory molecule that shares homology with other B7 family members, including PD-L1. B7-H4 is a type I transmembrane protein composed of both IgV and IgC ectodomains. Although B7-H4 expression in healthy tissues is relatively limited at the protein level, B7-H4 is expressed in some solid tumors. Expression of B7-H4 in tumors tends to correlate with poor prognosis. B7-H4 has a unique structure that includes a highly glycosylated IgC domain and a very short cytoplasmic tail (Figure 1A).
[0065] In one aspect, the disclosure provides a fusion protein comprising an antibody that binds to B7-H4, or an antigen-binding fragment thereof. The portion of such a fusion protein can be any antibody, or antibody fragment thereof, that specifically binds to B7-H4, including those that include the corresponding heavy and light chain variable regions or CDRs of the antibodies provided in Table 1, Table 5, Table 7, Table 9, and Tables 16-20, or those described herein.
[0066] Disclosed herein are fusion proteins that include a stimulatory domain. As used herein, a "stimulatory domain" is a domain that promotes an immune response. The stimulatory domain may stimulate an immune response mediated, for example, by inducing activity and / or proliferation of T cells or NK cells. In an embodiment, the stimulatory domain stimulates cells that are responsive to interleukins or interferons, such as, but not limited to, IL-2, IL-7, IL-15, and IL-21. In one embodiment, the stimulatory domain binds to and stimulates a receptor that is responsive to an interleukin or interferon, such as, but not limited to, IL-2, IL-7, IL-13, IL-15, and IL-21. The stimulatory domain may also be a hybrid domain, which is a heterocomplex of two or more ligands covalently linked to each other.
[0067] In embodiments, the stimulatory domain comprises a sequence or domain that enhances IL-15 stimulation of the IL-15 receptor (IL-15R).
[0068] In one embodiment, the stimulatory domain that promotes IL-15R stimulation comprises IL-15 or an IL-15 derivative.
[0069] In one embodiment, the stimulatory domain that promotes IL-15R stimulation comprises an IL-15Rα polypeptide that comprises an IL-15Rα sushi domain or a derivative thereof. In one embodiment, the stimulatory domain comprises the sushi domain of the IL-15Rα chain.
[0070] In one embodiment, the stimulatory domain comprises IL-15 or a derivative thereof, but the binding may be enhanced by the presence of an IL-15Rα polypeptide comprising an IL-15Rα sushi domain or a derivative thereof. In one embodiment, the stimulatory domain comprises a complex of IL-15 or a derivative thereof and an IL-15Rα polypeptide comprising an IL-15Rα sushi domain or a derivative thereof. Stimulatory Domain In some embodiments, the stimulatory domain comprises IL-15 or a derivative thereof and an IL-15Rα polypeptide comprising an IL-15Rα sushi domain or a derivative thereof, where the two polypeptides are covalently linked by a linker.
[0071] In one embodiment, the IL-15 or derivative thereof is located at the N-terminus of the IL-15Rα polypeptide comprising the IL-15Rα sushi domain or a derivative thereof. In one embodiment, the IL-15 or derivative thereof is located at the C-terminus of the IL-15Rα polypeptide comprising the IL-15Rα sushi domain or a derivative thereof. In one embodiment, the stimulatory domain comprises the sequence of SEQ ID NO: 169.
[0072] Provided herein is a fusion protein comprising (1) an anti-B7H4 binding domain that blocks the binding of B7-H4 to its ligand and inhibits immune suppression, and (2) a stimulatory domain that promotes an immune response, which can enhance immune cell activity when compared to two different molecules that separately provide the aforementioned functions. Specifically, experiments disclosed herein demonstrate that a fusion protein containing a B7-H4 binding domain that blocks the binding of B7-H4 to its ligand, a stimulatory domain IL-15 or a derivative thereof, and an IL-15Rα polypeptide containing an IL-15Rα sushi domain or a derivative thereof, all kills tumor cells, induces T cell proliferation, and activates the STAT5 pathway downstream of IL-2Rβγ.
[0073] The fusion proteins provided herein may exhibit (a) blocking of binding to B7-H4 and downstream signaling events; (b) blocking of binding of B7-H4 to its cognate ligand; (c) enhancing T cell proliferation; (d) upregulation of T cell-mediated immune responses; (e) stimulation of cytokine secretion; (f) reduction of inhibitory signals via B7-H4; and / or (g) killing of tumor cells. The fusion proteins disclosed herein exhibit potent binding and inhibitory activity and are useful for therapeutic and diagnostic applications.
[0074] In certain embodiments, the fusion protein comprises a stimulatory domain disclosed herein covalently linked to an anti-B7-H4 antibody, or antigen-binding fragment thereof, disclosed herein via a flexible linker. In some embodiments, a fusion protein is provided herein, in which a stimulatory domain disclosed herein is fused directly to an anti-B7-H4 antibody, or antigen-binding fragment thereof, disclosed herein.
[0075] As used herein, "covalently linked" or "fused" refers to the association of two or more polypeptides via a covalent bond. In some embodiments, the two covalently linked polypeptides are directly fused to each other. This means that there is no additional polypeptide sequence between the first and second peptides. Thus, in some embodiments, the N-terminus of the first polypeptide is directly fused to the C-terminus of the second polypeptide, or vice versa. In other embodiments, the two covalently linked polypeptides are part of a continuous polypeptide chain but are not directly fused to each other (i.e., the two polypeptides may be separated by one or more amino acids, a linker, or another polypeptide). The term "covalently linked" does not imply a particular orientation of the two or more polypeptides fused to each other.
[0076] IL-15 is a 14-15 kDa cytokine with structural similarity to IL-2. IL-15 is also known as MGC9721. A variety of cell types constitutively produce IL-15 mRNA, including monocytes, macrophages, DCs, keratinocytes, epidermal skin cells, fibroblasts, various epithelial cells, bone marrow stromal cells, and neuronal cells. In addition, IL-15 mRNA is also produced in kidney, placenta, lung, heart, skeletal muscle, and brain tissues. However, only monocytes, DCs, epithelial cells, bone marrow stromal cells, fibroblasts, and very few other cells and tissues secrete detectable levels of IL-15. IL-15 and IL-2 have been found to bind to the same hematopoietin subunit and share many biological activities. IL-15 regulates the activation and proliferation of T cells and NK cells, and the number of CD8+ memory cells is influenced by the balance between IL-15 and IL-2. In embodiments, the IL-15 or IL-15 derivatives disclosed herein have at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the activity of human IL-15. The IL-15 can be a mammalian IL-15, preferably a primate IL-15, more preferably a human IL-15. The human IL-15 amino acid sequence is provided as SEQ ID NO: 164 (full length protein) and SEQ ID NO: 165 (mature protein).
[0077] The term "IL-15 derivative" refers to a polypeptide having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 164 (mature form of human IL-15) or SEQ ID NO: 165 (mature form of human IL-15 with N65S mutation). Techniques for making such derivatives are known in the art. In some embodiments, the IL-15 or IL-15 derivative sequence may include one or more amino acid substitutions. In embodiments, the fusion protein disclosed herein comprises an IL-15 polypeptide comprising N65S. In embodiments, the fusion protein disclosed herein comprises an IL-15 polypeptide comprising SEQ ID NO: 165.
[0078] The IL-15 receptor, i.e., the IL-15 receptor complex, specifically binds IL-15 with high affinity and consists of a unique interleukin 15 receptor α subunit, IL-2 / IL-15Rβ and a common γ-chain / IL-2Rγ subunit. IL-15Rα is expressed by mitogen-activated macrophages, NK cells and CD4+ and CD8+ T cells. Human IL-15Rα consists of seven exons and alternative mRNA splicing can result in eight molecular IL-15Rα isoforms with different extra or intracellular domains. The full-length isoform consists of an extracellular portion containing a conserved protein-binding motif (sushi domain), a transmembrane domain and an intracellular tail. As used herein, the term "sushi domain" of IL-15Rα refers to the domain that starts at the first cysteine residue (C1) after the signal peptide of IL-15Rα and ends at the fourth cysteine residue (C4) after the signal peptide. The sushi domain, which corresponds to a portion of the extracellular region of IL-15Rα, is involved in binding to IL-15. The sushi domain of the present disclosure has at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the activity of the sushi domain of the human IL-15Rα chain. The amino acid sequence of the sushi domain of human IL-15Rα is provided in SEQ ID NO:167.
[0079] The term "IL-15Rα sushi domain derivative" or "IL-15Rα sushi domain variant" refers to a polypeptide having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the sequence of the human IL-15Rα sushi domain (SEQ ID NO: 167). Techniques for making such derivatives or variants are known in the art. All such derivatives contain the four cysteine residues of the sushi domain of IL-15Rα. In some such derivatives, naturally occurring amino acids may be replaced with chemically modified amino acids to alter the half-life of the polypeptide. In some embodiments, the IL-15Rα sushi domain or IL-15Rα sushi domain derivative sequence may contain one or more amino acid substitutions.
[0080] IL-15 binds with high affinity to IL-15Rα and then associates with the IL-15Rβ complex expressed by the same target cell (cis-presentation). IL-15Rα is also known to trans-present IL-15 with high affinity to different target cells expressing the IL-15Rβ / γ(c) complex (trans-presentation). IL-15 cis-presentation and trans-presentation mechanisms result in different dynamics of receptor activation and signaling, with cis-presentation inducing a rapid and transient response and trans-presentation inducing a slower and more sustained response.
[0081] In some embodiments, the fusion proteins disclosed herein comprise a stimulatory domain comprising a hybrid domain comprising the sushi domain of the IL-15Rα chain attached to IL-15 by a linker. In certain embodiments, the stimulatory domain disclosed herein is covalently linked to an anti-B7-H4 antibody, or antigen-binding fragment thereof, disclosed herein via a second linker. In other embodiments, the stimulatory domain exemplified herein is fused directly to an anti-B7-H4 antibody, or antigen-binding fragment thereof, disclosed herein.
[0082] In one embodiment, a "C-terminal fusion protein" is provided in which a stimulatory domain is linked, either directly or via a linker (e.g., via one or more peptides) to the C-terminus of the anti-B7-H4 binding portion of the fusion protein (e.g., the C-terminus of the heavy chain of an anti-B7-H4 antibody disclosed herein).
[0083] C-terminal fusion proteins include the following (exemplary) fusion proteins (components are listed from N-terminus to C-terminus, with "-" indicating a direct covalent bond or a bond via a linker (e.g., one or more peptides): (a) (heavy chain of anti-B7-H4 antibody or antigen-binding fragment thereof)-(IL-15 or a derivative thereof) (b) (a heavy chain of an anti-B7-H4 antibody or an antigen-binding fragment thereof)-(an IL-15Rα polypeptide comprising an IL-15Rα sushi domain or a derivative thereof), and (c) (heavy chain of an anti-B7-H4 antibody or an antigen-binding fragment thereof)-(IL-15Rα polypeptide comprising an IL-15Rα sushi domain or a derivative thereof)-(IL-15 or a derivative thereof) are included, but are not limited to these.
[0084] The C-terminal fusion protein may contain two or more stimulatory domains.
[0085] In one embodiment, a fusion protein is provided in which a stimulatory domain is covalently linked to the C-terminus (and only one) of the heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof.
[0086] Provided herein is a fusion protein comprising: (1) a stimulatory domain; (2) a first heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, where the stimulatory domain is covalently linked to the C-terminus of the first heavy chain; and (3) a second heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, where the second heavy chain is not linked to the stimulatory domain. In some embodiments, the stimulatory domain comprises (i) IL-15 or a derivative thereof, or (ii) an IL-15Rα polypeptide comprising an IL-15Rα sushi domain or a derivative thereof, or (iii) both.
[0087] FIG. 1B shows a schematic diagram of a non-limiting example of a fusion protein described herein.
[0088] In one aspect, (a) an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) an IL-15Rα sushi domain polypeptide, and (c) an IL-15 polypeptide.
[0089] In one aspect, (a) an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) an IL-15Rα sushi domain polypeptide; (c) an IL-15 polypeptide, and (d) a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide.
[0090] In one aspect, (a) an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) a linker that links the anti-B7-H4 antibody, or an antigen-binding fragment thereof, to the IL-15Rα sushi domain polypeptide; (c) an IL-15Rα sushi domain polypeptide; (d) a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and (e) a fusion protein comprising an IL-15 polypeptide is provided.
[0091] In one aspect, (a) an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; and (c) an IL-15 polypeptide comprising SEQ ID NO:166, or an amino acid sequence which is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:166.
[0092] In one aspect, (a) an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence which is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; (c) an IL-15 polypeptide comprising SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166, and (d) a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide.
[0093] In one embodiment, from the N-terminus to the C-terminus: (a) the variable heavy chain of an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) constant heavy chain, (c) an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence which is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; (d) a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and (e) A fusion protein comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166.
[0094] In one embodiment, from the N-terminus to the C-terminus: (a) the variable heavy chain of an anti-B7-H4 antibody or an antigen-binding fragment thereof; (b) constant heavy chain, (c) a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; (d) an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; (e) a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and (f) A fusion protein comprising an IL-15R polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166.
[0095] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, and b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0096] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, and b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0097] In one embodiment, (a) From the N-terminus to the C-terminus, a. a first variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof; b. a first constant heavy chain; c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first heavy chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; (b) From the N-terminus to the C-terminus, a. a second variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, and b. a second heavy chain comprising a second constant heavy chain; (c) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, and b. a constant light chain; Optionally, a fusion protein is provided, wherein the first constant heavy chain and the second constant heavy chain comprise one or more modifications that result in heterodimerization.
[0098] In one embodiment, (a) From the N-terminus to the C-terminus, a. a first variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof; b. a first constant heavy chain; c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first heavy chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. a second variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, and b. a second heavy chain comprising a second constant heavy chain; (c) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, and b. a constant light chain; Optionally, a fusion protein is provided, wherein the first constant heavy chain and the second constant heavy chain comprise one or more modifications that result in heterodimerization.
[0099] In one embodiment, the IL-15Rα sushi domain polypeptide comprises SEQ ID NO: 167. In one embodiment, the IL-15Rα sushi domain polypeptide consists of SEQ ID NO:167.
[0100] In one embodiment, the IL-15 polypeptide comprises SEQ ID NO: 166. In one embodiment, the IL-15 polypeptide consists of SEQ ID NO:166.
[0101] In one embodiment, the linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide comprises SEQ ID NO: 168. In one embodiment, the linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide consists of SEQ ID NO:168.
[0102] In one embodiment, the fusion protein comprises SEQ ID NO:169.
[0103] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region being a fusion protein comprising CDR1, CDR2 and CDR3.
[0104] In one embodiment, the fusion protein comprises an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 73, CDR2L comprises SEQ ID NO: 74, and CDR3L comprises SEQ ID NO: 75.
[0105] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 20, CDR2L comprises SEQ ID NO: 21, and CDR3L comprises SEQ ID NO: 22.
[0106] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 66, CDR2L comprises SEQ ID NO: 67, and CDR3L comprises SEQ ID NO: 68.
[0107] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72.
[0108] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 84, CDR2L comprises SEQ ID NO: 85, and CDR3L comprises SEQ ID NO: 86.
[0109] Provided herein is a fusion protein comprising a B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 8, CDR2L comprises SEQ ID NO: 9, and CDR3L comprises SEQ ID NO: 10.
[0110] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 77, CDR2L comprises SEQ ID NO: 78, and CDR3L comprises SEQ ID NO: 79.
[0111] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 81, CDR2L comprises SEQ ID NO: 82, and CDR3L comprises SEQ ID NO: 83.
[0112] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:19, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:19.
[0113] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:65, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:65.
[0114] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:69, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69.
[0115] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3, and the light chain variable region comprises SEQ ID NO:7, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:7.
[0116] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3, and the light chain variable region comprises SEQ ID NO:76, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:76.
[0117] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3, and the light chain variable region comprises SEQ ID NO:80, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:80.
[0118] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:19.
[0119] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:65.
[0120] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:69.
[0121] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3 and the light chain variable region comprises SEQ ID NO:7.
[0122] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3 and the light chain variable region comprises SEQ ID NO:76.
[0123] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3 and the light chain variable region comprises SEQ ID NO:80.
[0124] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3.
[0125] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 111, CDR2L comprises SEQ ID NO: 112, and CDR3L comprises SEQ ID NO: 113.
[0126] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 50, CDR2L comprises SEQ ID NO: 51, and CDR3L comprises SEQ ID NO: 52.
[0127] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 88, CDR2L comprises SEQ ID NO: 89, and CDR3L comprises SEQ ID NO: 90.
[0128] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 92, CDR2L comprises SEQ ID NO: 93, and CDR3L comprises SEQ ID NO: 94.
[0129] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 96, CDR2L comprises SEQ ID NO: 97, and CDR3L comprises SEQ ID NO: 98.
[0130] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 100, CDR2L comprises SEQ ID NO: 101, and CDR3L comprises SEQ ID NO: 102.
[0131] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 104, CDR2L comprises SEQ ID NO: 105, and CDR3L comprises SEQ ID NO: 106.
[0132] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 108, CDR2L comprises SEQ ID NO: 109, and CDR3L comprises SEQ ID NO: 110.
[0133] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:49, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:49.
[0134] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:87, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:87.
[0135] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:91, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:91.
[0136] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:95, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:95.
[0137] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:99, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:99.
[0138] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:103, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:103.
[0139] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:107, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:107.
[0140] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:49.
[0141] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:87.
[0142] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:91.
[0143] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:95.
[0144] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:99.
[0145] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:103.
[0146] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:107.
[0147] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3.
[0148] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:134, CDR2L comprises SEQ ID NO:135, and CDR3L comprises SEQ ID NO:136.
[0149] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:62, CDR2L comprises SEQ ID NO:63, and CDR3L comprises SEQ ID NO:64.
[0150] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:115, CDR2L comprises SEQ ID NO:116, and CDR3L comprises SEQ ID NO:117.
[0151] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:119, CDR2L comprises SEQ ID NO:120, and CDR3L comprises SEQ ID NO:121.
[0152] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:123, CDR2L comprises SEQ ID NO:124, and CDR3L comprises SEQ ID NO:125.
[0153] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:127, CDR2L comprises SEQ ID NO:128, and CDR3L comprises SEQ ID NO:129.
[0154] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:131, CDR2L comprises SEQ ID NO:132, and CDR3L comprises SEQ ID NO:133.
[0155] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:61, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:61.
[0156] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:114, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:114.
[0157] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:118, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118.
[0158] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:122, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:122.
[0159] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:126, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:126; or
[0160] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:130, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:130.
[0161] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:61.
[0162] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:114.
[0163] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:118.
[0164] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:122.
[0165] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:126.
[0166] Provided herein is a fusion protein comprising an anti-B7-H4 antibody, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:130.
[0167] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising CDR1H, CDR2H, and CDR3H, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, and CDR3H comprises SEQ ID NO: 18; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, comprising CDR1L, CDR2L and CDR3L, wherein CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71 and CDR3L comprises SEQ ID NO: 72; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0168] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising CDR1H, CDR2H, and CDR3H, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, and CDR3H comprises SEQ ID NO: 18; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, comprising CDR1H, CDR2H and CDR3H, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17 and CDR3H comprises SEQ ID NO: 18; and b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0169] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising CDR1H, CDR2H, and CDR3H, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, and CDR3H comprises SEQ ID NO: 48; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. a variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, comprising a variable light chain, a CDR1L, a CDR2L, and a CDR3L, wherein CDR1L comprises SEQ ID NO: 108, CDR2L comprises SEQ ID NO: 109, and CDR3L comprises SEQ ID NO: 110; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0170] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising CDR1H, CDR2H, and CDR3H, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, and CDR3H comprises SEQ ID NO: 48; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. a variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, comprising a variable light chain, a CDR1L, a CDR2L, and a CDR3L, wherein CDR1L comprises SEQ ID NO: 108, CDR2L comprises SEQ ID NO: 109, and CDR3L comprises SEQ ID NO: 110; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0171] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising CDR1H, CDR2H, and CDR3H, wherein CDR1H comprises SEQ ID NO: 58, CDR2H comprises SEQ ID NO: 59, and CDR3H comprises SEQ ID NO: 60; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15Rα sushi domain polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, comprising CDR1L, CDR2L, and CDR3L, wherein CDR1L comprises SEQ ID NO: 119, CDR2L comprises SEQ ID NO: 120, and CDR3L comprises SEQ ID NO: 121; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0172] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising CDR1H, CDR2H, and CDR3H, wherein CDR1H comprises SEQ ID NO: 58, CDR2H comprises SEQ ID NO: 59, and CDR3H comprises SEQ ID NO: 60; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody or antigen-binding fragment thereof, comprising CDR1L, CDR2L, and CDR3L, wherein CDR1L comprises SEQ ID NO: 119, CDR2L comprises SEQ ID NO: 120, and CDR3L comprises SEQ ID NO: 121; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0173] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:15, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising SEQ ID NO:69, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0174] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:15, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable light chain of an anti-B7-H4 antibody, or antigen-binding fragment thereof, comprising SEQ ID NO:69, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0175] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:45, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:107, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:107; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0176] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:45, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:107, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:107; b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0177] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:57, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57; b. constant heavy chain, c. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; d. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and e. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 166, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:118, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118; and b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0178] In one embodiment, (a) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:57, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57; b. constant heavy chain, c. a linker connecting the constant heavy chain and the IL-15Rα sushi domain polypeptide; d. an IL-15Rα sushi domain polypeptide, wherein the IL-15Rα sushi domain polypeptide comprises an amino acid sequence set forth in SEQ ID NO:167, or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; e. a linker linking the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide; and f. a first chain comprising an IL-15 polypeptide, wherein the IL-15 polypeptide comprises SEQ ID NO: 166, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; and (b) From the N-terminus to the C-terminus, a. the variable heavy chain of an anti-B7-H4 antibody or antigen-binding fragment thereof comprising SEQ ID NO:118, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118; and b. a constant light chain; and Optionally, a fusion protein is provided in which the constant heavy chain comprises one or more modifications that result in heterodimerization.
[0179] In one embodiment, (a) a light chain comprising SEQ ID NO:69, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69, and / or SEQ ID NO:145, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:145; (b) a first heavy chain comprising an amino acid sequence of SEQ ID NO:150, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:150; and (c) a second heavy chain comprising SEQ ID NO:157, or an amino acid sequence which is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:157.
[0180] In one embodiment, (a) a light chain comprising SEQ ID NO:69, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69, and / or SEQ ID NO:145, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:145; (b) a first heavy chain comprising an amino acid sequence of SEQ ID NO:151, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:151; and (c) a second heavy chain comprising SEQ ID NO:158, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:158.
[0181] In one embodiment, (a) a light chain comprising SEQ ID NO:118, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118, and / or SEQ ID NO:144, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:144; (b) a first heavy chain comprising an amino acid sequence of SEQ ID NO:148, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:148; and (c) a second heavy chain comprising SEQ ID NO:155, or an amino acid sequence which is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:155.
[0182] In one embodiment, (a) a light chain comprising SEQ ID NO:118, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118, and / or SEQ ID NO:144, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:144; (b) a first heavy chain comprising an amino acid sequence of SEQ ID NO:149, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:149; and (c) a second heavy chain comprising SEQ ID NO:156, or an amino acid sequence which is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:156.
[0183] In one embodiment, (a) a light chain comprising SEQ ID NO: 69 and / or SEQ ID NO: 145; (b) a first heavy chain comprising SEQ ID NO: 150; and (c) a second heavy chain comprising SEQ ID NO: 157.
[0184] In one embodiment, (a) a light chain comprising SEQ ID NO: 69 and / or SEQ ID NO: 145; (b) a first heavy chain comprising SEQ ID NO: 151; and (c) a second heavy chain comprising SEQ ID NO: 158.
[0185] In one embodiment, (a) a light chain comprising SEQ ID NO: 118 and / or SEQ ID NO: 144; and (b) a first heavy chain comprising SEQ ID NO: 148; and (c) a second heavy chain comprising SEQ ID NO: 155.
[0186] In one embodiment, (a) a light chain comprising SEQ ID NO: 118 and / or SEQ ID NO: 144; and (b) a first heavy chain comprising SEQ ID NO: 149; and (c) a second heavy chain comprising SEQ ID NO: 156.
[0187] In one embodiment, (a) a light chain comprising SEQ ID NO: 145; and (b) a first heavy chain comprising SEQ ID NO: 150; and (c) a second heavy chain comprising SEQ ID NO: 157.
[0188] Provided herein are fusion proteins comprising one or more sequences disclosed in Table 13, Table 21 or Table 22.
[0189] Antibodies and antigen-binding fragments thereof The term antibody is used herein in the broadest sense and includes monoclonal antibodies (full-length or intact monoclonal antibodies), polyclonal antibodies, bispecific antibodies, humanized antibodies, single-chain antibodies, chimeric antibodies, synthetic antibodies, recombinant antibodies, hybrid antibodies, mutated and grafted antibodies (grafted antibodies), bispecific antibodies, specific antibody portions (e.g., domain antibodies), and any antigen-binding portion thereof that competes with the intact antibody for specific binding, antigen-binding portions thereof (e.g., paratopes, CDRs), and any other modified conformation of an immunoglobulin molecule that contains an antigen recognition site, provided that it exhibits the desired biological activity and specificity. Thus, an antibody is an immunoglobulin molecule, or a fragment or derivative thereof, that comprises any polypeptide that contains an antigen-binding site that is capable of specifically binding to a target via at least one antigen recognition site located in the variable region of the immunoglobulin molecule. The disclosed antibodies can be of murine, rat, human, or any other origin (including chimeric or humanized antibodies).
[0190] In certain embodiments, the framework regions of an antibody (or antigen-binding fragment thereof) can be identical to human germline sequences, or can be naturally or artificially modified.
[0191] In a preferred embodiment, the disclosed antibody structure belongs to the IgG class of immunoglobulin molecules. A standard IgG immunoglobulin molecule comprises two identical light chain polypeptides and two identical heavy chain polypeptides. The molecular weight of the light chain polypeptide is approximately 23,000 daltons, while the molecular weight of the heavy chain polypeptide varies between 53,000 and 70,000 daltons. The four chains are typically linked by disulfide bonds in a "Y" configuration.
[0192] The two heavy chains (HC) and two light chains (LC) of an immunoglobulin molecule are covalently linked to each other, and the terminal portions of the two heavy chains are linked to each other by covalent disulfide bonds or non-covalent bonds when the immunoglobulin is produced by either a hybridoma, a B cell, or a genetically modified host cell. Both the light and heavy chains contain regions that are structurally and functionally homologous. The terms "variable" and "constant" are used functionally. Each heavy chain is composed of a heavy chain variable region ("HCVR" or "VH") and a heavy chain constant region (composed of domains CH1, CH2, and CH3). Each light chain is composed of a light chain variable region ("LCVR" or "VL") and a light chain constant region (CL). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0193] The variable region allows the antibody to recognize and specifically bind to an epitope located on an antigen. Both the variable light (VL) and variable heavy (VH) domain portions determine antigen recognition and specificity. The antigen-binding site of an antibody is composed of the VL and VH domains, or a subset of CDRs. More specifically, the antigen-binding site is defined by one, two or three CDRs in the VH and VL chains, respectively (i.e., CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3). Conversely, the constant light chain domain (CL) and the constant heavy chain domain (CH1, CH2 or CH3) provide biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, etc. By convention, the numbering of the constant region domains increases as these domains become more distal from the antigen-binding site or amino terminus of the antibody.
[0194] As used herein, "complementarity determining region" (CDR) refers to the portion of an antibody variable domain that is (typically) involved in antigen binding. Each variable region has three non-contiguous CDRs, known as CDR1, CDR2 and CDR3. The CDRs are separated by structurally conserved regions called framework regions (FR-1, FR-2, FR-3 and FR-4), which form a "core" β-sheet structure that displays loops on the surface of the variable domain. When the antibody assumes its three-dimensional configuration in an aqueous environment, the six CDRs present in each antigen-binding domain are short, non-contiguous sequences of amino acids that are specifically arranged to form the antigen-binding domain. The length and composition of the CDR sequences are highly variable, especially in CDR3. The remainder of the amino acids located in the antigen-binding domain or "framework" regions show little inter-molecular variation. The antigen-binding domain formed by the arranged CDRs defines a surface that is complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to its cognate epitope. Each CDR comprises, for example, the amino acid residues of the CDRs as defined by Kabat (i.e., for the light chain variable domain, residues 24-34 (L1), 50-56 (L2), and 89-97 (L3), and for the heavy chain variable domain, residues 31-35 (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, 2001). Health, Bethesda, Md. (1987, 1991)). Each CDR may also include amino acid residues of a "hypervariable loop" (i.e., for residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain, and for residues 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain (Chothia & Lesk 196 J. Mol. Biol. 901 (1987)). In some instances, a CDR may include amino acids from both the CDR regions and the hypervariable loops as defined by Kabat.The Kabat numbering may not always correspond to the linear numbering on the amino acid residues due to truncations or insertions of either the framework or CDR structural components of the basic variable domain structure. The exact Kabat numbering of residues can be determined for a given antibody or antigen-binding fragment thereof by alignment of the homologous residues of the sequence of the antibody or antigen-binding fragment thereof with the "standard" Kabat numbered sequence, or defined according to the ImMunoGeneTics (IMGT) system (Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003)).
[0195] As used herein, the terms "antigen-binding portion" or "antigen-binding fragment" can be fragments including Fab, Fab', F(ab')2, Fd, Fv, domain antibodies (dAbs such as shark antibodies and camel antibodies), ScFv, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv, or polypeptides that contain at least a certain portion of an immunoglobulin sufficient to confer specific antigen binding to the polypeptide.
[0196] The antibody may be of any class, IgG, IgA or IgM (or subclasses thereof), and the antibody need not be of any particular class but may include immunoglobulin molecules containing an antigen recognition site of the required specificity, other modified configurations, including glycosylation variants of the antibody, amino acid sequence variants of the antibody, and covalently modified antibodies. Modified versions of each of these classes and isotypes are known to those of skill in the art and, accordingly, are within the scope of the present disclosure.
[0197] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is a Fab fragment, which comprises or consists essentially of the variable domain (VL) and constant domain (CL) of the light chain, and the variable domain (VH) and the first constant domain (CH1) of the heavy chain.
[0198] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is a Fab' fragment, which refers to a Fab fragment having one or more cysteine residues at the C-terminus of the CH1 domain.
[0199] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is an Fd fragment comprising or consisting essentially of a VH domain and a CH1 domain.
[0200] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is an Fd' fragment that includes the VH and CH1 domains, and one or more cysteine residues at the C-terminus of the CH1 domain.
[0201] A single-chain Fv or scFv antibody fragment comprises or consists essentially of the VH and VL domains of an antibody, wherein the domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. Thus, in some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is an Fv fragment comprising or consisting essentially of the VL and VH domains of a single arm of an antibody.
[0202] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is a diabody comprising two antigen-binding sites comprising a heavy chain variable domain (VH) linked to a light chain variable domain (VL) on the same polypeptide chain.
[0203] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is a dAb fragment that comprises or consists essentially of a VH domain.
[0204] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is a F(ab')2 fragment, which comprises a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge in the hinge region.
[0205] In some embodiments of the aspects described herein, the anti-B7-H4 antibody fragment is a linear antibody comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) that form, together with complementary light chain polypeptides, a pair of antigen-binding regions.
[0206] Those skilled in the art can use various techniques that have been developed and are available for the production of antibody fragments. Traditionally, these fragments have been derived by proteolytic digestion of intact antibodies. However, F(ab')2 fragments can be directly isolated from recombinant host cell cultures. Other techniques for producing antibody fragments will be apparent to those skilled in the art. In other embodiments, the antibody fragment selected is a single chain Fv fragment (scFv). See, for example, WO 93 / 16185. Alternatively, these fragments can also be directly produced by recombinant host cells. For example, antibody fragments can be isolated from antibody phage libraries described herein. In another approach, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (Carter et al., 1992).
[0207] In one embodiment, the antibody is a bispecific antibody that contains a complementary region that binds to B7-H4.
[0208] Contemplated antibodies or antigen-binding fragments may have all types of constant regions, including IgM, IgG, IgD, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4. In one embodiment, the isotype is human IgG1. In another embodiment, human isotype IgG4 is used. The light chain constant region may be lambda or kappa. An antibody, or antigen-binding fragment thereof, may contain sequences from more than one class or isotype.
[0209] The present disclosure describes antibodies and antigen-binding fragments thereof that bind B7-H4, and fusion proteins comprising such anti-B7-H4 antibodies or B7-H4-binding fragments thereof. Terms such as "B7-H4" refer to V-set domain-containing T-cell activation inhibitor 1 (VTCN1), also known as B7 homolog 4, B7h.5, immune costimulatory protein B7-H4, protein B7S1, or T cell costimulatory molecule B7x. The sequence of human B7-H4 is provided in SEQ ID NO: 161. The sequence of mouse B7-H4 is provided in SEQ ID NO: 162. Terms such as B7-H4 encompass recombinant B7-H4 and / or fragments thereof. The term also includes B7-H4, or fragments thereof, that are bound to, for example, mouse or human Fc, histidine tags, and / or signal sequences. The term may further encompass fusion proteins comprising B7-H4.
[0210] In embodiments, the anti-B7-H4 antibodies or antigen-binding fragments thereof, or fusion proteins comprising the anti-B7-H4 antibodies or antigen-binding fragments thereof, specifically bind to B7-H4 and counteract B7-H4-mediated immune suppression. The anti-B7-H4 antibodies and antigen-binding fragments thereof disclosed herein (as well as fusion proteins comprising such anti-B7-H4 antibodies and antigen-binding fragments thereof) may interfere with, inhibit, or attenuate B7-H4 biological activity, including downstream events mediated by B7-H4. The anti-B7-H4 antibodies and antigen-binding fragments thereof disclosed herein (as well as fusion proteins comprising such anti-B7-H4 antibodies and antigen-binding fragments thereof) may exhibit any one or more of the following characteristics: (a) blocking binding to B7-H4 and downstream signaling events; (b) blocking binding of B7-H4 to its cognate ligand; (c) enhancing T cell proliferation; (d) upregulating T cell-mediated immune responses; (e) stimulating cytokine secretion; (f) reducing inhibitory signals via B7-H4; and / or (g) killing of tumor cells. The anti-B7-H4 antibodies and antigen-binding fragments thereof disclosed herein (as well as fusion proteins comprising such anti-B7-H4 antibodies and antigen-binding fragments thereof) exhibit potent binding and inhibitory activity and are useful for therapeutic and diagnostic applications.
[0211] In one aspect, the disclosure provides antibodies and antigen-binding fragments thereof that bind to B7-H4 (as well as fusion proteins comprising such anti-B7-H4 antibodies and antigen-binding fragments thereof). In certain embodiments, the disclosure provides bispecific antibodies and binding proteins that specifically bind to B7-H4 and at least one other molecule.
[0212] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3.
[0213] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 73, CDR2L comprises SEQ ID NO: 74, and CDR3L comprises SEQ ID NO: 75.
[0214] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 20, CDR2L comprises SEQ ID NO: 21, and CDR3L comprises SEQ ID NO: 22.
[0215] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 66, CDR2L comprises SEQ ID NO: 67, and CDR3L comprises SEQ ID NO: 68.
[0216] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72.
[0217] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 84, CDR2L comprises SEQ ID NO: 85, and CDR3L comprises SEQ ID NO: 86.
[0218] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 8, CDR2L comprises SEQ ID NO: 9, and CDR3L comprises SEQ ID NO: 10.
[0219] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 77, CDR2L comprises SEQ ID NO: 78, and CDR3L comprises SEQ ID NO: 79.
[0220] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 81, CDR2L comprises SEQ ID NO: 82, and CDR3L comprises SEQ ID NO: 83.
[0221] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72.
[0222] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 172, CDR2H comprises SEQ ID NO: 173, CDR3H comprises SEQ ID NO: 174, CDR1L comprises SEQ ID NO: 175, CDR2L comprises SEQ ID NO: 176, and CDR3L comprises SEQ ID NO: 177.
[0223] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 178, CDR2H comprises SEQ ID NO: 179, CDR3H comprises SEQ ID NO: 180, CDR1L comprises SEQ ID NO: 181, CDR2L comprises SEQ ID NO: 182, and CDR3L comprises SEQ ID NO: 183.
[0224] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 184, CDR2H comprises SEQ ID NO: 185, CDR3H comprises SEQ ID NO: 186, CDR1L comprises SEQ ID NO: 187, CDR2L comprises SEQ ID NO: 188, and CDR3L comprises SEQ ID NO: 189.
[0225] Anti-B7-H4 antibodies, or antigen-binding fragments thereof, are provided, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:19, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:19.
[0226] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:65, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:65.
[0227] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:69, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69.
[0228] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3, and the light chain variable region comprises SEQ ID NO:7, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:7.
[0229] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3, and the light chain variable region comprises SEQ ID NO:76, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:76.
[0230] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3, and the light chain variable region comprises SEQ ID NO:80, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:80.
[0231] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:19.
[0232] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:65.
[0233] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:15 and the light chain variable region comprises SEQ ID NO:69.
[0234] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3 and the light chain variable region comprises SEQ ID NO:7.
[0235] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3 and the light chain variable region comprises SEQ ID NO:76.
[0236] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:3 and the light chain variable region comprises SEQ ID NO:80.
[0237] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3.
[0238] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 111, CDR2L comprises SEQ ID NO: 112, and CDR3L comprises SEQ ID NO: 113.
[0239] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 50, CDR2L comprises SEQ ID NO: 51, and CDR3L comprises SEQ ID NO: 52.
[0240] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 88, CDR2L comprises SEQ ID NO: 89, and CDR3L comprises SEQ ID NO: 90.
[0241] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 92, CDR2L comprises SEQ ID NO: 93, and CDR3L comprises SEQ ID NO: 94.
[0242] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 96, CDR2L comprises SEQ ID NO: 97, and CDR3L comprises SEQ ID NO: 98.
[0243] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 100, CDR2L comprises SEQ ID NO: 101, and CDR3L comprises SEQ ID NO: 102.
[0244] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 104, CDR2L comprises SEQ ID NO: 105, and CDR3L comprises SEQ ID NO: 106.
[0245] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO: 46, CDR2H comprises SEQ ID NO: 47, CDR3H comprises SEQ ID NO: 48, CDR1L comprises SEQ ID NO: 108, CDR2L comprises SEQ ID NO: 109, and CDR3L comprises SEQ ID NO: 110.
[0246] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:49, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:49.
[0247] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:87, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:87.
[0248] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:91, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:91.
[0249] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:95, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:95.
[0250] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:99, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:99.
[0251] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:103, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:103.
[0252] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:107, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:107.
[0253] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:49.
[0254] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:87.
[0255] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:91.
[0256] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:95.
[0257] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:99.
[0258] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:103.
[0259] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:45 and the light chain variable region comprises SEQ ID NO:107.
[0260] In one aspect, an anti-B7-H4 antibody or antigen-binding fragment thereof is provided, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3.
[0261] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:134, CDR2L comprises SEQ ID NO:135, and CDR3L comprises SEQ ID NO:136.
[0262] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:62, CDR2L comprises SEQ ID NO:63, and CDR3L comprises SEQ ID NO:64.
[0263] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:115, CDR2L comprises SEQ ID NO:116, and CDR3L comprises SEQ ID NO:117.
[0264] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:119, CDR2L comprises SEQ ID NO:120, and CDR3L comprises SEQ ID NO:121.
[0265] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:123, CDR2L comprises SEQ ID NO:124, and CDR3L comprises SEQ ID NO:125.
[0266] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:127, CDR2L comprises SEQ ID NO:128, and CDR3L comprises SEQ ID NO:129.
[0267] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein CDR1H comprises SEQ ID NO:58, CDR2H comprises SEQ ID NO:59, CDR3H comprises SEQ ID NO:60, CDR1L comprises SEQ ID NO:131, CDR2L comprises SEQ ID NO:132, and CDR3L comprises SEQ ID NO:133.
[0268] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:61, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:61.
[0269] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:114, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:114.
[0270] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:118, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:118.
[0271] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:122, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:122.
[0272] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:126, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:126; or
[0273] Provided herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, wherein the heavy chain variable region comprises SEQ ID NO:57, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:130, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:130.
[0274] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:61.
[0275] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:114.
[0276] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:118.
[0277] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:122.
[0278] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:126.
[0279] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:130.
[0280] Tables 5, 7, 9, 16-20 and 24 show the heavy and light chain variable regions and associated CDRs of the antibodies disclosed herein as set forth in the attached sequence listing, which is incorporated herein in its entirety. As shown in the Examples below, light chain shuffling of anti-B7-H4 antibodies led to the identification of antibody variants that provided substantial improvements in B7-H4 binding affinity. Analysis of the variants revealed certain CDR positions that remained relatively unchanged in amino acids among the light chain shuffled antibodies, and other CDR positions where mutations could be introduced without abolishing B7-H4 binding.
[0281] The anti-B7-H4 antibodies and antigen-binding fragments thereof disclosed herein, as well as the fusion proteins disclosed herein, can have one or more amino acid substitutions, deletions, insertions, and / or additions. In some embodiments, one or more CDR residues or one or more framework residues of the anti-B7-H4 antibodies or antigen-binding fragments thereof disclosed herein (or fusion proteins comprising the anti-B7-H4 antibodies or antigen-binding fragments thereof) are altered with amino acid substitutions, deletions, insertions, and / or additions. The amino acid substitutions can be conservative or non-conservative substitutions. The present disclosure also includes anti-B7-H4 antibodies and antigen-binding fragments thereof (as well as fusion proteins comprising the anti-B7-H4 antibodies or antigen-binding fragments thereof) derived from the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue in the germline sequence from which the antibody is derived, to the corresponding residue in another human germline sequence, or to a conserved amino acid substitution of the corresponding germline residue (such sequence changes are collectively referred to herein as "germline mutations"). In certain embodiments, an anti-B7-H4 antibody, or binding fragment thereof (or a fusion protein comprising an anti-B7-H4 antibody or antigen-binding fragment) comprises one or more CDRs, or one or more variable domains, having an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% identical to the CDR and / or variable domain sequences set forth in Table 5, Table 7, Table 9, Tables 16-20, or Table 24.
[0282] Also provided herein are variable heavy and light chain sequences (and pairs thereof) similar, but not identical, to the variable heavy and light chains (and pairs thereof) disclosed in Tables 16-20. It will be apparent that any of the frameworks described herein may be utilized in combination with any of the CDRs and CDR motifs described herein. In some embodiments, the anti-B7-H4 antibodies, or antigen-binding fragments thereof, utilize the frameworks described in Tables 16-20.
[0283] Also provided herein are chimeric antigen receptors (CARs) that include one, two, three, four, five, or six CDRs of the anti-B7-H4 antibodies and antigen-binding fragments disclosed herein. Also provided herein are CARs that include six CDRs of any one of the anti-B7-H4 antibodies and antigen-binding fragments disclosed herein.
[0284] Disclosed are immune cells expressing a CAR comprising one, two, three, four, five or six CDRs of the anti-B7-H4 antibodies and antigen-binding fragments disclosed herein. Disclosed are immune cells expressing a CAR comprising six CDRs of any one of the anti-B7-H4 antibodies and antigen-binding fragments disclosed herein. In some embodiments, the immune cell is a T cell.
[0285] "Identity" refers to the number or percentage of identical positions shared by two amino acid or nucleic acid sequences in optimally aligned sequences, after taking into account the number and length of each gap necessary for optimal alignment. "Substantially identical" means an amino acid sequence that differs from the original sequence only by conservative amino acid substitutions that do not disrupt protein function.
[0286] Also disclosed herein are anti-B7-H4 antibodies, or antigen-binding fragments thereof, or fusion proteins comprising an amino acid sequence that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 98%, or at least 99% identical to an amino acid sequence disclosed herein. Methods and computer programs for determining sequence similarity are publicly available, including, but not limited to, the GCG program package (Devereux et al., Nucleic Acids Research 12:387, 1984), BLASTP, BLASTN, FASTA (Altschul et al., J. Mol. Biol. 215:403 (1990) and the ALIGN program (version 2.0). The Smith Waterman algorithm may also be used to determine similarity. BLAST programs are conveniently available from NCBI and other sources (BLAST Manual, Altschul, et al., NCBI NLM NIH, Bethesda, Md. 20894; http: / / www.ncbi.nlm.nih.gov / blast / (BLAST2.0)). In comparing sequences, these methods account for various substitutions, deletions and other modifications.
[0287] Some embodiments of the aspects described herein contemplate amino acid sequence modifications of an antibody or antigen-binding fragment thereof that binds B7-H4, or a fusion protein that binds B7-H4 as described herein. Amino acid sequence variants of an anti-B7-H4 antibody or antigen-binding fragment thereof, or a fusion protein are prepared by introducing appropriate nucleotide changes into a nucleic acid encoding the anti-B7-H4 antibody or antigen-binding fragment thereof, or a fusion protein, or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the antibody or antigen-binding fragment thereof. Any combination of deletions, insertions, and substitutions may be made to arrive at the final construct, provided that the final construct retains the desired properties, e.g., binding specificity, reduced biological activity, etc.
[0288] Amino acid substitutions may be made, in some cases, by selecting substitutions that are not significantly different in their effect on maintaining (a) the structure of the peptide backbone in the region of substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain (conservative amino acid substitution variants). These variants have at least one amino acid residue of an antibody, or antigen-binding fragment thereof, or fusion protein replaced with a different residue having similar side chain properties. Amino acids may be classified according to similarities in the properties of their side chains (see Lehninger, BIOCHEMISTRY (2nd ed., Worth Publishers, New York, 1975): (1) Non-polar: Ala(A), Val(V), Leu(L), Ile(I), Pro(P), Phe(F), Trp(W), Met(M); (2) uncharged but polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) Acidic: Asp(D), Glu(E); (4) Basic: Lys(K), Arg(R), His(H).
[0289] Thus, a non-limiting example of a conservative amino acid substitution is the replacement of a non-polar amino acid with another non-polar amino acid.
[0290] Alternatively, naturally occurring residues can be selected based on common side chain properties, such as: (1) Hydrophobicity: Ala(A), Val(V), Leu(L), Ile(I), Met(M); (2) Hydrophilic neutrality: Ser(S), Thr(T), Cys(C), Asn(N), Gln(Q); (3) Acidic: Asp(D), Glu(E); (4) Basic: Lys(K), Arg(R), His(H); (5) Residues that affect chain orientation: Gly (G), Pro (P); (6) Aromatic: Phe(F), Trp(W), Tyr(Y).
[0291] Substitutions made within these groups may be considered to be conservative substitutions. Non-limiting examples of substitutions include alanine for valine, arginine for lysine, asparagine for glutamine, aspartic acid for glutamic acid, cysteine for serine, glutamine for asparagine, glutamic acid for aspartic acid, glycine for proline, histidine for arginine, isoleucine for leucine, lysine for arginine, methionine for leucine, phenylalanine for leucine, proline for glycine, serine for threonine, serine for threonine, tryptophan for tyrosine, phenylalanine for tyrosine, and / or valine for leucine.
[0292] Amino acid sequence insertions which may include amino- and / or carboxyl-terminal fusions ranging in length from one base to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues, are further contemplated.
[0293] Examples of terminal fusions include an antibody, or antigen-binding fragment thereof, with an N-terminal methionyl residue, or an antibody, or antigen-binding fragment thereof, fused to a cytotoxic polypeptide (or a fusion protein comprising such an antibody or antigen-binding fragment thereof). Other examples of terminal fusions of an antibody, or antigen-binding fragment thereof, include fusions to the N-terminus or C-terminus of the antibody, or antigen-binding fragment thereof, or fusions to an enzyme or a polypeptide (e.g., biotin) that increases the serum half-life of the antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody, or antigen-binding fragment thereof).
[0294] In some embodiments, an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody or antigen-binding fragment thereof) comprises a modification (including, but not limited to, an amino acid modification or substitution) that enhances the affinity of the anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody or antigen-binding fragment thereof) for FcRn. In some embodiments, an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody or antigen-binding fragment thereof) comprises an M428L amino acid substitution (EU index numbering as per Kabat). In some embodiments, an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody or antigen-binding fragment thereof) comprises an N434S amino acid substitution (EU index numbering as per Kabat). In some embodiments, an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody or antigen-binding fragment thereof) comprises an M428L and an N434S amino acid substitution (EU index numbering as per Kabat).
[0295] Any cysteine residue not involved in maintaining the proper conformation of an antibody, or antigen-binding fragment thereof, that binds B7-H4 also can be substituted, for example with serine or alanine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking.
[0296] Conversely, cysteine bond(s) can be added to an anti-B7-H4 antibody, or antigen-binding fragment thereof, to improve its stability (particularly where the anti-B7-H4 antibody, or antigen-binding fragment thereof, is an antibody fragment such as an Fv fragment).
[0297] In some embodiments, an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, described herein) has amino acid changes that alter the original glycosylation pattern of the anti-B7-H4 antibody, or antigen-binding fragment thereof. "Altering the original glycosylation pattern" means deleting one or more carbohydrate moieties found in the antibody, or antigen-binding fragment thereof, and / or adding one or more glycosylation sites that are not present in the antibody, or antigen-binding fragment thereof. Glycosylation of antibodies is typically either N-linked or O-linked. N-linked refers to the attachment of a carbohydrate moiety to the side chain of an asparagine residue. The tripeptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are recognition sequences for enzymatic attachment of a carbohydrate moiety to an asparagine side chain. Thus, the presence of either of these tripeptide sequences in a polypeptide creates a potential glycosylation site. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used. The modification may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original antibody or antigen-binding fragment thereof (for O-linked glycosylation sites).
[0298] In some embodiments, the anti-B7-H4 antibodies, or antigen-binding fragments thereof, described herein (or fusion proteins comprising the anti-B7-H4 antibodies, or antigen-binding fragments thereof, described herein) may include modifications, including, but not limited to, glycosylation, acetylation, pegylation, phosphorylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, conjugation to cellular ligands or other proteins, etc. Processes for making chemical modifications are known in the art and may include, but are not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the molecules may contain one or more non-classical amino acids.
[0299] The anti-B7-H4 antibodies and antigen-binding fragments thereof disclosed herein may include anti-B7-H4 antibodies and antigen-binding fragments thereof whose binding properties have been modified by direct mutation, affinity maturation, phage display, or chain shuffling. Affinity and specificity may be modified by CDR maturation and screening for CDRs with desired properties. Mutagenesis methods are known to those of skill in the art.
[0300] Antibody and fusion protein binding Also provided herein are (i) anti-B7-H4 antibodies, and antigen-binding fragments thereof, and (ii) fusion proteins comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, that bind to the same epitope on B7-H4 as one of the anti-B7-H4 antibodies, or antigen-binding fragments thereof, disclosed herein.
[0301] In some embodiments, (i) anti-B7-H4 antibodies and antigen-binding fragments thereof, or (ii) fusion proteins comprising anti-B7-H4 antibodies or antigen-binding fragments thereof, bind to the IgV domain of B7-H4. The IgV domain is related to the variable domain of an immunoglobulin. The IgC domains of human and mouse B7-H4 are shown in Table 23 (see SEQ ID NOs: 161 and 162).
[0302] In some embodiments, (i) anti-B7-H4 antibodies and antigen-binding fragments thereof, or (ii) fusion proteins comprising anti-B7-H4 antibodies or antigen-binding fragments thereof, bind to the IgC domain of B7-H4. The IgC domain is related to the constant domain of immunoglobulins. The IgC domains of human and mouse B7-H4 are shown in Table 23 (see SEQ ID NOs: 161 and 162).
[0303] In some embodiments, (i) anti-B7-H4 antibodies, and antigen-binding fragments thereof, or (ii) fusion proteins comprising anti-B7-H4 antibodies or antigen-binding fragments thereof, bind to the IgV and IgC domains of B7-H4.
[0304] In some embodiments, (i) the anti-B7-H4 antibodies and antigen-binding fragments thereof, or (ii) fusion proteins comprising the anti-B7-H4 antibodies or antigen-binding fragments thereof bind to mouse B7-H4 or a domain thereof. In some embodiments, (i) the anti-B7-H4 antibodies and antigen-binding fragments thereof, or (ii) fusion proteins comprising the anti-B7-H4 antibodies or antigen-binding fragments thereof bind to human B7-H4 or a domain thereof. In some embodiments, (i) the anti-B7-H4 antibodies and antigen-binding fragments thereof, or (ii) fusion proteins comprising the anti-B7-H4 antibodies or antigen-binding fragments thereof bind to mouse and human B7-H4 or a domain thereof.
[0305] As used herein, "binding" by an antibody or antigen-binding fragment thereof, or a fusion protein comprising the antibody or antigen-binding fragment thereof, to B7-H4, an epitope on B7-H4, or, in certain embodiments described below, a specific residue on B7-H4, includes selective interaction of the antibody, or antigen-binding fragment thereof, with B7-H4. Binding thus includes primary and secondary interactions, including, for example, hydrogen bonds, ionic interactions, salt bridges, and hydrophilic and hydrophobic interactions.
[0306] In certain embodiments, the anti-B7-H4 antibodies, or antigen-binding fragments thereof, described herein (or fusion proteins comprising such anti-B7-H4 antibodies, or antigen-binding fragments thereof) are -2 ~10 -13 mol / L, 10 -3 ~10 -13 mol / L, 10 -4 ~10 -13 mol / L, 10 -5 ~10 -13 mol / L, 10 -6 ~10 -13 mol / L, 10 -7 ~10 -13 mol / L, 10 -8 ~10 -13 mol / L, 10 -9 ~10 -13 mol / L, 10 -10 ~10 -13 mol / L, 10 -12 ~10 -13 Dissociation equilibrium constant (K D In some embodiments, an anti-B7-H4 antibody, or antigen-binding fragment thereof, described herein (or a fusion protein comprising such an anti-B7-H4 antibody, or antigen-binding fragment thereof) binds to B7-H4 at 10 -2 ~10 -9 mol / L, 10 -3 ~10 -9 mol / L, 10 -4 ~10 -9 mol / L, 10 -5 ~10 -9 mol / L, 10 -6 ~10 -9 mol / L, 10 -7 ~10 -9 mol / L, 10 -8 ~10 -9 mol / L, 10 -10 ~10 -11 mol / L, 10 -11 ~10 -12 mol / L, 10 -12 ~10 -13 mol / L or 10 -12 ~10 -14 K in mol / L DIn one embodiment, an anti-B7-H4 antibody, or antigen-binding fragment thereof, described herein (or a fusion protein comprising such an anti-B7-H4 antibody, or antigen-binding fragment thereof) binds to B7-H4 at 10 -9 ~10 -13 K in mol / L D and binds to B7-H4.
[0307] As used herein, the K between an antigen and an antigen-binding protein D "Affinity", as expressed by K, is a measure of the binding strength between an antigenic determinant and an antigen-binding site on an antigen-binding protein, such as an antibody or antibody fragment thereof. D The value is inversely proportional to the binding strength between an antigenic determinant and an antigen-binding molecule. Alternatively, affinity can also be expressed as the binding constant (K A , 1 / K D Affinity can be determined in a manner known per se by a person skilled in the art depending on the particular antigen of interest.
[0308] As used herein, the term "specificity" refers to the ability of an antibody or antigen-binding fragment thereof, such as an anti-B7-H4 antibody or antigen-binding fragment thereof, to recognize an epitope within B7-H4 but have only very weak or undetectable reactivity with other portions of B7-H4. Specificity can be relatively determined by competitive assays or by epitope identification / characterization techniques described herein or their equivalents known in the art.
[0309] As used herein, "epitope" refers to the specific target to which an antibody binds. Epitopes can be formed both by a contiguous stretch of amino acids (continuous epitopes) and by a three-dimensional arrangement of amino acid residues that are only present when the target protein is folded in a particular configuration (discontinuous epitopes). Generally, epitopes include at least 3 amino acids, at least 4 amino acids, at least 5 amino acids, or about 7-10 amino acids.
[0310] Disclosed herein are anti-B7-H4 antibodies, and antigen-binding fragments thereof, that specifically bind to the same epitope as anti-B7-H4 antibody 38B2, as well as fusion proteins comprising the anti-B7-H4 antibody, or antigen-binding fragment thereof. Also disclosed herein are anti-B7-H4 antibodies, and antigen-binding fragments thereof, that specifically bind to the same epitope as anti-B7-H4 antibody 31B1, as well as fusion proteins comprising the anti-B7-H4 antibody, or antigen-binding fragment thereof.
[0311] As used herein, a "blocking" antibody or antibody "antagonist" is one that inhibits or attenuates the biological activity of the antigen to which it binds. For example, in some embodiments, an anti-B7-H4 antagonist antibody, or antigen-binding fragment thereof, binds to B7-H4 and inhibits the activity of B7-H4 and / or the binding of B7-H4 to its binding partner. Inhibition of activity and inhibition of binding include partial inhibition. Methods for identifying B7-H4 antibodies that block B7-H4 interaction are described herein and known to those of skill in the art. For example, competing, cross-blocking, or cross-blocked antibodies can be identified using any suitable method known in the art, including competitive ELISA or BIACORE® assays in which the binding of a competing or cross-blocking antibody to human B7-H4 interferes with the binding of an antibody disclosed herein, or vice versa.
[0312] In certain embodiments, not all CDRs are directly involved in antigen binding. In one embodiment, four of the six CDRs of an anti-B7-H4 antibody, or antigen-binding fragment thereof, contact the antigen. In one embodiment, five of the six CDRs of an anti-B7-H4 antibody, or antigen-binding fragment thereof, contact the antigen. In one embodiment, six of the six CDRs of an anti-B7-H4 antibody, or antigen-binding fragment thereof, contact the antigen.
[0313] As used herein, terms such as "selective" and "selectivity" refer to the preferential binding of an antibody, or antigen-binding fragment thereof (i.e., a B7-H4 antibody or antigen-binding fragment thereof), to a particular region, target or peptide, typically a region or epitope in B7-H4, in contrast to one or more other biological molecules, including other B7-H4 family members.
[0314] In one aspect, anti-B7-H4 antibodies and antigen-binding fragments thereof are provided that specifically bind to at least a portion of the binding site on B7-H4, thereby blocking B7-H4 interaction with one or more B7-H4 ligands.
[0315] In certain embodiments, the anti-B7-H4 antibody, or antigen-binding fragment thereof, described in the present disclosure comprises an Fc domain composed of a first subunit and a second subunit. The Fc domain of an antibody consists of a pair of polypeptide chains comprising the heavy chain domain of an immunoglobulin molecule. The two subunits of the Fc domain form a stable association. In embodiments, the two subunits of the Fc domain are identical. In alternative embodiments, the two subunits of the Fc domain are not identical. In embodiments, one of the subunits of the Fc domain may be fused to an immune complex molecule. In embodiments, the Fc domain of an antibody is an IgG Fc domain, an IgG 1 Fc domain, IgG 2 Fc domain, IgG 3 Fc domain and IgG 4 It may be an Fc domain. In a further particular embodiment, the Fc domain is a human Fc domain.
[0316] Fc domain modifications that promote heterodimerization Modifications in the Fc domain of the disclosed anti-B7-H4 antibodies or antigen-binding fragments thereof that promote dimerization are further contemplated. The modifications can be amino acid substitutions, insertions, deletions, or other chemical or physical modifications. In embodiments, the Fc domain of the anti-B7-H4 antibodies or antigen-binding fragments thereof comprises a modification that promotes the association of the first and second subunits of the Fc domain. In one embodiment, the modification is present in the CH3 domain of the Fc domain. In certain embodiments, the modification that promotes the association of the first and second subunits of the Fc domain is a so-called "Knob-into-hole" mutation, which comprises a "Knob" mutation in one of the two subunits of the Fc domain and a "hole" mutation in the other of the two subunits of the Fc domain.
[0317] Knob-into-hole mutations are a "knob-into-cavity" strategy. They function to engineer the interface between a first and a second polypeptide for hetero-oligomerization. A "knob" (i.e., knob) is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain. A compensatory "cavity" (i.e., hole) of identical or similar size to the knob is optionally created on the interface of the second polypeptide by replacing the large amino acid side chain with a small one. In certain embodiments, an amino acid residue in the CH3 domain of a first Fc subunit is replaced with an amino acid residue having a larger side chain volume, thereby generating a knob in the CH3 domain of the first Fc subunit that can be positioned into a hole present in the CH3 domain of the second Fc subunit generated by replacing one amino acid residue with an amino acid residue having a smaller side chain in the CH3 domain of the second Fc subunit. Preferably, the amino acid residue having a larger side chain volume is selected from the group consisting of cysteine (C), valine (V), alanine (A), phenylalanine (F), tyrosine (Y), leucine (L), lysine (K), proline (P), glutamic acid (E), and tryptophan (W). Preferably, the amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), arginine (R), tryptophan (W), cysteine (C), lysine (L), glutamic acid (E), aspartic acid (D), and valine (V).
[0318] Mutations corresponding to knobs and holes can be made by altering a nucleic acid encoding a polypeptide, for example by site-directed mutagenesis or peptide synthesis.
[0319] In embodiments of fusion proteins in which only one heavy chain is bound to IL-15 / IL-15Rα sushi, the Fc domain of the anti-B7-H4 antibody, or antigen-binding fragment thereof, may contain one or more amino acid substitutions that promote heterodimer formation (i.e., association of the heavy chain fusion with a heavy chain lacking the fusion). In embodiments, an amino acid residue in the CH3 domain (CH3-1) of one heavy chain contains an amino acid substitution that replaces the amino acid with an amino acid residue having a larger side chain volume, thereby creating a "knob" in the CH3 domain that can be positioned into a "hole" present in the CH3 domain (CH3-2) of the other heavy chain created by replacing the amino acid residue with an amino acid residue having a smaller side chain volume.
[0320] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody, or antigen-binding fragment thereof), (a) the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); (b) the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat), and the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); (c) the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat), and the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); (d) the first heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V (EU index numbering according to Kabat); or (e) the second heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A, and Y407V (EU index numbering according to Kabat).
[0321] Provided herein is an anti-B7-H4 antibody, or antigen-binding fragment thereof (or a fusion protein comprising such an antibody or antigen-binding fragment thereof), the antibody, or antigen-binding fragment thereof, comprising a heavy chain comprising a sequence selected from the group consisting of SEQ ID NOs: 147-160, and / or a portion thereof comprising a sequence selected from the group consisting of SEQ ID NOs: 147-160.
[0322] Linker In embodiments, the fusion proteins provided herein may include one or more linkers connecting the components of the fusion proteins disclosed herein. The linker may be located (i) between the IL-15 polypeptide and the IL15Rα polypeptide comprising a sushi domain, (ii) between the heavy chain of the anti-B7-H4 antibody, or antigen-binding fragment thereof, and the IL-15 polypeptide or the IL15Rα polypeptide comprising a sushi domain, or (iii) for both. In embodiments of the present disclosure, the IL-15 polypeptide and the IL15Rα polypeptide comprising a sushi domain are joined or linked with a first linker amino acid sequence. In embodiments, the IL15Rα polypeptide is joined to the antibody or antigen-binding fragment thereof described herein by a second linker amino acid sequence. The first linker and the second linker may have the same or different amino acid sequences.
[0323] The linker amino acid sequences described herein may be of sufficient length to ensure that the fusion protein forms the appropriate secondary and tertiary structures. The length of the linker amino acid may be 5 to 40 amino acids, preferably 10 to 40 amino acids, more preferably 15 to 40 amino acids, even more preferably 20 to 40 amino acids, and most preferably 25 to 35 amino acids.
[0324] Preferably, the linker sequence comprises near neutral amino acids selected from the group comprising Gly(G), Asn(N), Ser(S), Thr(T), Ala(A), Leu(L) and Gln(Q), most preferably selected from the group comprising Gly(G), Asn(N) and Ser(S). Preferably, the linker sequence is glycine- and serine-rich, and in some embodiments the linker contains only serine and glycine residues.
[0325] In some embodiments, the linker comprises a portion of the IL15Rα polypeptide outside of the sushi domain, including but not limited to, the sequence of SEQ ID NO: 171 (IRDPALVHQRPAPP). In some embodiments, the linker comprises SEQ ID NO: 168 (SGGSGGGGSGGGSGGGGSLQ). In some embodiments, the linker comprises SEQ ID NO: 171 and SEQ ID NO: 168. In some embodiments, the linker comprises SEQ ID NO: 170.
[0326] In embodiments, the heavy and light chains of an anti-B7-H4 antibody, or antigen-binding fragment thereof, disclosed herein may be linked into a single chain polypeptide ("single-chain Fv" or "scFv") using a third linker that associates with the VR and VL domains to form an antigen-binding site. The amino acid sequences of the linkers may be the same or different.
[0327] In one embodiment, the IL-15 polypeptide or IL-15 derivative is covalently linked to the IL-15Rα sushi polypeptide or IL-15Rα sushi derivative by a linker.
[0328] In some embodiments, the IL-15 polypeptide or IL-15 derivative is covalently linked to the IL-15Rα sushi polypeptide or IL-15Rα sushi derivative by a first linker, and either the IL-15 polypeptide or IL-15 polypeptide or IL-15Rα sushi polypeptide or IL-15Rα sushi derivative is covalently linked to the anti-B7-H4 antibody, or antigen-binding fragment thereof, by a second linker. In some embodiments, the amino acid sequences of the first linker and the second linker are identical. In other embodiments, the amino acid sequences of the first linker and the second linker are different.
[0329] combination The anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins disclosed herein can further comprise one or more functional moieties. Examples of useful functional moieties include, but are not limited to, blocking moieties, detectable moieties, diagnostic moieties, targeting moieties, and therapeutic moieties.
[0330] For example, the blocking moiety may comprise sufficient conformational bulk and / or charge moieties to block the ability of glycosidases to glycosylate the antibody or antigen-binding fragment thereof, resulting in attenuated glycosylation. Preferred blocking moieties include cysteine adducts such as cysteine, mixed disulfide adducts, or disulfide bonds and PEG moieties such as polyethylene glycol ("PEG"), polypropylene glycol ("PPG"), polyoxyethylated glycerol ("POG") and other polyoxyethylated polyols, polyvinyl alcohol ("PVA") and other polyalkylene oxides, polyoxyethylated sorbitol or polyoxyethylated glucose. PEG is a preferred moiety for biological applications for several reasons. PEGylation can improve the pharmacokinetic performance of a molecule by increasing the apparent molecular weight of the molecule. Increasing the apparent molecular weight reduces the rate of clearance from the body after subcutaneous or systemic administration. In many cases, PEGylation can reduce antigenicity and immunogenicity. PEGylation can also improve the solubility of biologically active molecules. Moreover, PEG is typically clear, colorless, odorless, water soluble, heat stable, inert to many chemical agents, does not hydrolyze, and is non-toxic, making it a favorable choice for biological applications.
[0331] Examples of detectable moieties that can be attached to the anti-B7-H4 antibodies, or antigen-binding fragments, or fusions disclosed herein can include fluorescent moieties or labels, imaging agents, radioisotope moieties, radio-opaque moieties, and the like, such as detectable labels, e.g., biotin, fluorophores, chromophores, spin resonance probes, or radioactive labels. Examples of fluorophores include fluorescent dyes (e.g., fluorescein, rhodamine, and the like) and other luminescent molecules (e.g., luminophores). Fluorophores can be environmentally sensitive, such that their fluorescence changes when located near one or more residues of a modified protein that undergo a conformational change upon substrate binding. Exemplary radiolabels include one or more less sensitive nuclei ( 13 C. 15 N, 2 H,125 I, 123 I, 99 Tc, 43 K, 52 Fe, 67 Ga, 68 Ga, 111 This includes small molecules containing atoms with .alpha.-In, etc.
[0332] Diagnostic moieties include detectable moieties suitable for revealing the presence of a disease or disorder. Typically, diagnostic moieties allow for the determination of the presence, absence or level of a molecule, e.g., a target peptide, a protein associated with a disease or disorder. Such diagnostics are also suitable for prognosis and / or diagnosis of a disease or disorder and its progression.
[0333] Examples of therapeutic moieties include anti-inflammatory drugs, anti-cancer drugs, anti-neurodegenerative drugs, anti-infective drugs, or therapeutic drugs in general. Functional moieties may also have one or more of the above-mentioned functions. Exemplary therapeutic moieties may include antibiotics, a second anti-B7-H4 antibody, or an antibody to another antigen, such as a tumor-specific antigen, an autoimmune tissue antigen, a virus-infected cell antigen, an Fc receptor, a T cell receptor, or a T cell co-inhibitor, or an immunotoxin, or any other therapeutic moiety that is useful for treating a disease or condition, including cancer, an autoimmune disease, or a chronic viral infection. Exemplary therapeutic moieties may also be cytotoxins, radioactive substances, cytokines, interferons, target or reporter moieties, enzymes, toxins, peptides, or therapeutic drugs at any position with the molecule, so long as they are capable of binding to the target. Examples of immunoconjugates include antibody-drug conjugates and antibody-toxin fusion proteins. In certain embodiments, the antibody may be conjugated to an agent specific for tumor cells or virus-infected cells.
[0334] For example, the salvage receptor binding epitopes described in U.S. Patent No. 5,739,277 can also be attached to antibodies, antigen-binding fragments thereof (particularly antibody fragments) to enhance the half-life of the antibodies or antigen-binding fragments described herein. The term "salvage receptor binding epitope" can refer to an epitope in the Fc region of an IgG molecule (e.g., IgG1, IgG2, IgG3 or IgG4) that is responsible for increasing the in vivo serum half-life of the IgG molecule (see, e.g., Ghetie et al., 18 Ann. Rev. Immunol. 739 (2000)).
[0335] nucleic acid Nucleic acids encoding the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins disclosed herein, as well as vectors, host cells, and expression systems, are also provided herein. As used herein, the term "nucleic acid" refers to a polymeric form of nucleotides of any length, ribonucleotides or desoxyribonucleotides, including, but not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derived nucleotide bases. Nucleic acids encoding the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins disclosed herein are, for example, DNA, cDNA, RNA, synthetically produced DNA or RNA, or recombinantly produced chimeric nucleic acid molecules comprising any of these polypeptides, either alone or in combination.
[0336] The term "vector" refers to a vehicle that contains a nucleic acid molecule capable of transporting the nucleic acid molecule into a cell. A "vector" includes, but is not limited to, a viral vector, a plasmid, an RNA vector, or a linear or circular DNA or RNA molecule, and may consist of a chromosomal, non-chromosomal, semisynthetic, or synthetic nucleic acid. In some embodiments, the vector utilized is one that is capable of autonomous replication (episomal vector) and / or expression of the nucleic acid to which it is linked (expression vector). Many suitable vectors are known to those of skill in the art and are commercially available.
[0337] Provided herein is a nucleic acid, or a set of nucleic acids, encoding an antibody, or an antigen-binding fragment thereof, disclosed in Table 1, Table 5, Table 7, Table 9, Tables 16 to 20, or Table 24. Provided herein is a nucleic acid, or a set of nucleic acids, encoding a fusion protein disclosed in Table 13, Table 21, or Table 22.
[0338] Provided herein are nucleic acids encoding the VH sequences disclosed in Tables 16-21. Provided herein are nucleic acids encoding the VL sequences disclosed in Tables 16-21. Provided herein are nucleic acids encoding the HC sequences disclosed in Tables 21-22. Provided herein are nucleic acids encoding the LC sequences disclosed in Tables 21-22.
[0339] Disclosed herein is a vector, or a set of vectors, comprising one or more of the nucleic acid sequences disclosed herein.
[0340] Disclosed herein is a cell comprising a vector or set of vectors disclosed herein. In some embodiments, the cell is an immune cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is an isolated cell.
[0341] Preparation and expression systems of antibodies and fusion proteins The anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins disclosed herein are typically produced by recombinant expression. The nucleic acids encoding the light and heavy chain variable regions, optionally linked to a constant region, may be introduced into the same expression vector. Alternatively, the nucleic acids encoding the light and heavy chain variable regions, optionally linked to a constant region, may be introduced into different expression vectors. The expression vector may further comprise one or more expression control sequences, including but not limited to a promoter (e.g., a homologous or heterologous promoter), a signal sequence, an enhancer element, and a transcription termination sequence. Preferably, the expression control sequence is a eukaryotic promoter system in a vector capable of transforming or transfecting a eukaryotic host cell. Typically, the host is maintained under conditions suitable for high level expression of the nucleotide sequence, recovery and purification of the cross-reactive antibody after the vector is introduced into the appropriate host.
[0342] Commonly, expression vectors contain selection markers (eg, ampicillin-resistance, hygromycin-resistance, tetracycline-resistance or nemomycin-resistance) permitting detection of cells transformed with the desired DNA sequences.
[0343] The host used to express the anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins disclosed herein can be a prokaryotic or eukaryotic host. Examples of suitable hosts include bacterial or eukaryotic hosts, including yeast, insect, fungal, avian, and mammalian cells, either in vivo or in situ, or mammalian host cells of insect, avian, or yeast origin. Mammalian cells or tissues can be of human, primate, hamster, rabbit, rodent, bovine, porcine, ovine, equine, caprine, canine, or feline origin, although any other mammalian cells may be used.
[0344] Examples of bacterial hosts that can be used to express the antibodies, antigen-binding fragments, or fusion proteins disclosed herein can be E. coli, bacilli such as Bacillus subtilus, and other Enterobacteriaceae such as Salmonella, Serratia, and various Pseudomonas species.
[0345] Yeast can also be used as a host for expressing the antibodies, antigen-binding fragments, or fusion proteins disclosed herein. Saccharomyces and Pichia are exemplary yeast hosts, with suitable vectors having expression control sequences (e.g., promoters), origins of replication, termination sequences, etc., as desired. Exemplary promoters include 3-phosphoglycerate kinase and other glycolytic enzymes. Inducible yeast promoters include, inter alia, alcohol dehydrogenase, isocytochrome C, and enzymes responsible for methanol, maltose, and galactose utilization.
[0346] Mammalian cells in culture can also be used as host cells for expressing the antibodies, antigen-binding fragments, or fusion proteins disclosed herein. Examples of suitable host cell lines capable of secreting heterologous proteins (e.g., intact immunoglobulins) that are well known in the art include CHO cell lines, various COS cell lines, HeLa cells, 293 cells, myeloma cell lines, transformed B cells, and hybridomas. Expression vectors for these cells can include expression control sequences such as origins of replication, promoters, enhancers, and necessary processing information sites such as ribosome binding sites, RNA splice sites, and / or transcription terminator sequences. Examples of expression control sequences include SV40, adenovirus, bovine papilloma virus, cytomegalovirus, and the like.
[0347] The anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins disclosed herein can be expressed using a single expression construct or vector, or multiple expression constructs or vectors (e.g., two or three expression constructs). When antibody heavy and light chains are cloned on separate expression vectors, the vectors are co-transfected to obtain a collection of expressed and intact immunoglobulins. Upon expression, whole antibodies disclosed herein, their dimers, individual light and heavy chains, or other immunoglobulin forms can be purified according to procedures that are standard in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, HPLC purification, gel electrophoresis, and the like (see generally, Scopes, Protein Purification (Springer-Verlag, NY, (1982)). For pharmaceutical uses, substantially pure immunoglobulins that are at least about 90-95% homogeneous are preferred, and those that are 98-99% or more homogeneous are most preferred.
[0348] The disclosed anti-B7-H4 antibodies, antigen-binding fragments, and fusion proteins can be made by any method known in the art. General techniques for producing human or mouse antibodies or fusion molecules are known in the art.
[0349] Methods of Modulating B7-H4 Activity In one aspect, methods are provided for using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to reduce the interaction between B7-H4 and its cognate ligand, which may include internalization of the receptor following binding of the antibody, or attenuating expression of the receptor on target cells.
[0350] In one aspect, methods are provided for using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to reduce signaling that occurs as a result of B7-H4-cognate receptor binding. Such reduction can be partial (i.e., attenuation, but not abolition, of B7-H4 activity) or can be complete abolition of such activity (e.g., abrogation of the ability of B7-H4 to mediate signaling). Such reduction can include internalization of the receptor following antibody binding, or attenuation of expression of the receptor on the target cell.
[0351] In one aspect, methods are provided for using anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to attenuate immune suppression (e.g., T cells). Immune suppression can be mediated by immune suppressive receptors expressed on the immune cell surface and their interactions with their ligands. Methods for measuring T cell activity are known in the art. By way of non-limiting example, T cell tolerance can be induced by contacting T cells with the canceling antigen anti-CD3 in the absence of costimulation and / or ionomycin. To determine the degree of immune tolerance generation of T cells (with levels of IL-2, interferon-γ, and TNF correlating with T cell tolerance), for example, levels of IL-27, LDH-A, RAB10, and / or ZAP70 (both intracellular and secreted) can be monitored.
[0352] In one aspect, methods are provided for using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to enhance T cell development, activation, and / or proliferation. + Methods are provided for using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to enhance T cell proliferation. + Methods of using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to enhance T cell proliferation are provided.
[0353] In one aspect, methods are provided using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to deplete B7-H4-expressing tumor cells or tumor-associated macrophages (TAMs) in a recipient human or in human tissues (in situ or ex vivo). Depletion of B7-H4 positive tumor cells or TAMs can be monitored by immunohistochemistry (IHC) of tumor cells using the disclosed anti-B7-H4 antibodies (or another tumor-specific or TAM-specific marker), or by reduction of B7-H4 mRNA levels by PCR, in situ hybridization, or another method known to one of skill in the art.
[0354] In one aspect, methods are provided using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in B7-H4-expressing cells in a subject in need of treatment.
[0355] By "attenuation" (or "reduction") is meant the ability to cause an overall decrease of about 20% or more, about 30% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, or about 75% or more, about 80% or more, about 85% or more, about 90% or more, or about 95% or more as compared to an untreated control.
[0356] Cells targeted by the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins described herein include, but are not limited to, cells that express B7-H4, e.g., transformed cells that do not typically express B7-H4 upon transformation, or cells characterized by increased expression compared to control cells. Preferred target cells include cancer cells and tumor-associated macrophages.
[0357] Treatment method In one aspect, the disclosure provides anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins that are useful for treating a subject in need of treatment.
[0358] In the methods described herein, a therapeutically effective amount of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein disclosed herein is administered to a mammal in need thereof. As used herein, the term "mammal" includes, but is not limited to, humans, laboratory animals, domestic pets, and livestock. Preferably, the mammal is a human. As used herein, a "therapeutically effective amount" refers to an amount of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein that is effective to produce a desired therapeutic effect upon administration to a mammal.
[0359] In embodiments, a "subject" is a mammal. In embodiments, a subject is a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, mice, etc.) or a primate (e.g., monkeys and humans). In this specification, individuals and patients are also referred to as subjects.
[0360] As used herein, the terms "treat," "treated," "treating," or "treatment" refer to a therapeutic regimen in which the subject delays (mitigates) an undesirable physiological condition, disorder, or disease, or obtains a beneficial or desired clinical outcome. For purposes of this disclosure, beneficial or desired clinical outcomes include, but are not limited to, alleviation of symptoms; attenuation of the extent of a condition, disorder, or disease; stabilization (i.e., not worsening) of the condition, disorder, or disease state; delay in onset or slowing of progression of a condition, disorder, or disease; amelioration of one or more symptoms of a condition, disorder, or disease state; and remission (whether partial or total). Treatment includes eliciting a clinically beneficial response without excessive levels of side effects. Treatment also includes prolonging survival compared to expected survival in the absence of treatment.
[0361] The terms "prevent", "prevention" and the like refer to acting before the obvious onset of a disease or disorder to prevent the disease or disorder from occurring, or to minimize the extent of the disease or disorder or slow the course of its development.
[0362] Subjects who may benefit from treatment with anti-B7-H4 antibodies express the target B7-H4 protein on either tumors or TAMs. This may be assessed by IHC, FAC, in situ hybridization of tumor samples, or other methods known to those of skill in the art. In embodiments, the subject upregulates expression of B7-H4.
[0363] Provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein. Provided is an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein for use in treating a subject in need of cancer treatment. Provided is a use of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein for use in treating a subject in need of cancer treatment. Provided is an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein in the manufacture of a medicament for treating a subject in need of cancer treatment.
[0364] Provided herein is a method of attenuating tumor growth in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein. Provided is an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein for use in attenuating tumor growth in a subject in need thereof. Provided is a use of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein for use in attenuating tumor growth in a subject in need thereof. Provided is an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein in the manufacture of a medicament for attenuating tumor growth in a subject in need thereof.
[0365] Provided herein is a method of reducing tumor metastasis in a subject in need thereof, the method comprising administering to the subject an effective amount of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein disclosed herein. Provided is an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein for use in reducing tumor metastasis in a subject in need thereof. Provided is a use of an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein for use in reducing tumor metastasis in a subject in need thereof. Provided is an anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein in the manufacture of a medicament for reducing tumor metastasis in a subject in need thereof.
[0366] Cancers and related disorders that may be treated or prevented using the anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins disclosed herein include, but are not limited to, the following: acute myeloid leukemias, such as acute leukemia, acute lymphocytic leukemia, myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia, and chronic leukemias, such as myelodysplastic syndromes, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Lymphomas, including but not limited to Hodgkin's lymphoma and non-Hodgkin's lymphoma; multiple myelomas, including but not limited to smoldering multiple myeloma, non-secretory myeloma, osteosclerosing myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; osteosarcoma sarcoma), osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal osteosarcoma, soft tissue sarcoma, angiosarcoma, fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, schwannoma, rhabdomyosarcoma, synovial sarcoma; brain tumors, including but not limited to glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, non-glial tumors, acoustic neuroma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; adenocarcinoma, lobular (small cell) carcinoma, ductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, page breast cancer, including but not limited to, pulmonary edema, inflammatory breast cancer; adrenal cancer, including but not limited to, pheochromocytoma and adrenocortical carcinoma; thyroid cancer, such as but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumors, carcinoid or islet tumors; pituitary cancer, including but not limited to, Cushing's disease, prolactin-secreting tumors, acromegaly, diabetes insipidus; eye cancer, including but not limited to, ocular, iris and ciliary body melanoma, and retinoblastoma;Vaginal cancer, including but not limited to squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including but not limited to squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, including but not limited to squamous cell carcinoma and adenocarcinoma; uterine cancer, including but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancer, including but not limited to ovarian epithelial carcinoma, borderline malignant tumors, germ cell tumors, and stromal tumors; squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucocutaneous tumors, and uterine sarcoma; Esophageal cancer, including but not limited to epidermal carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, oat cell carcinoma (small cell carcinoma); gastric cancer, including but not limited to adenocarcinoma, fungus (polypoid), ulcerating, superficial spreading, diffuse spreading, malignant lymphoma, liposarcoma, fibrosarcoma, carcinosarcoma; colon cancer; rectal cancer; liver cancer, including but not limited to hepatocellular carcinoma and hepatoblastoma; gallbladder cancer, including but not limited to adenocarcinoma; including but not limited to papillary, nodular, diffuse cholangiocarcinoma, including but not limited to non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large cell carcinoma, and small cell lung carcinoma; testicular cancer, including but not limited to germinal tumors, seminoma, undifferentiated, classical (classical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma, and choriocarcinoma (yolk sac tumor); prostate cancer, including but not limited to adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancer; oral cancer, including but not limited to squamous cell carcinoma; basal carcinoma; glandular salivary gland carcinoma, including but not limited to, mucoepidermoid carcinoma, and adenoid cystic carcinoma; pharyngeal carcinoma, including but not limited to, squamous cell carcinoma and verrucous carcinoma; skin cancer, including but not limited to, basal cell carcinoma, squamous cell carcinoma, and melanoma, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma; kidney cancer, including but not limited to, renal cell carcinoma, adenocarcinoma, Grawitz tumor, fibrosarcoma, and transitional cell carcinoma (renal pelvis and / or ureter); Wilms tumor;bladder cancer, including but not limited to transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteosarcoma, endothelial sarcoma, lymphangioendothelial sarcoma, mesothelioma, synovium, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, salivary gland carcinoma, sebaceous gland, papillary carcinoma, and papillary adenocarcinoma;
[0367] Accordingly, the anti-B7-H4 antibodies, antigen-binding fragments and fusion proteins thereof disclosed herein are useful in treating the following cancers, including carcinomas of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervical, thyroid and skin; carcinomas, including squamous cell carcinoma; leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Burkitt's lymphoma, and other cancers. The compositions are also useful for treating or preventing various cancers (especially ovarian, breast, prostate, stomach, kidney, thyroid and uterine cancers) or neoproliferative diseases, including (but not limited to) hematopoietic tumors of lymphoid system, including acute and chronic myeloid and promyelocytic leukemias; hematopoietic tumors of myeloid lineage, including acute and chronic myeloid and promyelocytic leukemias; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; other tumors, including melanoma, seminoma, teratoma (tetratocarcinoma), neuroblastoma and glioma; tumors of central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannoma; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma and osteosarcoma; and other tumors, including melanoma, xenoderma pigmentosum, keratoacanthoma, seminoma, follicular thyroid cancer and teratoma. Cancers caused by abnormalities in apoptosis are also treated with the methods and compositions disclosed herein. Such cancers may include, but are not limited to, follicular lymphoma, carcinomas with p53 mutations, hormone-dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis, and myelodysplastic syndromes. In certain embodiments, malignant or neoplastic transformation (such as metaplasia and dysplasia), or hyperproliferative disorders, are treated or prevented by the disclosed methods and compositions in the ovary, bladder, breast, colon, lung, skin, pancreas, or uterus. In other specific embodiments, sarcoma, melanoma, or leukemia are treated or prevented with the provided methods and compositions.
[0368] Cancer cells require a set of characteristic functional capabilities during their development, albeit through various mechanisms. Such capabilities include evasion of apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion / metastasis, limitless replicative potential, and persistent angiogenesis. The term "cancer cell" is meant to encompass both pre-malignant and malignant cancer cells. In some embodiments, cancer refers to a benign tumor that remains localized. In other embodiments, cancer refers to a malignant tumor that has invaded and destroyed adjacent body structures and spread to distant sites. In still other embodiments, cancer is associated with a specific cancer antigen (e.g., hemicarcinoma antigen (KS 1 / 4), ovarian carcinoma antigen (CAI25), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), CD19, CD20, HER2 / neu, etc.).
[0369] Combination therapy The anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins disclosed herein may be advantageously combined with additional therapeutic agents, including, but not limited to, cytotoxic drugs, chemotherapeutic drugs, antiproliferative drugs, anti-inflammatory drugs, anticancer drugs, antineurodegenerative drugs, immunosuppressants, and anti-infective drugs. The administration of the anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins and the additional therapeutic agents (or additional therapies) may be simultaneous, continuous, or intermittent. The administration of the anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins and the additional therapeutic agents (or additional therapies) may be administered separately or as a mixture. Furthermore, the therapeutic methods provided herein may involve combined treatment with one or more therapies, including, but not limited to, the following group: antibody therapy, chemotherapy, cytokine therapy, dendritic cell therapy, gene therapy, hormone therapy, laser phototherapy, and radiation therapy.
[0370] The anti-B7-H4 antibodies, antigen-binding fragments thereof, and fusion proteins of the present disclosure may be synergistically combined with one or more anti-cancer drugs or therapies used to treat cancers, including, but not limited to, renal cell carcinoma, colorectal cancer, glioblastoma multiforme, squamous cell carcinoma of the head and neck, non-small cell lung cancer, colon cancer, ovarian cancer, adenocarcinoma, prostate cancer, glioma, and melanoma. Examples of such agents include antibodies to PD-L1 (e.g., nivolumab), LAG-3 inhibitors, CTLA-4 inhibitors (e.g., ipilimumab), TIM3 inhibitors, BTLA inhibitors, T IGIT inhibitors, CD47 inhibitors, antagonists of another T cell co-inhibitor or ligand (e.g., CD-28, 2B4, LY108, LAI R 1, ICOS, CD1 60, or VISTA), indoleamine-2,3-dioxygenase (IDO) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, and / or other T cell inhibitors. VEGF (vascular endothelial growth factor) antagonists (e.g., "VEGF-Trap" such as aflibercept or other VEGF inhibitory fusion proteins described in U.S. Pat. No. 7,087,411, or anti-VEGF antibodies, or antigen-binding fragments thereof (e.g., bevacizumab or ranibizumab), or small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib, or pazopanib)), Ang2 inhibitors (e.g., nesbacumab), transforming growth factor β (TGF3) inhibitors, epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib, cetuximab), agonists to costimulatory receptors (e.g., glucocorticoid derivatives of TNFR-related protein), tumor-specific antigens (e.g., CA9, CA1 25, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), antiviral drugs (e.g., zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine, and corticosteroids), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1, and CA19-9 antibodies, vaccines (e.g., Bacillus Calmette-Guerin), cancer vaccines), adjuvants that enhance antigen presentation (e.g., granulocyte-macrophage colony-stimulating factor), bispecific antibodies (e.g., CD3×CD20 bispecific antibody, PSMA×CD3 bispecific antibody), cancer vaccines (e.g., MAGE3, MUC1, EGFRv3, ALVAC-CEA), cytotoxins, chemotherapeutic agents (e.g., dacarbazine, temozolomide, cyclophosphamide, docetaxel, doxorubicin, daunorubicin, cisplatin, carboplatin, gemcitabine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, and vincristine), radiation therapy, IL-6R inhibitors (e.g., sarilumab), IL-4R inhibitors (e.g., dupilumab), IL-10 inhibitors, cytokines such as IL-2, IL-7, IL-21, and IL-15, antibody-drug conjugates (ADCs) (e.g., anti-CD1 These include, but are not limited to, anti-DS6-DM4 ADCs, anti-inflammatory drugs (e.g., corticosteroids and nonsteroidal anti-inflammatory drugs), nutritional supplements such as antioxidants, or any palliative therapy for treating cancer, radiation therapy, and / or antibodies against Fc receptors on immune cells for the treatment of autoimmune diseases.
[0371] Method of administration Therapeutic compositions comprising any of the anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins described herein may be administered to a subject in need in any convenient manner, including, but not limited to, injection, transfusion, implantation, or transplantation. The compositions described herein may be administered to a subject in need thereof subcutaneously, intradermally, intratumorally, intranasally, intramedullary, intramuscularly, intracranially, intravenously, or intralymphatic injection, or intraperitoneally. In one embodiment, the cell compositions of the present disclosure are preferably administered by intravenous injection.
[0372] In certain embodiments, the anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein is administered to the mammal by intravenous infusion, i.e., introduction of the anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein into the vein of the mammal for a certain period of time, which in certain embodiments is about 5 minutes, about 10 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, or about 8 hours.
[0373] In some embodiments, the compositions are administered directly to the tumor or tumor microenvironment, enhancing localization of the composition to the tumor site and reducing toxicity to non-target cells that express B7-H4.
[0374] Dosing regimen The methods according to this aspect of the disclosure include sequentially administering to a subject multiple doses of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the disclosure. As used herein, "sequential administration" means that each dose of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the disclosure is administered to a subject at different times in time (e.g., on various days separated by predetermined intervals (e.g., hours, days, weeks, or months)). The disclosure includes methods that include sequentially administering to a patient a single initial dose of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the disclosure, followed by one or more secondary doses of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the disclosure, optionally followed by one or more tertiary doses of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the disclosure. The anti-B7-H4 antibody, antigen-binding fragment, or fusion protein thereof of the present disclosure may be administered at a dose of 0.01 mg / kg to 100 mg / kg.
[0375] In certain embodiments, the compound or composition dose is administered to the subject daily, every other day, every 2 days, every 3 days, once a week, twice a week, three times a week, once every 2 weeks, or once a month. In other embodiments, two, three, or four doses of the compound or composition are administered to the subject daily, every 2 days, every 3 days, once a week, once every 2 weeks, or once a month. In some embodiments, the compound or composition dose is administered for 2 days, 3 days, 5 days, 7 days, 14 days, 21 days, or 28 days. In certain embodiments, the compound or composition dose is administered for 1 month, 1.5 months, 2 months, 2.5 months, 3 months, 4 months, 5 months, 6 months, or more.
[0376] Pharmaceutical Compositions In another aspect, there is provided a pharma- ceutically acceptable composition comprising a therapeutically effective amount of an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the present disclosure, formulated with one or more pharma- ceutically acceptable excipients.
[0377] The dosage of the active agent may vary depending on the reason for use, the individual subject and the mode of administration. The dosage may be adjusted based on the subject's weight, the subject's age and health condition, and the tolerability of the compound or composition.
[0378] The active agents and excipients may be formulated into compositions and dosage forms as described in a manner known in the art. The pharmaceutical compositions provided herein may be specifically formulated in solid or liquid form, including those adapted for parenteral administration, e.g., by subcutaneous, intratumoral, intramuscular or intravenous injection, e.g., as a sterile solution or suspension.
[0379] Therapeutic compositions comprising an anti-B7-H4 antibody, or antigen-binding fragment thereof, or a fusion protein thereof may be formulated with one or more pharma- ceutically acceptable excipients, which may be pharma- ceutically acceptable substances, compositions or vehicles, such as liquid or solid fillers, diluents, carriers, manufacturing aids (e.g., lubricants, hydrous magnesium silicate, calcium or zinc stearate, or stearic acid), solvents or encapsulating materials, bulking agents, salts, surfactants and / or preservatives that are involved in carrying or transporting the therapeutic compound for administration to a subject. Some examples of materials that can function as pharma- ceutically acceptable excipients include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; gelatin; talc; waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as ethylene glycol and propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers; water; isotonic saline; pH buffers; and other non-toxic, compatible substances used in pharmaceutical formulations.
[0380] The bulking agent referred to herein can be described as a compound added to increase the mass of the pharmaceutical composition and contribute to the physical structure of the formulation in cryopreserved form. Examples of bulking agents can include, but are not limited to, suitable mannitol, glycine, polyethylene glycol and sorbitol.
[0381] The therapeutic composition may optionally include a surfactant. The use of a surfactant can reduce aggregation of the reconstituted protein and / or reduce the formation of particulates in the reconstituted formulation. Examples of suitable surfactants that may be used, as described in this disclosure, include polysorbates (e.g., polysorbate 20 or 80); poloxamers (e.g., poloxamer 188); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate (sodium laurel sulfate); and the like. sulfate); sodium octyl glycoside; lauryl sulfobetaine, myristyl sulfobetaine, linoleyl sulfobetaine or stearyl sulfobetaine; lauryl sarcosine, myristyl sarcosine, linoleyl sarcosine or stearyl sarcosine; linoleyl betaine, myristyl betaine or cetyl betaine; lauroamidopropyl betaine, cocamidopropyl betaine, linoleamidopropyl betaine, myristamidopropyl betaine, palmidopropyl betaine or isostearamidopropyl betaine (e.g., lauroamidopropyl); myristamidopropyl dimethylamine, palmidopropyl dimethylamine or isostearamidopropyl dimethylamine; sodium cocoyl or oleoyl methyl taurate; and polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g., Pluronics, PF68, etc.).
[0382] Preservatives may optionally be used in the therapeutic compositions described herein.Preservatives suitable for use in the formulations provided herein include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzoalkonium chloride (a mixture of alkylbenzyl-dimethylammonium chlorides, where the alkyl group is a long-chain compound), and benzethonium chloride.Other types of preservatives include phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
[0383] The therapeutic compositions described herein may have various concentrations of anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins. For example, the compositions may contain anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins at 10 mg / mL to 200 mg / mL, 25 mg / mL to 130 mg / mL, 50 mg / mL to 125 mg / mL, 75 mg / mL to 110 mg / mL, or 80 mg / mL to 100 mg / mL. The compositions may also contain anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins at 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, 110 mg / mL, 120 mg / mL, 130 mg / mL, 140 mg / mL, or 150 mg / mL. In some embodiments, the therapeutic compositions may be stored frozen and provided in a composition for reconstitution prior to administration.
[0384] Diagnostic Uses The anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins of the present disclosure may be used to detect and / or measure B7-H4 in a sample, for example, for diagnostic purposes. The anti-B7-H4 antibodies, antigen-binding fragments thereof, or fusion proteins disclosed herein may be used in assays to detect a disease or disorder, such as cancer. An exemplary diagnostic assay for B7-H4 may include, for example, contacting a sample obtained from a patient with an anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein of the present disclosure. The anti-B7-H4 antibody, antigen-binding fragment thereof, or fusion protein may be labeled with a detectable label or reporter molecule, or used as a capture ligand to selectively isolate B7-H4 from a patient sample, or alternatively used in combination with a detectably labeled secondary antibody. The detectable label or reporter molecule can be a radioisotope, a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate or rhodamine, or an enzyme such as alkaline phosphatase, β-galactosidase, horseradish peroxidase or luciferase. Certain exemplary assays that can be used to detect or measure B7-H4 in a sample include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS).
[0385] The kits of the present disclosure may include any combination of agents, compositions, components, reagents, administration devices, or mechanisms, or other entities provided herein. For example, the kits of the present disclosure may include one or more of the anti-B7-H4 antibodies, or antigen-binding fragments thereof, or fusion proteins disclosed herein, and one or more of a carrier composition, an administration device, and a combination therapy. The kits may further include a device for facilitating delivery, such as a syringe for injection, or a tool for facilitating delivery of the therapeutic composition to a subject in need thereof. Any of the kits provided herein may be included in a container, pack, or dispenser, together with instructions for administration.
[0386] All other referenced patents and patent applications are incorporated herein in their entirety. Furthermore, to the extent that a definition or use of a term in a reference incorporated herein contradicts or is contrary to a definition of the term provided herein, the definition of the term provided herein shall apply and the definition of the term in the reference shall not apply.
[0387] It will be understood that the disclosure is not limited to the specific molecules, compositions, methods, or protocols described, as these may vary. Any methods and materials similar or equivalent to those described herein may be used in the practice or testing of embodiments of the disclosure. It will be further understood that the disclosure herein includes all possible combinations of such specific features. For example, if a specific feature is disclosed in a particular aspect or embodiment of the disclosure herein, or in the context of a particular claim, this feature may also be used in combination with and / or in the context of other specific aspects and embodiments of the disclosure, and in the disclosure generally, to the extent possible.
[0388] When reference is made herein to a method including two or more specified steps, the specified steps may be performed in the order listed or in any order or simultaneously (unless the context excludes this possibility), and the method may include one or more other steps performed before any of the specified steps, between two of the specified steps, or after all of the specified steps (unless the context excludes this possibility).
[0389] In order to facilitate a better understanding of the present disclosure, the following examples of specific embodiments are provided. The following examples should not be read to limit or define the entire scope of the present disclosure. EXAMPLES
[0390] Example 1: Materials and Methods for Examples 1-21 Generation of human / mouse B7-H4-Fc, the IgV domains of human / mouse B7-H4 and the IgC domains of human and mouse B7-H4. The genes for human B7-H4 (NCBI accession number: NP_078902, Phe29-Ala258) and mouse B7-H4 (NCBI accession number: Q7TSP5, Phe29-Pro258) were synthesized and fused to a gene encoding the N-terminus of human IgG1 Fc (NCBI accession number: P01587, Pro100-Lys330). The gene encoding the B7-H4-Fc fusion protein was inserted into a mammalian expression vector such as pcDNA3.1 (ThermoFisher) and transfected into Expi293F cells (ThermoFisher). The cells were incubated at 30 °C in a large-capacity reach-in CO2 incubator (Thermo Scientific) for 4 to 5 days, after which the clear supernatant was loaded onto a MabSelect SuRe Protein A column. The purified protein was eluted with glycine buffer at pH 3. After neutralization with Tris buffer pH 7.5, the proteins were analyzed by SDS-PAGE and / or SE-HPLC. The same method was used to generate the IgV domains of both human B7-H4-Fc and mouse B7-H4-Fc (Phe29-Val157) and the IgC domains of human B7-H4-Fc (Asp158-Ala258) or mouse B7-H4-Fc (Asp158-Pro258).
[0391] Antibody identification with the Superman 2.0 phage display library Human B7-H4-his and mouse B7-H4-his were biotinylated using EZ-Link™ NHS-PEG4-biotin (ThermoFisher). Purified phages from the Superman 2.0 phage display library (Distributed Bio) were mixed with 100 μg–0.5 μg of human / mouse B7-H4-Fc or biotinylated human / mouse B7-H4-his. After 0.5–1 h incubation at RT, the B7-H4 / phage mixture was captured with protein G (for Fc-fused B7-H4) or strep (for biotinylated B7-H4) magnetic beads. Unbound phages were washed with PBS-T and PBS and eluted with 100 mM triethylamine (TEA). The eluted phages were neutralized with Tris buffer, pH 7.5, and used to infect electrocompetent ER2738 Escherichia coli (E. coli) cells growing in logarithmic phase. After overnight incubation at 30°C, the bacteria were harvested and used to inoculate 2YT containing glucose, tetracycline, and carbenicillin. M13 helper phage was used to infect logarithmic phase bacteria, and the medium was changed to 2YT containing kanamycin and carbenicillin to continue phage growth overnight. The next day, the phages were purified with PEG and resuspended in PBS. The purified phages were prepared for the next round of panning. To monitor the panning, individual bacterial colonies were picked and grown to logarithmic phase. Phages were amplified by adding M13 helper phage as described above. Crude phage mixture was added to B7-H4 coated plates. Binding was detected using HRP-anti-M13 antibody. Typically, 3-4 rounds of panning were performed until the positive rate reached more than 50%.
[0392] A light chain shuffling method was used to improve the affinity of the lead. Briefly, a novel phage library was constructed by pairing the lead heavy chain with a pool of light chains from the Superman2.0 library. Antibodies with higher affinity under harsh conditions, such as higher temperature, lower or higher pH, and the presence of additional B7-H4 antigen in the wash buffer, were identified.
[0393] scFv to IgG conversion, expression and purification The genes encoding the variable light and heavy chains were fused to genes encoding the constant domains of human IgG1 light or heavy chains, respectively. The entire protein coding sequence (encoding both the variable and constant domains) was introduced into a mammalian expression vector such as pcDNA3.1 (ThermoFisher). The vector was transfected into an expression cell line such as HEK293, Chinese Hamster Ovary (CHO) cells or α1,6-fucosyltransferase (FUT8) transfected CHO (enhancing ADCC activity). The antibodies were purified using a Protein A column and SEC-HPLC to produce pure antibodies containing more than 95% monomer.
[0394] Generation of fusion proteins The IL-15 receptor sushi domain (residues 33-93 of NCBI accession number EAW86418.1) and mature IL-15 (residues 49-162 of NCBI accession number P40933) were synthesized and fused to the 3' end of the sequence encoding the heavy chain of the anti-B7-H4 antibody (residues 49-162 of NCBI accession number P40933 were obtained encoding a C-terminal fusion protein). Mutations in the heavy chain (S354C and T366W in one heavy chain, Y349C, T366S, L368A and Y407V in the other heavy chain) were introduced to stabilize the heterodimer of the two heavy chains. Further mutations in the Fc region of the antibody (M428L and N434S) were introduced to increase the antibody binding to FcRn at pH 6, thereby extending the serum half-life of the protein. Expression and purification of the fusion antibody were performed as described above.
[0395] Dose-response ELISA Approximately 1-2 μg of human or mouse B7-H4-Fc (or his-tagged) was immobilized on an ELISA plate (Immuno 2HB, Thermo scientific, Cat. No. 3455) overnight at 4°C. After blocking the plate with 3% PBS+milk, serially diluted antibodies were added to the blocked plate and incubated at RT for 1-1.5 h. After washing the plate with PBS-T (0.05%), horse radish peroxidase (HRP)-conjugated antibodies targeting hFab were added to the plate. Signal was developed by adding 3,3',5,5'-tetramethylbenzidine (TMB) (followed by 1N H 2 SO 4 The reaction was stopped by adding 50 mM NaCl. The OD at 450 nm was read using an ELISA plate reader (TECAN Infinite M1000). The OD450 concentration curve for the antibody was plotted using Prism's GraphPad, and the EC50 value was calculated.
[0396] Biacore Kinetics Surface plasmon resonance experiments were performed using a Biacore T200 instrument equipped with a CM5 sensor chip. The system was equilibrated with running buffer HBS-EP, pH 7.4. Ligands were immobilized using amine coupling chemistry. The surfaces of flow cells 1-4 were activated with an amine coupling kit for 5 min at a flow rate of 10 μL / min. Ligands (human B7-H4-Fc, human B7-H4-hism and mouse B7-H4-Fc, at a concentration of 5 μg / mL in 10 mM sodium acetate, pH 5.0) were immobilized at a density of 50-100 RU on flow cells 2, 3 and 4, respectively. Flow cell 1 was left blank and served as the reference surface. All flow cell surfaces were blocked by injecting 1 M ethanolamine, pH 8.0, for 5 min. To collect kinetic binding data, each analyte (1X HBS-EP buffer, pH 7.4) was injected into four flow cells at concentrations ranging from 100 nM to 0.1 nM, at a flow rate of 30 μL / min and at a temperature of 25°C. Protein complexes were allowed to associate and dissociate for 180 s and 1000 or 1200 s, respectively. The surface was regenerated by injecting 1.5 M NaCl / 0.05 M NaOH for 30 s. Data were fitted to a simple 1:1 interaction model using the Langmuir fit option available within the Biaevaluaton software.
[0397] Generation of mB7-H4-expressing CT26 cell line Mouse carcinoma CT26 cell line (CT26.CL25, Cat. No. CRL-2639) was obtained from ATCC. Mouse B7-H4 (Vtcn1) ORF cDNA in pReceiver-M68 vector (Cat. No. EX-32401-M68) and its empty control vector pReceiver-M68 vector (Cat. No. EX-NEG-M68) were purchased from GeneCopoeia. CT26 cells were transfected with purified plasmids using Lipofectamine® 2000 DNA transfection reagent. After 48-72 hours of transfection, transfected CT26 cell colonies were selected and cultured in puromycin-containing medium, and the mB7-H4 expression levels of selected clones were detected by staining with PE anti-mouse B7-H4 antibody (Cat. No. 139406, Biolegend) using Guava® flow cytometry easyCyte™ system.
[0398] Assessment of antibody / fusion protein binding to cell-expressed B7-H4 by FACS Cells were harvested, washed once, and then resuspended in ice-cold FACS buffer at a concentration of 1 × 10 6 Cells were resuspended at 1:100 cells / mL. 25 μL of cell suspension was added to each well of a 96-well round-bottom microliter plate. Serially diluted antibodies to the fusion proteins were added to each well and incubated at 4°C for 1 h. Cells were washed three times by centrifugation at 1500 rpm for 5 min and then stained with secondary antibodies (1:200 dilution) for 30 min at 4°C in the dark. Cells were washed once and resuspended in 100 μL of PBS buffer before analysis using a Guava flow cytometry EasyCyte system.
[0399] M-07e cell culture and proliferation assay Human acute megakaryoblastic leukemia M-07e cell line was cultured in IMDM medium supplemented with 15% heat-inactivated FBS and 20% conditioned medium of cell line 5637. After serial dilutions of antibodies or fusion proteins were added to 96-well plates, cells were plated at 2.5 × 10 per well in complete IMDM medium. 4The cells were incubated at 37° C. for 3 days and cell proliferation was detected using the CellTiter-Glo® Luminescent Cell Viability Assay Kit.
[0400] Proliferation of human PBMCs and T cell subtype analysis On the day of the experiment, human frozen PBMCs were thawed and immediately prepared in complete IMDM medium supplemented with 10% heat-inactivated FBS for the proliferation assay. Serial dilutions of antibodies were added to 96-well plates, after which cells were plated at 1 × 10 per well. 5 The cells were cultured at 37° C. for 6 days and cell proliferation was detected using the CellTiter-Glo® Luminescent Cell Viability Assay Kit.
[0401] For T cell population analysis, cells were washed once and stained with the fixable viability dye eFluor780 for 10 min at 4° C. After washing, cells were fixed and permeabilized with Foxp3 transcription factor staining buffer set, then stained with anti-CD3-PE, anti-CD4-APC, anti-CD8α-PECy7, and anti-Ki67-FITC for 1 h at 4° C. Proliferating CD4 (CD4+Ki67+) or CD8 (CD8+Ki67+) T cell populations were analyzed and defined using the Guava flow cytometry EasyCyte system.
[0402] Secretion of IFNγ cytokines by T cells The human B7-H4 transfected cell line, hB7-H4-CHO, was placed in a 96-well U-bottom plate at 4 × 10 cells per well. 4 Cells were seeded into each well. Serially diluted antibodies were added to each well. Cell suspensions of effector cells and human T cells (isolated from LeuPak using EasySep human T cell isolation kit) were prepared and seeded into each well at the desired effector to target cell ratio (e.g., 5:1). Co-cultures were incubated at 37°C for 96 hours and harvested for IFNγ cytokine ELISA (R&D).
[0403] Antibody internalization assay Target cells (such as SK-BR-3 MDA-MB-468 cells) were seeded at 6,000 cells per well into 96-well flat-bottom plates and incubated for 3 hours to allow the cells to settle on a horizontal surface. Antibody / Incucyte FabFlour reagent mix (IncuCyte® Human FabFlour-pH Red Antibody Labeling Dye) was added to each well and tested at a final concentration of 2 μg / mL. Assay plates were repeatedly scanned every hour using the IncuCyte® Viable Cell Analysis System. Images were analyzed with IncuCyte® software.
[0404] Assessment of tumor cell killing using the Promega ADCC reporter bioassay The ADCC reporter bioassay uses genetically modified effector cells. The analysis was performed using an ADCC reporter bioassay kit (ADCC reporter bioassay G7010 for hIgG1). Briefly, target cancer cells were plated in a 96-well flat-bottom plate at 1.5 × 1.0 μg / well. 4 The following day, growth medium was aspirated and ADCC assay buffer and serial dilutions of antibody were added to each well. A cell suspension of ADCC bioassay effector cells was prepared and seeded at the desired effector cell to target cell ratio (e.g., 5:1). After incubation at 37°C for 6 hours, Bio-Glo™ Luciferase Assay Reagent was added to each well and incubated for 15 minutes. Luminescence signal was measured using a plate reader.
[0405] Tumor cell killing by hPBMC (immune cell killing assay) To measure tumor cell killing by immune cells in the presence of antibodies or fusion proteins, SKB-R3 / hPBMC co-culture models were prepared for antibody-dependent cell-mediated cytotoxicity (ADCC) analysis (short-term analysis) or cytotoxic T cell killing analysis (long-term analysis). Target cancer cells, SKB-R3 cells, were labeled with IncuCyte® CytoLight red rapid reagent and seeded at 5,000 cells per well in 96-well flat-bottom plates. The next day, growth medium was aspirated and IncuCyte® Annexin V green dye and antibody dilutions were added to each well. Effector cells, cell suspensions of hPBMCs, were prepared and seeded at the desired effector to target cell ratio (10:1 or 5:1). Assay plates were scanned repeatedly and images were analyzed using the IncuCyte® Viability Analysis System and IncuCyte® software according to the instructions.
[0406] pSTAT5 measurement using HEK-Blue IL-2 reporter cells Human HEK-Blue™ IL-2 cells were generated by stable transfection of human embryonic kidney HEK293 cell line with human IL-2Rα, IL-2Rβ and IL-2Rγ genes along with human JAK3 and STAT5 genes to obtain a fully functional IL-2 signaling pathway. In addition, a STAT5-inducible SEAP reporter gene was also introduced. Upon IL-2 stimulation, HEK-Blue™ IL-2 cells trigger the activation of STAT5 and the subsequent secretion of SEAP. The level of STAT5-inducible SEAP can be easily monitored using QUANTI-Blue™ solution.
[0407] HEK-Blue IL-2 cells were maintained and subcultured in complete DMEM medium (supplemented with 10% heat-inactivated FBS) containing 1 μg / mL puromycin and 1X HEK-Blue CLR Selection. For reporter assays, cells were cultured at 2.8 × 10 520 μL of serially diluted antibody or fusion antibody was first added to each well of a flat-bottom 96-well plate, followed by 180 μL of cell suspension. The cells were incubated at 37°C for 20–24 h in CO 2 After incubation in an incubator, the SEAP levels were detected at 630 nm using QUANTI-Blue™ solution according to the manufacturer's instructions.
[0408] Antibody nomenclature An antibody simply designated "X" refers to an antibody that contains both a variable heavy chain designated "X" and a variable light chain designated "X." For example, antibody 3F2 contains a 3F2 variable light chain and a 3F2 variable heavy chain.
[0409] An antibody designated "X / Y" contains a variable heavy chain designated "X" and a variable light chain designated "Y." For example, the antibody 3F2 / 50A10 contains a 3F2 variable heavy chain and a 50A10 variable light chain.
[0410] Control antibodies The following antibodies were used as controls: (1) B7-H4 IgV domain-binding antibody FPA150 (Five Prime), see antibody “20502” in U.S. Patent Application Publication No. 2019 / 0085080A1 ("Control Antibody 1", binds to the IgC domain of B7-H4, also referred to as FPA150), (2) B7-H4 IgC domain-binding antibody 6H3 (Medimmune), see U.S. Patent No. 9,574,000 (antibody “6H3”, “Control Antibody 2”, binds to the IgC domain of B7-H4), and (3) DP47.
[0411] Example 2: Generation of high affinity anti-B7-H4 antibodies Phage display was performed as described above. First, panning was performed on immobilized hB7-H4-Fc or biotin-hB7-H4-his captured on strep beads. See Figure 1 (step 1). In this step, the following antibodies were identified: (1) Antibodies that bind to hB7-H4: 1A12, 1D3, 1F11, 3D1, 3F2, 4H6, 6C3, 9H2 and 4B9 (Figure 2 (Batch A-1)). Antibodies 1A12, 1D3, 1F11, 3D1, 3F2, 4H6, 6C3 and 9H2 bound to both soluble and cellular hB7-H4, specifically to the IgV domain of hB7-H4 (Figures 2 to 5). 4B9 bound tightly to hB7-H4-Fc but not to mB7-H4. Binding of 4B9 to hB7-H4 required both IgV and IgC (Figure 6). (2) Antibodies that bind to the IgC domain of human and mouse hB7-H4: 5E4, 5F4, 5G6, 9D11, 9E1, 15B11, 24B6, 24F4 and 30G4 (Figure 2 (batch A-2) and Figures 6 to 7). (3) Antibodies that bind to the IgV domain of human and mouse hB7-H4: 31D7 and 39A11. See Figure 1 (batch A-3) and Figure 8.
[0412] The specificities and specific binding sites of the isolated antibodies are summarized in Table 1.
[0413] [Table 1]
[0414] Example 3: Kinetics of binding of isolated anti-B7-H4 antibodies to soluble B7-H4 Biacore analysis was used to examine the kinetics of binding of various antibodies to the target, and the results are summarized in Tables 2-4.
[0415] Antibodies 1D3 and 3F2 bind tightly to hB7-H4 and were selected for affinity maturation (light chain shuffling) (Figure 1(Step B)). The h / mB7 H4-cross-reactive antibodies 9D11 (IgC domain binding antibody) and 39A11 (IgV domain binding antibody) bind tightly to these targets and were also selected for affinity maturation (light chain shuffling) (Figure 1(Step B)).
[0416] [Table 2]
[0417] [Table 3]
[0418] [Table 4]
[0419] Example 4: Affinity maturation of anti-B7-H4 antibodies 3F2 and 1D3 (hB7-H4 IgV domain binding antibodies) by light chain shuffling Affinity maturation of 3F2 and 1D3 was performed by light chain shuffling. For this, the heavy chains of 3F2 or 1D3, respectively, were shuffled at 1.0×10 8 The resulting library was panned on immobilized hB7-H4-Fc or biotin-hB7-H4-his captured on strep beads under the difficult conditions described in Example 1. The sequences of the isolated 3F2 and 1D3 derivatives are shown in Table 5.
[0420] The isolated 3F2 derivatives 3F2 / 50A10 and 3F2 / 49A2 had the same heavy chain sequence as 3F2, but a different light chain sequence from 3F2 (Figure 1 (Batch B-1)). Like their parent antibodies, only the derivatives 3F2 / 50A10 and 3F2 / 49A2 bound to the IgV domain of hB7-H4. The 3F2 derivatives 3F2 / 50A10 and 3F2 / 49A2 showed tighter binding to cellular human B7-H4 than the parent antibody 3F2 (Table 6).
[0421] The isolated 1D3 derivatives 1D3 / 47B2 and 1D3 / 45A2 have the same heavy chain sequence as 1D3, but a different light chain sequence from 1D3 (Figure 1 (Batch B-2)). Like their parent antibodies, only the derivatives 1D3 / 47B2 and 1D3 / 45A2 bound to the IgV domain of hB7-H4. The 1D3 derivatives 1D3 / 47B2 and 1D3 / 45A2 showed tighter binding to cellular human B7-H4 than the parent antibody 1D3 (Table 6).
[0422] The binding of these antibodies to soluble and cellular B7-H4 is shown in Figures 9-10.
[0423] [Table 5]
[0424] [Table 6]
[0425] Example 5: Affinity maturation of anti-B7-H4 antibody 9D11 (h / mB7-H4 IgC domain binding antibody) by light chain shuffling Affinity maturation of 9D11 was performed by light chain shuffling. For this, the heavy chain of 9D11 was shuffled at 1.0×10 8 The resulting library was panned on immobilized hB7-H4-Fc or biotin-hB7-H4-his captured on strep beads under the difficult conditions described in Example 1. See Figure 1 (Step B). The sequences of the isolated 9D11 derivatives are shown in Table 7.
[0426] The isolated 9D11 derivatives 9D11 / 67E12, 9D11 / 67C3, 9D11 / 67C6, 9D11 / 67H9, 9D11 / 67G3 and 9D11 / 68F5 have the same heavy chain sequence as 9D11 but a different light chain sequence than 9D11 (Figure 1 (Batch B-3)). The binding affinities of these antibodies are shown in Table 8 and the binding of these antibodies to soluble and cellular B7-H4 is shown in Figures 11-13.
[0427] [Table 7]
[0428] [Table 8]
[0429] Example 6: Affinity maturation of anti-B7-H4 antibody 39A11 (h / mB7-H4 IgV domain binding antibody) by light chain shuffling Affinity maturation of 39A11 was performed by light chain shuffling. For this, the heavy chain of 39A11 was shuffled at 1.0×10 8 The resulting library was panned on immobilized hB7-H4-Fc or biotin-hB7-H4-his captured on strep beads under the difficult conditions described in Example 1 (FIG. 1 (Step B)). The sequences of the isolated 39A11 derivatives are shown in Table 9.
[0430] The isolated 39A11 derivatives 39A11 / 57H3, 39A11 / 57G8, 39A11 / 56A9, 39A11 / 56H7 and 39A11 / 62F9 have the same heavy chain sequence as 39A11 but a different light chain sequence than 39A11 (Figure 1 (Batch B-4)). Like the parent 39A11, all derivatives bound only to the IgV domain of human and mouse B7-H4. The 39A11 derivatives generally showed tighter binding to cellular human B7-H4 than the parent antibody 39A11. The binding of these antibodies to soluble and cellular B7-H4 is shown in Table 10 and Figures 14-15.
[0431] [Table 9]
[0432] [Table 10]
[0433] The top three antibodies from Examples 3 to 6, 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody), were selected for further characterization.
[0434] Example 7: Binding of anti-B7-H4 antibodies to soluble and cell-expressed B7-H4 Binding of antibodies 3F2 / 50A10 (hB7-H4 IgV domain-binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain-binding antibody), and 9D11 / 68F5 (h / mB7-H4 IgC domain-binding antibody) to soluble B7-H4 or cell-expressed B7-H4 was determined by ELISA or flow cytometry, respectively.
[0435] ELISA experiments demonstrated that both antibodies 3F2 / 50A10 and 39A11 / 57G8 bound tightly to the IgV domain of hB7-H4. Antibody 39A11 cross-reacted with mB7-H4. Antibody 9D11 / 68F5 bound to the IgC domain of human and mouse B7-H4 (Figure 16).
[0436] Flow cytometry experiments demonstrated that both antibodies 3F2 / 50A10 and 39A11 / 57G8 bound tightly to cellular hB7-H4 expressed on the triple-negative breast cancer cell line MDA-MB-468 and the ovarian cancer cell line SK-BR-3. Antibodies 39A11 / 57G8 and 9D11 / 68F5 also bound to cellular mB7-H4 expressed on the mB7-H4-transfected mouse colon cancer cell line CT26 (Figure 17).
[0437] Example 8: Anti-B7-H4 antibodies induce B7-H4 internalization Antibodies specific for cell surface antigens can induce antigen-mediated endocytosis of antibody / antigen complexes. To determine whether binding of anti-B7-H4 antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to their targets results in internalization of the antibody / antigen complex, IncuCyte® FabFluor antibody labeling reagent was used. FabFluor is an Fc region-targeted Fab fragment conjugated to a pH-sensitive fluorescent probe. Fluorogenic signals are observed as Fab-Ab complexes are internalized and processed through acidic (pH 4.5-5.5) lysosomes and endosomes.
[0438] The IgC domain antibody 9D11 / 68F5 and the IgV domain antibody 39A11 / 57G8 triggered internalization by binding to B7-H4 (FIG. 18).
[0439] Example 9: Anti-B7-H4 antibodies restore T cell function Binding of cell-expressed B7-H4 to its (unknown) cognate receptor on T cells suppresses the cytokine secretion function of T cells. Therefore, we tested whether the anti-B7-H4 antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) could restore the cytokine secretion function (e.g., IFNγ secretion) of T cells by inhibiting the interaction of B7-H4 with its cognate receptor on T cells.
[0440] The IgV-binding antibodies 39A11 / 57G8 and 3F2 / 50A10 were highly potent in restoring T cell function as measured by IFNγ secretion (FIG. 19).
[0441] Example 10: Anti-B7-H4 antibodies kill tumor cells To determine the ability of anti-B7-H4 antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody) and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) to kill tumor cells, an antibody-dependent cell-mediated cytotoxicity (ADCC) bioassay was used (Promega G7010 / G7018). The assay works as follows: when the FcγRIIIa receptor on the cell surface of an effector cell (e.g., a natural killer cell) binds to the Fc effector portion of an antibody bound to its target on, for example, a cancer cell, cross-linking of the effector cell and the cancer cell occurs. This leads to the activation of ADCC. The ADCC reporter assay utilized in this experiment detects an early step in the activation of the ADCC pathway: activation of gene transcription via the NFAT (nuclear factor of activated T cells) pathway in the effector cell. In addition, the assay uses genetically modified Jurkat cells stably expressing the V158 (high affinity) variant of the FcγRIIIa receptor and an NFAT response element driving the expression of firefly luciferase as effector cells.
[0442] All three antibodies tested were effective in killing both SK-BR-3 and MDA-MB-468 cells (FIG. 20).
[0443] Tumor cell killing was also evaluated using the IncuCyte® immune cell killing assay. For this purpose, a SKBR3 / hPBMC co-culture model was set up to analyze ADCC.
[0444] The IgV domain-binding antibodies 3F2 / 50A10 and 39A11 / 57G8, but not the negative control antibody DP47, were effective in killing SK-BR-3 cancer cells when mixed with hPBMCs (FIG. 21).
[0445] Example 11: Binding characteristics for selected anti-B7-H4 antibodies The kinetics for antigen binding were determined for the anti-B7-H4 antibodies 3F2 / 50A10 (hB7-H4 IgV domain binding antibody), 39A11 / 57G8 (h / mB7-H4 IgV domain binding antibody), and 9D11 / 68F5 (h / mB7-H4 IgC domain binding antibody) (Tables 11 and 12). These experiments were performed in separate experiments from the Biacore analysis described above.
[0446] [Table 11]
[0447] [Table 12]
[0448] Example 12: Construction of a fusion protein containing an anti-B7-H4 antibody Several heterodimeric C-terminal fusion proteins containing anti-B7-H4 antibodies were generated (Table 13). As shown in FIG. 1B, the fusion proteins contained a first heavy chain (containing the variable and constant regions from N-terminus to C-terminus), a second heavy chain (containing the variable region, constant region, IL-15Rα sushi domain, and IL-15 from N-terminus to C-terminus) and two light chains. Heterodimerization was achieved by introducing so-called Knob-into-hole (CW-CSAV) mutations in the Fc region of the antibody, which further stabilized the heterodimer. The "LS" mutations (M428L / N434S) enhanced the affinity to FcRn and reduced the K at pH 6. off This slows down the rate of IL-15 production, resulting in an increased serum half-life. Finally, the N65S mutation in IL-15 reduces the ability of IL-15 to stimulate lymphocyte proliferation.
[0449] [Table 13]
[0450] Example 13: Binding of fusion proteins containing anti-B7-H4 antibodies to soluble B7-H4 Binding of the fusion proteins 57G8 / IL15 and 50A10 / IL15 to soluble B7-H4 was determined by Biacore and ELISA. The Biacore results are shown in Table 14.
[0451] Similar to their parental antibodies, the fusion protein 50A10 / IL15 bound only to hB7-H4 (IgV domain) and 57G8 / IL15 bound to h / mB7-H4 (IgV domain) (see Table 14 and Figures 22 and 23). No significant differences were observed between the antibodies and the fusion antibodies for binding to soluble B7-H4 by both ELISA and Biacore.
[0452] [Table 14]
[0453] Example 14: Binding of fusion proteins containing anti-B7-H4 antibodies to cell-expressed B7-H4 Binding of the fusion proteins to cells expressing B7-H4 was assessed using FACS. Antibody 3F2 / 50A10 and fusion protein 3F2 / 50A10 bound to human B7-H4 expressed on SK-BR-3 (Figures 24A and 24C). Antibody 39A11 / 57G8 and fusion protein 57G8 / IL15 bound to both human and mouse B7-H4 expressed on SK-BR-3 and mB7-H4-CT26, respectively (Figures 24B and 24D).
[0454] Both antibodies 39A11 / 57G8 and 3F2 / 50A10 bound to B7-H4 expressed on triple-negative breast cancer cell lines MDA-MB-468 and MX-1 (Figure 25 and Table 15). IL-15 fusion proteins containing 39A11 / 57G8 or 3F2 / 50A10, respectively, also bound to B7-H4 expressed on MDA-MB-468 and MX-1 with similar affinity as the respective monospecific parent antibodies (Figure 25 and Table 15).
[0455] [Table 15]
[0456] Example 15: Fusion proteins containing anti-B7-H4 antibodies kill tumor cells in a tumor cell / hPBMC co-culture model The ability of fusion proteins containing anti-B7-H4 antibodies to kill tumor cells was evaluated using the IncuCyte® immune cell killing assay. For this, SKBR3 / hPBMC co-culture models or MDA-MB-468 / hPBMC co-culture models were prepared to analyze ADCC. Tumor cell killing was tested at a low effector to target cell ratio (5:1) and monitored for up to 96 hours in the Incucyte.
[0457] Fusion proteins 57G8 / IL15 and 50A10 / IL15 fusions showed stronger killing than the parental antibodies 39A11 / 57G8 and 3F2 / 50A10, respectively. Fusion proteins 50A10 / IL15 and 57G8 / IL15 fusions showed stronger killing than the non-targeting fusion DP47 / IL15 (Figure 26).
[0458] After 7 days of treatment with the fusion proteins 57G8 / IL15 or 50A10 / IL15, respectively, the majority of MDA-MB-468 cells were killed (FIG. 26E).
[0459] Example 16: Effect of fusion proteins containing anti-B7-H4 antibodies on hPBMC proliferation The effect of antibodies 39A11 / 57G8 and 3F2 / 50A10 and fusion proteins 57G8 / IL15 and 50A10 / IL15 on hPBMC proliferation was determined. As controls, antibody DP47 and an IL-15 fusion protein containing DP47 were used. All fusions showed a similar ability to induce lymphocyte proliferation in human PBMCs that do not express B7-H4 (Figure 27A). CD4 + More CD8 than T cells + T cells expanded (Figures 27B and 27C).
[0460] Example 17: Fusion proteins containing anti-B7-H4 antibodies activate the STAT5 signaling pathway The ability of the fusion proteins 57G8 / IL15 and 50A10 / IL115 to activate the p-STAT5 signaling pathway via the IL-2 receptor was tested. As a control, an IL-15 fusion protein containing DP47 was used. All fusions exhibited similar potency in activating the STAT5 pathway downstream of IL-2Rβγ (Figure 28).
[0461] Example 18: Fusion proteins containing anti-B7-H4 antibodies kill tumor cells in a Promega bioassay An antibody-dependent cell-mediated cytotoxicity (ADCC) bioassay (Promega) was used to assess the ability of the fusion proteins 57G8 / IL15 and 50A10 / IL115 to kill tumor cells.
[0462] Antibodies 39A11 / 57G8 and 3F2 / 50A10 and fusion proteins 57G8 / IL15 and 50A10 / IL15 triggered B7-H4-mediated ADCC of SK-Br-3 and MDA-MB-468 cells (Figure 29). In MDA-MB-468 cells, 3F2 / 50A10 and 50A10 / IL-15 showed stronger ADCC function than 39A11 / 57G8 and 57G8 / IL-15 due to increased binding of the antibodies to B7-H4 expressed on MDA-MB-468 cells.
[0463] Example 19: Binding of fusion proteins (anti-B7-H4 antibody and LS mutations) to soluble B7-H4 The "LS" mutation (M428L / N434S) in the antibody constant region enhances affinity to FcRn and has a K off This slows down the rate of release, resulting in an increased serum half-life.
[0464] Fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS bound to soluble human B7-H4Fc and human B7-H4his. No difference in binding was observed for these four fusion proteins (Figures 30A and 30C). Fusion proteins 57G8 / IL-15 and 57G8 / IL-15_LS bound to soluble mouse B7-H4Fc and mouse B7-H4his. No difference in binding was observed for 57G8 / IL-15_LS and 57G8 / IL-15 (Figures 30B and 30D).
[0465] Example 20: Binding of fusion proteins (anti-B7-H4 antibodies and LS mutations) to cells expressing B7-H4 FACS was used to assess binding of the fusion proteins to cells expressing B7-H4.
[0466] Fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS all bound to human tumor cell-expressed B7-H4. Fusion proteins 50A10 / IL-15 and 50A10 / IL-15_LS showed stronger binding to SK-BR-3 cells than fusion proteins 57G8 / IL-15 or 57G8 / IL-15_LS (Figure 31A). Fusion proteins 57G8 / IL-15 and 57G8 / IL-15_LS bound to mouse B7-H4 transfected into the mouse tumor cell line CT-26 (Figure 31B). No differences in binding were observed for 57G8 / IL-15 compared to 57G8 / IL-15, or for 50A10 / IL-15_LS compared to 50A10 / IL-15 (Figure 31).
[0467] Example 21: Ability of fusion protein (containing anti-B7-H4 antibody and LS mutation) to induce proliferation of IL-2-dependent M07e cells The ability of the fusion proteins 57G8 / IL-15, 57G8 / IL-15_LS, 50A10 / IL-15 and 50A10 / IL-15_LS to induce proliferation of IL-2-dependent M07e cells was determined. All fusions were able to induce proliferation of M07e cells (FIG. 32).
[0468] array
[0469] [Table 16]
[0470] [Table 17]
[0471] [Table 18]
[0472] [Table 19]
[0473]
Table 20
[0474]
Table 21
[0475]
Table 22
[0476]
Table 23
[0477]
Table 24
[0478]
Table 25
[0479]
Table 26
[0480]
Table 27
[0481]
Table 28
[0482]
Table 29
[0483]
Table 30
[0484]
Table 31
[0485]
Table 32
[0486]
Table 33
[0487]
Table 34
[0488]
Table 35
[0489]
Table 36
[0490]
Table 37
[0491]
Table 38
[0492]
Table 39
[0493]
Table 40
[0494]
Table 41
[0495]
Table 42
Claims
1. An anti-B7-H4 antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3; a. CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, and CDR3H comprises SEQ ID NO: 18; i. CDR1L comprises SEQ ID NO:20, CDR2L comprises SEQ ID NO:21, and CDR3L comprises SEQ ID NO:22; or ii. CDR1L comprises SEQ ID NO:66, CDR2L comprises SEQ ID NO:67, and CDR3L comprises SEQ ID NO:68; or iii. CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO: 72; or b. CDR1H comprises SEQ ID NO:4, CDR2H comprises SEQ ID NO:5, and CDR3H comprises SEQ ID NO:6; i. CDR1L comprises SEQ ID NO:8, CDR2L comprises SEQ ID NO:9, and CDR3L comprises SEQ ID NO:10; or ii. CDR1L comprises SEQ ID NO:77, CDR2L comprises SEQ ID NO:78, and CDR3L comprises SEQ ID NO:79; or iii. CDR1L comprises SEQ ID NO: 81, CDR2L comprises SEQ ID NO: 82, and CDR3L comprises SEQ ID NO: 83; An anti-B7-H4 antibody or an antigen-binding fragment thereof.
2. The anti-B7-H4 antibody or antigen-binding fragment thereof of claim 1, wherein the CDR1H comprises SEQ ID NO: 16, the CDR2H comprises SEQ ID NO: 17, the CDR3H comprises SEQ ID NO: 18, the CDR1L comprises SEQ ID NO: 70, the CDR2L comprises SEQ ID NO: 71, and the CDR3L comprises SEQ ID NO:
72.
3. a. the heavy chain variable region comprises SEQ ID NO:15, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15; i. the light chain variable region comprises SEQ ID NO:19, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:19; ii. the light chain variable region comprises SEQ ID NO:65, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:65; or iii. the light chain variable region comprises SEQ ID NO:69, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:69; or b. the heavy chain variable region comprises SEQ ID NO:3, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:3; i. the light chain variable region comprises SEQ ID NO:7, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:7; ii. the light chain variable region comprises SEQ ID NO:76, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:76; or iii. the light chain variable region comprises SEQ ID NO:80, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:80; The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 1.
4. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 3, wherein the heavy chain variable region comprises SEQ ID NO:15 or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:15, and the light chain variable region comprises SEQ ID NO:69 or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:
69.
5. a. the heavy chain variable region comprises SEQ ID NO: 15; i. the light chain variable region comprises SEQ ID NO: 19; ii. the light chain variable region comprises SEQ ID NO:65; or iii. the light chain variable region comprises SEQ ID NO:69; or b. the heavy chain variable region comprises SEQ ID NO:3; i. the light chain variable region comprises SEQ ID NO:7; ii. the light chain variable region comprises SEQ ID NO: 76; or iii. the light chain variable region comprises SEQ ID NO: 80; The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 3.
6. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 5, wherein the heavy chain variable region comprises SEQ ID NO: 15 and the light chain variable region comprises SEQ ID NO:
69.
7. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 6, wherein the antibody or antigen-binding fragment thereof binds to the IgV domain of human hB7-H4.
8. An anti-B7-H4 antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3, CDR1H comprising SEQ ID NO: 46, CDR2H comprising SEQ ID NO: 47 and CDR3H comprising SEQ ID NO: 48; a. CDR1L comprises SEQ ID NO:50, CDR2L comprises SEQ ID NO:51, and CDR3L comprises SEQ ID NO:52; or b. CDR1L comprises SEQ ID NO:88, CDR2L comprises SEQ ID NO:89, and CDR3L comprises SEQ ID NO:90; or c. CDR1L comprises SEQ ID NO:92, CDR2L comprises SEQ ID NO:93, and CDR3L comprises SEQ ID NO:94; or d. CDR1L comprises SEQ ID NO:96, CDR2L comprises SEQ ID NO:97, and CDR3L comprises SEQ ID NO:98; or e. CDR1L comprises SEQ ID NO: 100, CDR2L comprises SEQ ID NO: 101, and CDR3L comprises SEQ ID NO: 102; or f. CDR1L comprises SEQ ID NO: 104, CDR2L comprises SEQ ID NO: 105, and CDR3L comprises SEQ ID NO: 106; or g. CDR1L comprises SEQ ID NO: 108, CDR2L comprises SEQ ID NO: 109, and CDR3L comprises SEQ ID NO: 110; An anti-B7-H4 antibody or an antigen-binding fragment thereof.
9. The anti-B7-H4 antibody or antigen-binding fragment thereof of claim 8, wherein the CDR1H comprises SEQ ID NO: 46, the CDR2H comprises SEQ ID NO: 47, the CDR3H comprises SEQ ID NO: 48, the CDR1L comprises SEQ ID NO: 108, the CDR2L comprises SEQ ID NO: 109, and the CDR3L comprises SEQ ID NO:
110.
10. the heavy chain variable region comprises SEQ ID NO:45, or a sequence which is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45; a. the light chain variable region comprises SEQ ID NO:49, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:49; b. the light chain variable region comprises SEQ ID NO:87, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:87; c. the light chain variable region comprises SEQ ID NO:91, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:91; d. the light chain variable region comprises SEQ ID NO:95, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:95; e. the light chain variable region comprises SEQ ID NO:99, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:99; f. the light chain variable region comprises SEQ ID NO: 103, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 103; or g. the light chain variable region comprises SEQ ID NO: 107, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 107; The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 8.
11. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 8 to 10, wherein the heavy chain variable region comprises SEQ ID NO:45, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:45, and the light chain variable region comprises SEQ ID NO:107, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:
107.
12. the heavy chain variable region comprises SEQ ID NO:45; a. the light chain variable region comprises SEQ ID NO:49; b. the light chain variable region comprises SEQ ID NO:87; c. the light chain variable region comprises SEQ ID NO:91; d. the light chain variable region comprises SEQ ID NO:95; e. the light chain variable region comprises SEQ ID NO:99; f. the light chain variable region comprises SEQ ID NO: 103; or g. the light chain variable region comprises SEQ ID NO:
107. The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 10.
13. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 8 to 12, wherein the heavy chain variable region comprises SEQ ID NO: 45 and the light chain variable region comprises SEQ ID NO:
107.
14. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 8 to 13, wherein the antibody or antigen-binding fragment thereof binds to the IgC domain of human and mouse hB7-H4.
15. An anti-B7-H4 antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, each of the heavy chain variable region and the light chain variable region comprising CDR1, CDR2 and CDR3, CDR1H comprising SEQ ID NO:58, CDR2H comprising SEQ ID NO:59 and CDR3H comprising SEQ ID NO:60; a. CDR1L comprises SEQ ID NO:62, CDR2L comprises SEQ ID NO:63, and CDR3L comprises SEQ ID NO:64; or b. CDR1L comprises SEQ ID NO: 115, CDR2L comprises SEQ ID NO: 116, and CDR3L comprises SEQ ID NO: 117; or c. CDR1L comprises SEQ ID NO: 119, CDR2L comprises SEQ ID NO: 120, and CDR3L comprises SEQ ID NO: 121; or d. CDR1L comprises SEQ ID NO: 123, CDR2L comprises SEQ ID NO: 124, and CDR3L comprises SEQ ID NO: 125; or e. CDR1L comprises SEQ ID NO: 127, CDR2L comprises SEQ ID NO: 128, and CDR3L comprises SEQ ID NO: 129, or f. CDR1L comprises SEQ ID NO: 131, CDR2L comprises SEQ ID NO: 132, and CDR3L comprises SEQ ID NO: 133; An anti-B7-H4 antibody or an antigen-binding fragment thereof.
16. The anti-B7-H4 antibody or antigen-binding fragment thereof of claim 15, wherein the CDR1H comprises SEQ ID NO: 58, the CDR2H comprises SEQ ID NO: 59, the CDR3H comprises SEQ ID NO: 60, the CDR1L comprises SEQ ID NO: 119, the CDR2L comprises SEQ ID NO: 120, and the CDR3L comprises SEQ ID NO:
121.
17. the heavy chain variable region comprises SEQ ID NO:57, or a sequence which is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57; a. the light chain variable region comprises SEQ ID NO:61, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:61; b. the light chain variable region comprises SEQ ID NO:114, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:114; c. the light chain variable region comprises SEQ ID NO: 118, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 118; d. the light chain variable region comprises SEQ ID NO: 122, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 122; e. the light chain variable region comprises SEQ ID NO: 126, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 126; or f. the light chain variable region comprises SEQ ID NO: 130, or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 130; The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 15.
18. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 15 to 17, wherein the heavy chain variable region comprises SEQ ID NO:57 or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:57, and the light chain variable region comprises SEQ ID NO:118 or a sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:
118.
19. the heavy chain variable region comprises SEQ ID NO:57; a. the light chain variable region comprises SEQ ID NO:61; b. the light chain variable region comprises SEQ ID NO: 114; c. the light chain variable region comprises SEQ ID NO: 118; d. the light chain variable region comprises SEQ ID NO: 122; e. the light chain variable region comprises SEQ ID NO: 126, or f. the light chain variable region comprises SEQ ID NO:
130. The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 17.
20. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 15 to 19, wherein the heavy chain variable region comprises SEQ ID NO:57 and the light chain variable region comprises SEQ ID NO:
118.
21. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 15 to 20, wherein the antibody or antigen-binding fragment thereof binds to the IgV domain of human and mouse hB7-H4.
22. An anti-B7-H4 antibody or antigen-binding fragment thereof, which binds to the same epitope on B7-H4 as the anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 21.
23. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 22, wherein the antibody or antigen-binding fragment is a chimeric antibody, a CDR-grafted antibody, or a humanized antibody, or an antigen-binding fragment thereof.
24. 24. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 23, wherein the antibody or antigen-binding fragment is a multispecific or bispecific antibody, or an antigen-binding fragment thereof.
25. The antibody or antigen-binding fragment is an scFv, Fv, Fab', Fab, F(ab') 2 25. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 24, which is a mAb, a serotype or a diabody.
26. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 25, wherein the antibody is an immunoglobulin of the IgG class.
27. 27. The anti-B7-H4 antibody or antigen-binding fragment thereof of claim 26, wherein the antibody or antigen-binding fragment has the isotype IgG1.
28. 28. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 27, wherein the antibody or antigen-binding fragment is aglycosylated.
29. 29. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 28, wherein the antibody or antigen-binding fragment thereof comprises a first heavy chain constant region and a second heavy chain constant region, and the antibody or antigen-binding fragment thereof comprises at least one modification in the CH3 domain of the first heavy chain constant region and the second heavy chain constant region that causes heterodimerization.
30. 30. The anti-B7-H4 antibody or antigen-binding fragment thereof of claim 29, wherein the modification in the CH3 domain of the first heavy chain constant region is different from the modification in the CH3 domain of the second heavy chain constant region.
31. 31. The anti-B7-H4 antibody or antigen-binding fragment thereof of claim 29 or 30, wherein the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat).
32. a. the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (Kabat EU index numbering) and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (Kabat EU index numbering); or b. the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat), and the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 31.
33. a. the first heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), or b. the second heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); The anti-B7-H4 antibody or antigen-binding fragment thereof according to claim 32.
34. 34. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 33, wherein the first heavy chain constant region, the second heavy chain constant region, or both, comprise the amino acid substitutions M428L and N434S (EU index numbering according to Kabat).
35. A fusion protein comprising: a. an anti-B7-H4 antibody or antigen-binding fragment thereof; b. an IL-15Rα sushi domain polypeptide comprising SEQ ID NO:167, or an amino acid sequence which is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:167; c. an IL-15 polypeptide comprising SEQ ID NO: 166, or an amino acid sequence that is at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 166; A fusion protein comprising:
36. The fusion protein of claim 35, wherein the B7H4 antibody comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), wherein CDR1H comprises SEQ ID NO: 16, CDR2H comprises SEQ ID NO: 17, CDR3H comprises SEQ ID NO: 18, CDR1L comprises SEQ ID NO: 70, CDR2L comprises SEQ ID NO: 71, and CDR3L comprises SEQ ID NO:
72.
37. The fusion protein of claim 35, wherein the B7H4 antibody comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), wherein CDR1H comprises SEQ ID NO: 172, CDR2H comprises SEQ ID NO: 173, CDR3H comprises SEQ ID NO: 174, CDR1L comprises SEQ ID NO: 175, CDR2L comprises SEQ ID NO: 176, and CDR3L comprises SEQ ID NO:
177.
38. The fusion protein of claim 35, wherein the B7H4 antibody comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), wherein CDR1H comprises SEQ ID NO: 178, CDR2H comprises SEQ ID NO: 179, CDR3H comprises SEQ ID NO: 180, CDR1L comprises SEQ ID NO: 181, CDR2L comprises SEQ ID NO: 182, and CDR3L comprises SEQ ID NO:
183.
39. The fusion protein of claim 35, wherein the B7H4 antibody comprises a heavy chain CDR1 (CDR1H), CDR2 (CDR2H), and CDR3 (CDR3H) and a light chain CDR1 (CDR1L), CDR2 (CDR2L), and CDR3 (CDR3L), wherein CDR1H comprises SEQ ID NO: 184, CDR2H comprises SEQ ID NO: 185, CDR3H comprises SEQ ID NO: 186, CDR1L comprises SEQ ID NO: 187, CDR2L comprises SEQ ID NO: 188, and CDR3L comprises SEQ ID NO:
189.
40. The fusion protein of any one of claims 35 to 39, wherein the IL-15Rα sushi domain polypeptide comprises SEQ ID NO:
167.
41. The fusion protein of claim 40, wherein the IL-15Rα sushi domain polypeptide consists of the amino acid sequence of SEQ ID NO:
167.
42. The fusion protein of any one of claims 35 to 41, wherein the IL-15 polypeptide comprises SEQ ID NO:
166.
43. The fusion protein of claim 42, wherein the IL-15 polypeptide consists of SEQ ID NO:
166.
44. The fusion protein of any one of claims 35 to 43, wherein the IL-15Rα sushi domain polypeptide is fused to the N-terminus of the IL-15 polypeptide.
45. The fusion protein of any one of claims 35 to 44, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a first heavy chain constant region and a second heavy chain constant region, and the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide are fused to the C-terminus of the first heavy chain constant region.
46. The fusion protein of claim 45, wherein the fusion protein comprises a linker joining (i) the IL-15Rα sushi domain polypeptide and the IL-15 polypeptide, and (ii) the C-terminus of the constant region.
47. The fusion protein of claim 46, wherein the linker is 25 to 35 amino acids in length.
48. 48. The fusion protein of claim 47, wherein the linker consists essentially of Gly (G), Asn (N), Ser (S), Thr (T), Ala (A), Leu (L) and Gln (Q).
49. The fusion protein of any one of claims 46 to 48, wherein the linker comprises SEQ ID NO:
168.
50. 50. The fusion protein of any one of claims 35 to 49, comprising SEQ ID NO:
169.
51. 51. The fusion protein of any one of claims 45 to 50, wherein the first heavy chain constant region and the second heavy chain constant region comprise at least one modification in the CH3 domain of the first heavy chain constant region and the second heavy chain constant region that causes heterodimerization.
52. 52. The fusion protein of claim 51 , wherein the modification in the CH3 domain of the first heavy chain constant region is different from the modification in the CH3 domain of the second heavy chain constant region.
53. 53. The fusion protein of claim 52, wherein the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C, T366W, Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat).
54. a. the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (Kabat EU index numbering) and the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (Kabat EU index numbering); or b. the second heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S354C and T366W (EU index numbering according to Kabat), and the first heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); 54. The fusion protein of claim 53.
55. a. the first heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the second heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat), or b. the second heavy chain constant region comprises the amino acid substitutions S354C and T366W (EU index numbering according to Kabat) and the first heavy chain constant region comprises the amino acid substitutions Y349C, T366S, L368A and Y407V (EU index numbering according to Kabat); 55. The fusion protein of claim 54.
56. 52. The fusion protein of any one of claims 35 to 51, wherein the first heavy chain constant region, the second heavy chain constant region, or both, comprise the amino acid substitutions M428L and N434S (EU index numbering according to Kabat).
57. The fusion protein of any one of claims 35 to 50, wherein the fusion protein comprises no more than one IL-15Rα sushi domain polypeptide and no more than one IL-15 polypeptide.
58. The fusion protein of any one of claims 35 to 57, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 22.
59. A fusion protein comprising: a. a light chain comprising SEQ ID NO:69 and / or SEQ ID NO:145; b. a first heavy chain comprising SEQ ID NO: 150 or SEQ ID NO: 151; c. A second heavy chain comprising SEQ ID NO: 157 or SEQ ID NO:
158.
60. a. the first heavy chain comprises SEQ ID NO: 150; b. The fusion protein of claim 59, wherein the second heavy chain comprises SEQ ID NO:
157.
61. a. the first heavy chain comprises SEQ ID NO: 151; b. The fusion protein of claim 59, wherein the second heavy chain comprises SEQ ID NO:
158.
62. A fusion protein comprising: a. a light chain comprising SEQ ID NO: 118 and / or SEQ ID NO: 144; b. a first heavy chain comprising SEQ ID NO: 148 or SEQ ID NO: 149; c. A second heavy chain comprising SEQ ID NO:155 or SEQ ID NO:
156.
63. a. the first heavy chain comprises SEQ ID NO: 148; b. The fusion protein of claim 62, wherein the second heavy chain comprises SEQ ID NO:
155.
64. a. the first heavy chain comprises SEQ ID NO: 149; b. The fusion protein of claim 62, wherein the second heavy chain comprises SEQ ID NO:
156.
65. A fusion protein comprising: a. a light chain comprising SEQ ID NO: 145; b. a first heavy chain comprising SEQ ID NO: 150; c. A second heavy chain comprising SEQ ID NO:
157.
66. A nucleic acid sequence encoding the anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 34, or the fusion protein of any one of claims 35 to 65.
67. A vector comprising the nucleic acid of claim 66.
68. 68. A cell comprising the nucleic acid of claim 66 or the vector of claim 67.
69. A cell expressing an anti-B7-H4 antibody or an antigen-binding fragment thereof according to any one of claims 1 to 34, or a fusion protein according to any one of claims 35 to 65.
70. A T cell expressing an anti-B7-H4 binding protein comprising the anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 34.
71. A T cell expressing an anti-B7-H4 binding protein comprising the heavy chain variable region and the light chain variable region of the anti-B7-H4 antibody or antigen-binding fragment thereof according to any one of claims 1 to 34.
72. The anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1 to 34, or the fusion protein of any one of claims 35 to 65, wherein the anti-B7-H4 antibody or antigen-binding fragment, or the fusion protein is conjugated to one or more of a cytotoxin, a fluorescent label, and an imaging agent.
73. 66. A pharmaceutical composition comprising: (i) an anti-B7-H4 antibody or antigen-binding fragment thereof according to any one of claims 1 to 34, or a fusion protein according to any one of claims 35 to 65; and (ii) a pharma- ceutically acceptable carrier.
74. 60. A method for producing an anti-B7-H4 antibody or antigen-binding fragment thereof, or a fusion protein, comprising culturing the cell of claim 59 under conditions such that the anti-B7-H4 antibody or antigen-binding fragment thereof, or fusion protein is produced.
75. 66. A method of inhibiting binding of B7-H4 to its ligand in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
76. 66. A method of enhancing T cell activation in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
77. 66. A method of enhancing CD8+ T cell proliferation in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
78. A method for inducing antibody-dependent cell-mediated cytotoxicity (ADCC) in B7-H4 expressing cells in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof described in any one of claims 1 to 34, or a fusion protein described in any one of claims 35 to 65.
79. 66. A method of stimulating the immune system in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
80. 66. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
81. 81. The method of claim 80, wherein the cancer is ovarian cancer, melanoma, pancreatic cancer, thyroid cancer, lung cancer, colon cancer, squamous cell carcinoma, prostate cancer, breast cancer, bladder cancer or gastric cancer.
82. 81. The method of claim 80, wherein the cancer is triple negative breast cancer or ovarian cancer.
83. 66. A method of attenuating tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
84. 66. A method of reducing tumor metastasis in a subject in need thereof, comprising administering to the subject an effective amount of an anti-B7-H4 antibody or antigen-binding fragment thereof of any one of claims 1-34, or a fusion protein of any one of claims 35-65.
85. 85. The method of any one of claims 75-84, wherein the subject is unresponsive to therapy with a checkpoint inhibitor or is initially unresponsive to checkpoint inhibitor treatment but later becomes resistant to checkpoint inhibitor blocking.
86. 86. The method of any one of claims 75 to 85, further comprising administering a further therapeutic agent or a further therapy.
87. 86. The method of claim 85, wherein the additional therapeutic agent is selected from the group consisting of a cancer vaccine, a checkpoint inhibitor, an antibody against a tumor-specific antigen, a Bacillus Calmette-Guerin vaccine, a cytotoxin, an interleukin-6 receptor (IL-6R) inhibitor, an interleukin-4 receptor (IL-4R) inhibitor, an IL-10 inhibitor, IL-2, IL-7, IL-21, IL-15, an antibody drug conjugate, an anti-inflammatory drug, and a dietary supplement.
88. 88. The method of claim 87, wherein the checkpoint inhibitor is a CTLA-4, PD-1, PD-L1 or PD-L2 inhibitor.
89. 86. The method of claim 85, wherein the additional therapeutic agent is an inhibitor of LAG3, TIGIT, LAP, podoplanin, protein C receptor, ICOS, GITR, CD226, or CD160.
90. 86. The method of claim 85, wherein the further therapy is chemotherapy, radiation therapy or surgery.
91. The method of any one of claims 85 to 90, wherein the additional therapeutic agent or therapy is administered simultaneously or sequentially with the anti-B7-H4 antibody, or antigen-binding fragment thereof, or fusion protein.
92. The method of any one of claims 85 to 88, wherein the additional therapeutic agent is administered separately or in admixture with the anti-B7-H4 antibody or antigen-binding fragment thereof, or the fusion protein.
93. The method of any one of claims 74 to 92, wherein the subject upregulates expression of B7-H4 or the subject is identified as positive for expression of B7-H4.
94. The method of any one of claims 74 to 93, wherein the subject is a human.
95. 11. A method for detecting B7-H4 in a sample, comprising contacting the sample with an anti-B7-H4 antibody, or antigen-binding fragment thereof, of any one of claims 1 to 34, or a fusion protein of any one of claims 35 to 65.
Citation Information
Patent Citations
IL-15 variants and uses thereof
JP2021516045A
Cytokine-based bioactive agents and methods of use thereof
JP2021528493A
